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Prologue 
‘Do you have any problem with knowing that you might have a thickened my-
ocardium?’, Emily Goldfield asks her son Ray, well into his twenties.  
‘No, not really’, he answers.  
‘You see, it’s not an issue in our family’, Emily turns to me. 
Ray enters the kitchen, where we are talking about the role the familial heart disease 
plays in the family’s life. Three months ago, a gene underlying the disease was found 
in Emily’s blood. She was the first member of the family to have the genetic test 
done. ‘This is an interesting family’, the clinical geneticist said, and so I contacted 
Emily. During our first telephone conversation she described how she felt about the 
labelling of the disease as genetic. ‘It doesn’t bother me at all; in fact, it gives me some 
certainty. I’ve had these complaints for years, I take my medicine and I feel well. I’ve seen 
in my family that it can all be over quite suddenly, but you have to take life as it comes. To 
be honest, I’d find cancer much more threatening.’ She agreed that I could come to her 
home for an interview.  
 When Ray joins us, Emily is elaborating on how the heart disease has been a 
common theme in family stories. Her father and grandfather died after cardiac 
arrests, as did two of her father’s brothers at a young age. Many in the family are 
diagnosed with a thickened myocardium; some have complaints, while others feel 
quite healthy. At some point, Emily brings out a small stack of brown, creased pieces 
of paper – the pedigree of her family, which she used to help the cardiologist map 
the family history. Carefully, she lays down on the table the papers on which one of 
her aunts once started to write down the names of several generations of the Gold-
field family. It appears to be a very large family; her father, for instance, was one of 14 
siblings. As Emily explains how she made sure that all branches of the family received 
the news about the gene, it becomes clear that she fosters relationships with her 
relatives.  
 Emily demonstrated to be quite happy to have taken the test. From her voice I 
can tell that she is disappointed that some in the family are not so enthusiastic: ‘It 
feels like they’re ignoring the issue and I have trouble understanding their carelessness; 
they all have children who may develop the disease’. She adds that the cardiologist has 
recommended that other family members undergo testing as well. ‘It might help to 
better understand the disease and to develop appropriate drugs’, he had said. ‘Our 
generation won’t profit from that, but we have to think of our children’. Yet at the same 
time, she sympathises with those who have doubts about the test or refuse to get 
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themselves tested. Visibly concerned, she mentions Ted, one of her cousins: ‘He’s a 
truck driver and is afraid of losing his job if he turns out to have the gene’.  
 At the end of the afternoon, Emily takes me to the railway station. On the way 
she shows me the place where, some years before, she brought her car to a stop. Her 
heart was beating so fast that she could not drive the short distance to her house. 
Fortunately, her daughter, Mary, was in the car as well. Emily had told me during the 
interview that Mary struggles with the issue: ‘Initially she was eager to know, particu-
larly because of Thomas, her young son; he was born just before I went to the clinic for the 
genetic test. But she decided to postpone genetic testing, as she wants to buy a new 
house first.’ Although she herself felt that the knowledge of her genetic status gave 
her more certainty about the risk of disease, and was therefore helpful in making 
plans for the future, Emily understood her daughter’s hesitation. ‘Imagine that Mary 
has the gene; I guess she’d then like to know whether Thomas has it too. Would that be 
good to know ... for him … for his future … for raising him?’ 
 At the railway station, we say goodbye and I travel back home. During the 
following years, Emily and I keep in touch by phone and email. She finds several 
relatives willing to share their stories with me. As most of them live near one another, 
I make the three-hour trip to the region a few more times, spending whole days with 
visiting members of the family. With many of them I have a second and sometimes a 
third interview, and am thus able to follow the processes they are going through. 
Emily plays a pivotal role; she always has news about others in the family, and so I 
hear through her who has decided to go for the test and who is holding off, and how 
the test results, negative as well as positive, are received. A year after our first meet-
ing, she contacts me about the sudden death of one of her cousins. Aged 53, he died 
while playing music near the place where his father had died 50 years before. ‘It gave 
us a fright and we all were very sad about it; particularly for his wife and children’, Emily 
reflects. ‘But after some time, for most of us life goes on; we’re a rather down-to-earth 
family. It’s just a fact of life that this disease runs in our family.’ 
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1.1 Introduction 
Recent decades have seen a great deal of debate among sociologists as well as in 
public life on the topic of family solidarity and cohesion within the family. The family 
has traditionally been considered an important source of cohesion in society, with 
family and kin relationships seen as ‘natural’ binds in people’s lives. However, it has 
been argued that in contemporary Western society, family life is increasingly eroding 
and family ties have been superseded by social ties with friends, colleagues and 
peers in clubs and societies (Beck and Beck-Gernshein, 2005; Popenoe, 1993). Rela-
tionships between parents and children have changed considerably: divorces imply 
that family units break down and new, composite families arise; increased mobility 
means family members can now live far away from one another; and the emancipa-
tion of women and decrease in family size has gone hand in hand with a process of 
individualisation. As many basic norms and values are passed on through family and 
kinship, and informal support and care are exchanged, great importance is attached 
to a stable parent–child relationship and concern has therefore been articulated 
about the effects of the loosening of family ties.  
 Notwithstanding these developments, there are indications that all is not lost for 
families. The family is still seen as the most important source of children’s norms and 
social skills. A study on ‘social inheritance’ in the late 1990s showed that parents 
equip their children with life attitudes that place value on social virtues such as a 
sense of responsibility and consideration for others (Brinkgreve and van der Stolk, 
1997). Recently, several large-scale studies on family and kin relationships, including 
in the Netherlands (Dijkstra et al, 2006; Dijkstra and Komter, 2012), Spain (Meil, 2011) 
and Canada (Beaujot and Ravanera, 2008), investigated the structure of interdepend-
encies in families and put the individualisation thesis into perspective. These studies 
concluded that although family ties have changed drastically, they have not been 
undermined: the family lives on. In other words, individualisation does not put an 
end to solidarity between family members. The studies highlight the care given to 
relatives in times of disease or other troubles and the support provided by grandpar-
ents in caring for grandchildren. The changes identified represent a transition to new 
family forms rather than a breakdown in family life. Obligations towards family 
members are still felt, but the individual’s free choice has become the new norm. 
Family relationships are increasingly beginning to resemble friendships: they are less 
obligatory and more voluntary, less hierarchical and more equal. People may choose 
to develop a close relationship with one parent, brother or sister while more or less 
neglecting others. These findings are in line with Strathern’s (2005) statement that in 
this ‘age of individualism’ children’s care for their parents depends on the kind of 
relationship they have developed.  
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With the developments in biomedicine and growth in genetic testing, questions 
have been raised about how familial diseases and the labelling of these diseases as 
‘genetic’ might influence family and kinship. The possibilities offered by genetic 
testing increase family members’ awareness that they are part of a family: they force 
them to face the fact that they share the same genes and the same diseases. When 
an individual family member starts genetic testing, the result inevitably reveals the 
risks for others within the family. Conversely, an individual might require blood or 
information from other family members to obtain a genetic diagnosis. In light of this 
familial involvement in genetic testing, it is surprising that the abovementioned 
studies on family relationships have not put the role of genetics on the agenda. 
 Emily Goldfield’s involvement in genetics, described in the prologue, demon-
strates feelings towards family members that could be interpreted in terms of inter-
dependency, responsibility, sympathy and concern. Does this mean that getting 
involved in genetic testing promotes solidarity in families and intensifies family ties? 
Or could it just create more distance, as family members might have different ideas 
about and expectations of a genetic diagnosis? While genetics might influence family 
relationships, Emily’s story also points to families’ contributions to the shaping of 
genetic practices. Families talk about genetic testing and genetic risks; they go for a 
test, have doubts about it or refuse to go. By dealing with genetics they reshape the 
very meaning of genetics. It can be questioned what would happen if families were 
to consider genetics not overly important. Will further developments in genetic 
technology stagnate if family members are not willing to have genetic tests? After all, 
without blood and family data, not much can be learned about familial diseases. 
 In this thesis I follow families living with hypertrophic cardiomyopathy (HCM). In 
2004 I came into contact with the Goldfield family as well as with five other extended 
HCM families and a number of professionals working in the field of cardio-genetics. 
Travelling between all these families and professionals, talking and listening to them 
as well as phoning and emailing them revealed a wealth of everyday experiences. It 
showed an enormous diversity in ways of dealing with genetic testing and making 
sense of genetic risks and test results. This thesis reports on the analysis of this 
collection of experiences and meanings. It serves to enrich the debates on the mean-
ing of living with genetics as a family. In this introduction chapter, I address the back-
ground to the study and the main research questions, and describe the case of HCM 
as well as the methodological approach to the study. Before elaborating on family, 
kinship and genetics, I first examine the changing expectations of genetic technolo-
gy for dealing with health and disease over the last decades, as this is relevant to 
understanding and interpreting the interrelatedness of family and genetics. 
C H A P T E R  1  
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1.2 Expectations of genetic technology: high hopes and dark sides put into 
perspective 
Since the start of the Human Genome Project in 1990, public and professionals’ 
debates on what genetic technology might mean for people’s future health have 
seen a change in perspective and expectations. In early debates, the role of genetics 
was characterised in terms of high hopes and dark sides. On the one hand, optimism 
was expressed about the deepening understanding of the molecular mechanisms of 
disease, leading to new forms of diagnostics, prognostics and therapeutics (NIH, 
1990; Watson, 1990). Initially, high hopes were fostered with respect to the identifica-
tion of individuals’ predisposition to ‘single gene’ disorders, such as Huntington 
disease, Duchenne muscular dystrophy, cystic fibrosis and polycystic kidney disease, 
but the excitement in the field soon shifted to the elucidation of the genetic basis of 
common diseases, such as various cancers and cardiovascular diseases (Bell, 1998; 
Varmus, 2002). Starting from the premise that every disease has a genetic compo-
nent, the new challenge became to unravel individuals’ predispositions to common 
diseases and to produce personalised prophylactic drugs for specific risk reduction 
(Collins and McKusick, 2001). Many clinical professionals embraced genetics. They 
viewed the individual genetic risk profile as a vehicle for rendering prevention more 
successful than ever. At the turn of the century, the cardiologist Roberts, for instance, 
sketched a new paradigm for cardiology: ‘Prevention will be the key to future successes, 
and the unraveling of human genes will catapult prevention as a major initiative for the 
21st century. In the management of coronary heart disease, individuals will be identified 
in their teens so that treatment and prevention appropriate for their medical risk profile 
and life style can be properly individualized’ (Roberts, 2000, p. 662). 
 On the other hand, others evaluated the consequences of the developments in 
genetic research in a negative light and voiced concerns about the dark sides of 
genetics. It was feared that the growing attention paid to genetic factors in the 
emergence of diseases would increasingly lead to disease being defined in terms of 
DNA, which would result in a devaluation of social and cultural approaches to health 
and disease (ten Have, 2001; Lippmann, 1992; 1993). This process of ‘geneticisation’ 
would imply that people were tied to their biological fate based on genetic test 
results, and their freedom to fashion their own lives would be seriously threatened 
(Horstman, 2008). In line with this, fear was voiced that genetic information would 
deprive people of an ‘open’ future. Those in favour of such arguments pointed to 
research reporting on the many psychological problems suffered by those who had 
undergone genetic testing (Shaw et al, 1999). Social science research had not only 
revealed a relationship between receiving a bad result and experiencing depression, 
anxiety and psychological distress; also those who had received a favourable result 
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often struggled with psychological problems, such as survivor’s guilt and emotional 
numbness (Tibben et al, 1992).  
 In addition to the above negative psychological effects, harmful social implica-
tions of genetic testing were also highlighted, such as potential stigmatisation and 
discrimination. Many were afraid of the consequences for individuals as well as 
families if insurance companies or employers were to access genetic data and that 
genetics would contribute to a ‘genetic underclass’ (Billings, 1992; Kitcher, 1996). 
Finally, concerns were also voiced about human enhancement. Kevles and Hood 
(1991), for instance, warned of the risks of eugenics programmes that would increase 
the prevalence of ‘socially good’ genes in the population and decrease that of ‘bad’ 
genes in order to produce better people and eliminate those considered biologically 
inferior. Others, like Steinberg (1997), pointed to the risk of human enhancement 
through the genetic manipulation of embryos. Although these optimists and pessi-
mists had very different views of genetics, they shared the same deterministic per-
spective, both expecting that in the near future genetic technology would leave its 
mark on people’s lives. 
 Around the turn of the century things started to change. The high hopes and 
fears of the dark sides of genetic technology appeared to have been tempered. It was 
argued that the optimists as well as pessimists based their opinions on rather high, 
even unrealistic, expectations of future developments in the field of genetics. The 
realisation grew that genetics researchers had overestimated the results of their work 
and that those focused on the psychological and social aspects of genetic technolo-
gy took the effects for granted. Expectations with respect to genetic technology were 
based on the assumption of full prediction and total control or, on the contrary, total 
powerlessness (Brown and Michael, 2003). The overly high expectations of the 
benefits of genetic research particularly concerned the therapeutic possibilities. 
Innovations in the field of pharmacogenetics – aiming to improve individuals’ health 
– proceeded much more slowly than expected: at the beginning of this century, little 
to no working pharmaceutical treatments for genetic disorders had yet appeared on 
the market (Hedgecoe and Martin, 2003). And a decade later, pharmacogenomics – 
which relates to the entire genome or a significant part thereof – is still a long way 
from personalised cures for common diseases (Burke et al, 2010). 
 Scepticism about the strong hopes and fears that genetics would change peo-
ple’s lives was associated with the idea that the predictive value of genetic testing 
had to be put into perspective. In genetic research it gradually became clear that 
genetics is much more complex than initially thought (Holtzman and Marteau, 2000). 
More and more publications on the concrete practices of genetic testing appeared, 
revealing that – contrary to the idea that genetic tests give clear answers and support 
people in shaping their life plans – uncertainties remain even after the identification 
of specific mutation (e.g. de Vries and Horstman, 2008). The classic notion that a 
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single gene causes a severe disease as well as the idea that a specific mutation for a 
common disease, such as the APOE gene associated with Alzheimer’s disease, gives a 
precise prediction of future disease transformed into notions of ‘complexity’ (Lock et 
al, 2006). In this view it was assumed that interaction between genes, as well as the 
interaction between genes and the environment, play a prominent role in the actual 
manifestation of diseases. This implied that genetic test results could no longer be 
considered as predictions of future disease or suffering, but merely as indications for 
the risk of disease (Bharadwaj, 2002). The question arises what this change in the 
framing of genetics, from a deterministic view to notions of complexity, means for 
the interrelatedness of family and genetics. 
 More insight into how families engage with the complexity of genetic testing 
might contribute to the contemporary debates on whole genome sequencing and 
direct-to-consumer genetic testing as well. After all, the emphasis on complexity and 
the nature of genetic testing with respect to assumed susceptibility has not done 
away with hopes for the ideal of personalised medicine. With the completion of the 
Human Genome Project in 2003, Frances Collins predicted that low-cost genome 
sequencing for all would allow for ‘individualized, preventive medical care based on our 
own predicted risk of disease’ and would generate a ‘new breed of designer drugs’ 
tailored to serve these needs (Collins, 2003). A decade later, the clinical significance 
of data yielded from genome-wide diagnostic testing remains unclear and largely 
hypothetical (Janssens, 2010), yet Collins remains optimistic: ‘learning your DNA 
secrets can be the best strategy for protecting your health and your life’ (Collins, 2010). 
He expects that those who know that they have even a slight increased risk of dis-
ease will be more motivated to change their lifestyles. 
 Whilst debates on the ethical aspects of whole genome sequencing are ongoing 
(Health Council of the Netherlands, 2010) and its practical use is negotiated (Avard 
and Knoppers, 2009), direct-to-consumer genetic testing has made its way onto the 
market, and nowadays these tests can easily be ordered online. This, again, has 
generated a great deal of discussion, as test results are often seen as potential threats 
for individuals (Samuel et al, 2010). The most important problem is the restricted 
validity of the tests, as most screening tests, for example those for BRCA1 and BRCA2, 
have not been evaluated in the general population and so may not indicate an 
increased risk for breast cancer in women with no family history (Fleming, 2008). In 
addition, the information provided about possible health risks can – partly due to a 
lack of qualified counselling – easily be misinterpreted, which might lead to people 
making behavioural changes that are unhealthy rather than healthy (Harris et al, 
2013; Caulfield et al, 2013). In recent years, the literature has addressed how users 
value and experience direct-to-consumer genetic testing (Myers and Bernhardt, 
2012). Apart from several first-hand accounts of experiences with these tests, which 
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also touch on their impact on family life (Corpas, 2012; Varga, 2012), to date there has 
been little empirical research on how families live with these genetic tests.  
1.3 Family life and genetics 
Technological innovations change our ideas about what is considered good family 
life, and so influence family members’ mutual relationships. A now relatively old, but 
nevertheless interesting study by Schwarz Cowan (1983) investigated how the 
introduction and development of new technologies create new norms and reshape 
family life. She showed how household technologies, such as the vacuum cleaner 
and washing machine, freed women of several negative aspects of their lives, but at 
the same time generated new definitions of adequate motherhood. The time saved 
through using these new technologies in the home had to be dedicated to the family 
in another way: in addition to feeding and bathing the children, mothers became 
responsible for the psychological work entailed in their character building. Another 
household technology, the microwave, changed family relationships as well. De-
signed to remove the pressure to find time to dine together and enable family 
members to play sports or take music classes at dinner time, this device contributed 
to individualisation in the family by eroding one of the most important family events, 
the family dinner. 
 Two recent studies on the use of telecare technologies show how ‘care at a 
distance’ not only redistributes responsibilities and tasks and transforms routines for 
users, but also creates new forms of trust and expectations for their relatives (Pols, 
2012; Oudshoorn, 2011). The use of video-communication in neonatal care – the 
Baby Watch –, which enables parents to visit their premature baby in a ‘virtual’ sense, 
encourages parents to experience their virtual babies as part of family life, but at the 
same time burdens them with new concerns; watching nurses and physicians caring 
for their child without communicating may create many new kinds of uncertainties 
(Oudshoorn et al, 2005). 
 In the context of genetics, prenatal screening techniques can be seen as an 
example of the interplay between technology on the one hand, and norms and 
responsibilities among parents on the other. In most western countries, these tests 
were initially offered as an alternative to the invasive amniocentesis or chorionic 
villus biopsies for pregnant women whose advanced age meant a higher risk of 
having a child with Down syndrome (Health Council of the Netherlands, 2001). As the 
screening tests became more reliable, in most countries they were offered to young-
er pregnant women as well, and they have now become part of routine pregnancy 
checks. With this, prenatal screening has transformed from a special service into a 
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moral obligation for all pregnant women towards their unborn child (Garcia et al, 
2012; Geelen et al, 2004; Reed, 2007). 
 Various researchers have studied the interplay between family, kinship and 
genetics. The anthropologist Finkler (2000), for instance, demonstrates how the 
process of genetic testing for breast cancer intensifies relationships within the family. 
Promoting awareness of family medical history brings back forgotten memories, 
forces family members to be more open and prompts them to reunite with es-
tranged relatives. Finkler’s interpretation as ‘medicalisation’ and ‘geneticisation’ of 
the family suggests that genetic technologies prescribe one’s kin relationships on the 
basis of birth and genes rather than choice, separated from feelings of love or friend-
ship. In the same vein, Hallowell (2003) points to the creation of new forms of re-
sponsibility when families start genetic testing. For women in families with a history 
of breast cancer, providing genetic information for their relatives contributed to 
good will. However, while genetic technology can promote family life and kinship, it 
may also have a negative impact. It has been argued that in families with Huntington 
disease genetic testing might lead to conflict and tension, driving family members 
apart and heightening existing individualistic tendencies (Sobel and Cowan, 2000; 
van der Meer et al, 2006). What is clear is that in both perspectives, genetic technolo-
gy is viewed as powerful: it is assumed to create possibilities to bring family members 
together or to burden families with worries.  
 With the growing awareness of the complexity of genetics and the uncertain 
nature of test results, however, the influence of genetic testing on family and kin 
relationships has been put into perspective. Several authors refute the idea that 
family and kinship are determined by biological facts (Featherstone et al, 2006; 
Horstman and Smand, 2008). Based on ethnographic research in families engaged in 
genetic testing, they argue that family life does not change dramatically when fami-
lies become enrolled in genetic testing and receive test results. In 2008, as part of this 
research project, we organised an international workshop in Maastricht, where 
various aspects of the interrelatedness of family and genetics were discussed. The 
participants reported on empirical – mainly sociological and anthropological – 
studies in different countries, specifically Great Britain, Denmark, the Netherlands, 
China, the United States, Canada, Mexico and Cuba. The studies concerned a variety 
of genetic risks, for instance breast cancer, Huntington disease, Alzheimer’s disease, 
familial hypercholesterolemia, diabetes and polycystic kidney disease. Afterwards, 
the participants’ contributions were published in a special issue of Social Science and 
Medicine (Horstman, Finkler, 2011). What these studies have in common is the idea 
that the time of unrestrained optimism and pessimism has passed: genetic infor-
mation can no longer be expected to have such a huge impact so as to ‘make’ or 
‘break’ the family, nor to incite families undergoing genetic testing to buy into the 
high hopes or dark sides previously attributed to genetic testing. However, although 
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established family patterns are not drastically altered by genetic technology, it 
cannot be said that genetic testing does not affect families at all. To some extent, it 
does stimulate the creation of new norms and new responsibilities for family mem-
bers, and thus requires a great deal of work. The contributions to the special issue 
also illustrate that living with genetic testing means different things for families in 
different national-political contexts.  
 Against the backdrop of these insights, in this study I focus on the questions and 
dilemmas HCM families as well as family members may be confronted with when the 
genetic risk of the disease enters their lives. I work towards answering the following 
questions: How do families live with the risk of a familial disease, and how do they 
balance the choice that is right for them with their responsibility towards their 
relatives? What does it mean to live with at-risk children and to speak for them with 
respect to genetic testing? How do families deal with genetic risks in a societal 
context, for instance with respect to insurance and employment? And how do indi-
vidual family members involved in genetic testing view their future lives? To aid in 
understanding how different families live with the familial heart disease, the next 
section provides further information on HCM itself.  
1.4 Hypertrophic cardiomyopathy: a ‘frayed’ entity 
To begin to understand hypertrophic cardiomyopathy (HCM), I turned to various 
medical journals published in recent decades. In brief, the disease is mainly charac-
terised by hypertrophy of the heart muscle, and the first sign of disease manifesta-
tion is often heart failure or arrhythmia. HCM is typically diagnosed by means of 
electrocardiography and echocardiography (although sometimes magnetic reso-
nance imaging (MRI) may be required). In the literature, the disease is particularly 
associated with the sudden cardiac death of apparently young healthy individuals, 
especially athletes (e.g. Hershberger et al, 2009; ICIN, 2010; Maron and Fananapazir, 
1992). As a result, whether an individual is at risk of developing HCM should be 
determined at the earliest opportunity. Since the identification of genetic mutations 
associated with the disease, genetic testing has been seen as a means to trace at-risk 
individuals. The journals also tell when within a family a genetic test trajectory can be 
started: the HRS/EHRA expert consensus statement on genetic testing (Ackerman et 
al, 2011) recommends ‘targeted genetic testing for any patient in whom a cardiologist 
has established a clinical diagnosis of HCM based on examination of the patient’s clinical 
history, family history, and electrocardiographic/echocardiographic phenotype’ (p 1311). 
If a mutation is identified, other family members can have (pre-symptomatic) genetic 
tests. 
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Over the last decades, HCM has been considered the most common genetic cardio-
vascular disease worldwide, diagnosed in 1 out of every 500 people. It affects both 
sexes and people of various ethnic and racial origins (Maron et al, 2012). The genetic 
underpinnings of the disease were not initially recognised. In the mid-19th century, 
hypertrophy of the heart was first described by the French pathologist Liouville 
(Maron et al, 2006). Clinical diagnosis was difficult at that time and, based on autopsy 
findings, Liouville (1869) identified chronic myocarditis as the cause of heart muscle 
disease. It was not until the 1950s that – again based on autopsies – the familial 
inheritance of hypertrophy of the heart was suggested in a detailed report about 
young patients who had died suddenly of a heart disorder (Teare, 1958). With the 
development of technologies such as invasive angiography, hemodynamic meas-
urement, electrocardiography and echocardiography, heart muscle diseases could 
be diagnosed more easily. For researchers, this brought the unravelling of the familial 
nature of the disease within reach (Braunwald, 1964; Frank, 1968), and in the 1970s it 
was stated that, in Mendelian terms, the pattern of inheritance has an autosomal 
dominant nature (Clark et al, 1973; van Dorp, 1976). This meant that children of a 
diseased parent run a 50 percent risk of carrying the ‘bad gene’ as well. The devel-
opment of new genetic diagnostic tools accelerated the race to unravel the molecu-
lar basis of HCM. After the first gene defect deemed responsible for the disease was 
identified in 1989 (Geisterfer-Lowrance, 1990), an increasing number of genes, 
mainly coding for cardiac sarcomere proteins, were associated with the disease. 
Whereas at the turn of the century about 50 mutations in 6 different genes were said 
to play a role in the manifestation of the disease (Spirito et al, 1997), genetic re-
searchers have now identified more than 1400 mutations in at least 11 genes (Maron 
and Maron, 2013). It is expected that, in the coming years, deep DNA sequencing 
techniques develop further and make genetic-based diagnosis increasingly practical 
(Marian, 2010; Smeets, 2010).  
 While the literature on the state of the art with respect to HCM provides a great 
deal of information about the disease, it also gives the impression that the develop-
ment of HCM diagnostics has been a rather straightforward process, resulting in 
increasing opportunities to establish genetic diagnoses in more and more families in 
the near future. It suggests and confirms the idea of a genetic revolution, promising 
new means of disease control and prevention, and of safeguarding families’ future. 
This description, however, does not do justice to the dynamics of genetic testing, the 
uncertainties and the unknown elements, and the impact thereof for families en-
gaged with genetic testing for HCM. For these families genetic diagnostics may 
rather have the character of a moving target, a trajectory with an unpredictable 
course and many loose ends. Instead of as a means to obtain certainty about one’s 
future health within a short time, genetic testing may better be seen as a trajectory in 
which the meaning of the test is uncertain and changes continuously.  
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Whereas thinking in terms of ‘a diagnostic test’ goes hand in hand with the idea that 
a test gives answers, when genetic testing within a family is started it is by no means 
clear how long it will take and whether a result will be obtained at all, even when 
clinical symptoms and family history indicate that the disease has a familial character. 
When the first family member is genetically tested, the laboratory work is biologically 
and logistically complex and often drags on for some time. Further, medical journals 
point to the still limited power of genetic testing. Notwithstanding the growing 
number of mutations associated with HCM, in approximately 40 percent of the 
families that undergo testing, no mutation will be found (Marian, 2010). In the labor-
atory, too, the possibilities are limited: available methods do not detect all types of 
mutations, and not all known ‘causal’ genes related to HCM can be analysed, as many 
mutations of these genes are considered to be uncommon or rare (Ho, 2012; Marian, 
2010). This means that a negative test result (i.e. where no mutation is found) can 
only be tentative, as other diagnostic procedures may be developed in the future. 
Ambiguity with regard to the genetic character of the disease is also reflected in the 
name given to it. Initially, due to the obstruction caused by the hypertrophy of the 
myocardium, the disorder was named hypertrophic obstructive cardiomyopathy 
(HOCM). After the first mutation was identified, the term familial hypertrophic cardio-
myopathy (FHC) came into use. Nowadays, however, the dominant name is hyper-
trophic cardiomyopathy (HCM), which emphasises neither the clinical symptom of 
obstruction nor the familial character of the disease (Maron et al, 2012). 
 If genetic testing results in the identification of a mutation, the question is what 
this means for the health of individual family members. Many studies on the molecu-
lar basis as well as on the clinical aspects of HCM point to the uncertain meaning of 
being ‘at risk’ and even of being ‘affected’. It is emphasised that family members who 
share a specific mutation have a variable risk of future disease. Even within one 
family, the expression of the disease can vary strongly: some carriers of a mutation 
demonstrate no clinical symptoms and remain asymptomatic throughout life, some 
have thickened myocardia or severe arrhythmia and suffer from serious heart failure, 
while others die after a cardiac arrest, often in the absence of previous symptoms 
(Hershberger et al, 2009; Mariam, 2010). An analysis of the literature on HCM teaches 
us that since the identification of the first genes involved, there has been much 
speculation with regard to the specific relationships between genotype and pheno-
type. Initially, ‘malignant’ and more ‘benign’ mutations were distinguished (Marian 
and Roberts, 2001; Bos et al, 2006). In more recent articles, however, it is stated that 
no clear correlations between specific mutations and disease expression are identi-
fied (Christiaans et al, 2010) and that the variation among mutation carriers within 
families suggests the existence of ‘modifier genes’ (van Driest, et al, 2005). It is as-
sumed that these genes prevent some carriers of an HCM mutation from developing 
severe complaints, or in some cases any complaints at all. Conversely, it can happen 
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that in a family known to have an HCM mutation, that mutation will not be identified 
in the DNA of a family member with HCM symptoms. Recently, further unravelling of 
the genetic complexity of the disease has revealed that HCM patients may carry two 
or even more mutations in the same or in different genes (Smeets, 2010; Marian, 
2012). So far, in genetic test procedures no further steps are taken in the laboratory 
after a first mutation is identified in a given family. The growing awareness of the 
possible presence of a second mutation playing a role in the familial heart disease, 
however, might make it difficult to reassure family members that HCM can be ex-
cluded when a test result demonstrates that they are not carriers of the first mutation 
(Marian, 2010). 
 In addition to the complex organisation of genetic test processes and the com-
plexity surrounding the interpretation of test results, another element of uncertainty 
for families is the lack of interventions to prevent the development of HCM. Notwith-
standing optimism about certain medications or septal reduction therapy, which are 
associated with functional improvement and long-term survival (Fasa and Sigwart, 
2010), no real cures have been reported for HCM families. When a specific mutation is 
identified in a family member’s DNA, all that can be offered is lifestyle advice (such as 
refraining from competitive sports) and echo- and electrocardiographic monitoring 
of the progression of the disease. Implanting a cardioverter defibrillator (ICD) is 
generally considered the only proven protection against sudden cardiac death 
(Maron, 2010). It is argued, however, that therapeutic decisions regarding the im-
plantation of an ICD should not be based solely on the result of a genetic test (Bos et 
al, 2009).  
 To conclude, a great deal of medical information is available about HCM and 
progress is being made from the perspective of medical researchers, for families, in 
contrast genetic testing will not provide the clarity that is often anticipated. Instead 
of removing uncertainty, genetic testing often results in uncertainty. While genetic 
testing can be considered a way to explain manifest HCM symptoms, and pre-
symptomatic genetic testing can be seen as a way to assess the disease risks of 
relatives long before clinically manifest dysfunctions appear, the question is how 
families experience the dynamics and the complexity of genetic testing as well as the 
uncertain meaning of being ‘at risk’ and ‘affected’.  
1.5 A qualitative approach: following families and genes in everyday lives 
This study is underpinned by the idea that, in order to gain more insight into how 
families live with genetics, it is important to focus on processes rather than on specif-
ic moments. This is because notions of dynamics and complexities imply develop-
ments and transformations, which in turn implies that – as we have seen in the 
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previous sections – neither the family nor genetics can be considered to be self-
evident objects or facts. Thus, to trace the interdependencies between families’ 
everyday lives and genetics, I explored the issue from within daily practice: I followed 
families involved in genetic testing for HCM for an extended period, and particularly 
studied the processes family members were undergoing. The inspiration for this 
methodological approach comes from the fields of ethnography and qualitative 
sociology, which consider daily practices as the starting point of investigation and 
take dynamicity and complexity as a given (Gupta and Ferguson, 1997; Hammersley 
and Atkinson, 1995). Our previous studies on women’s experiences with amniocen-
tesis and prenatal screening demonstrated the fruitfulness of longitudinal empirical 
sociological research (Geelen et al, 1999; Geelen et al, 2004). In those studies, we 
interviewed pregnant women at two or three subsequent moments; before they 
underwent the diagnostic or risk assessment procedure, in the period in which they 
were waiting for the result (in the case of amniocentesis), and after they had received 
the result. It became clear that decision making cannot be considered a momentary 
act of weighing pros and cons. Rather, the women in these studies started thinking 
about testing long before the test procedures were performed (often even before 
pregnancy), and over the course of time (including after a good result) they were 
regularly confronted with feelings of doubt and uncertainty about the step they had 
taken to undergo the test. We concluded that decision making has to be seen as a 
dynamic and contingent process, in which consequences need to be made sense of 
and meanings and perspectives change continually. In this process, a great deal of 
work is needed to stick to the decision. These conclusions formed the basis for the 
methodology in the present study.  
  A second starting point for this study was that the interdependencies between 
the family and genetics could only be traced by perceiving the idea of ‘following 
families’ in its broadest sense; in other words, by exploring the various networks in 
which families are involved when they start genetic testing. Thus, in addition to 
conducting in-depth interviews with families, I followed the route these families 
follow and studied the contacts they have with counsellors. Furthermore, I followed 
the trajectories of families’ blood, genes and data by observing the test procedures in 
the laboratory and the meetings of cardio-genetic professionals in which families 
were discussed. Rather than studying the latter processes systematically, I included 
them in the study more to develop a sense of the families’ experiences. The encoun-
ters with clinical professionals and researchers in the laboratory raised my awareness 
of the interwoven nature of patient care and research and the role families played in 
this. It became clear that clinicians not only talk about families in the sense of care, 
but also in terms of ‘mapping’ families: ‘Sometimes we meet really great families, 
families that are very interesting to investigate in terms of why the disease manifests 
seriously in some individuals whereas in others it does not.’ In the laboratory, in contrast, 
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not just blood and genes are talked about, but also what testing might mean for 
families: ‘Families are concerned, that’s inevitable, and we’re aware that the long waiting 
time is terrible for them; people want to close the issue. Sometimes they call us directly to 
ask whether we have any news.’ In the laboratory, researchers get a kick out of finding 
a new mutation, but at the same time reflect on its meaning for a family: ‘It will be 
better to have a result, even though it’s bad news; for instance, it gives them the oppor-
tunity to consider testing their children.’ The professionals’ perceptions of the families – 
their struggles, expectations, hopes, etc. – demonstrated how families are portrayed 
and shaped in the professional context. In this research, the encounters with clinical 
professionals and genetic researchers contributed to the way I entered and explored 
families’ lives and analysed the stories of the family members. 
Selecting families 
During the first phase of the study I spent some months familiarising myself with the 
field of the research. In addition to conducting literature studies on ‘family life’ and 
‘cardio-genetics’, I planned meetings with various cardio-genetics professionals. The 
cardiologist and the clinical geneticist who participated in the research team shared 
the stories of a number of ‘their’ families. This not only gave an impression of how 
they perceived the families’ expectations and experiences, but also revealed the 
variety within the families they met during their consultations, which confirmed the 
idea that genetic testing means different things in different situations. The profes-
sionals promised to recruit participants for the study. As the dynamics in HCM fami-
lies’ everyday lives formed the starting point of the interviews, we agreed that they 
would look for as much variety as possible, first based on family size and disease 
severity. Furthermore, they would approach families in which a mutation had been 
identified, families still waiting for their test results, families in which linkage analysis 
had begun, families that had just started the trajectory of genetic testing and families 
that had been involved with genetics for some time. Finally, they would look for 
families that had children who had been genetically tested.  
 After I had obtained approval from the relevant medical ethical committee, the 
physicians informed some of their clients about the study, both orally and by means 
of an information letter I had drawn up. All those asked to participate readily agreed, 
giving us a total of six extended families: the Redford, Goldfield, Lewis, Green, Ander-
son and Silverman families (pseudonyms are used). For the most part, these families 
lived in the southern and eastern Netherlands. This was related to the physicians’ 
workplaces; initially they both worked as specialists in a cardio-genetic centre in the 
south of the Netherlands, but transferred to other hospitals in central and eastern 
Netherlands during the course of the study.  
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Six extended families 
The six families that participated in the study were different in several respects and 
became involved in genetics in various ways. In this section, I provide a brief descrip-
tion of each family. 
 The Redford family was relatively small and included two brothers and their 
wives, their four children and the grandparents of these children. The two brothers 
and their father had suffered from severe to very severe heart complaints from young 
age. They had been clinically diagnosed with HCM years previously, and it was 
assumed that heredity played a role. When goal-oriented DNA testing for the disease 
became available at the turn of the century, the brothers – then in their thirties – as 
well as their father had themselves tested. A mutation for HCM was identified, which 
led to the testing of the four very young children. The children were too young to be 
interviewed themselves, but all other family members were willing to participate in 
the study except for the mother of two of the children and her parents. Indeed, the 
family, which can be characterised as a family of ‘social risers’, showed considerable 
interest in the study: ‘The more that is known about living with the disease, the better it 
is. Maybe the problems with insurance companies can be solved’, one of the brothers 
said when I approached him to participate. I had met the mother who ultimately 
declined to participate in the hospital when visiting her husband, and although we 
made an appointment for an interview she later cancelled it. She indicated that she 
did not mean to be a ‘spoilsport’ as all her family members were being so open, but 
that in the end she found it too difficult to talk about her experiences with her hus-
band’s disease and the genetic testing of her two children. 
 The Goldfield family, in contrast, was very large, with fourteen brothers and 
sisters in the fourth generation and even more in the third and second generations. 
Heart disease was a common theme in the family’s history and in recent years many 
family members had been diagnosed with thickened myocardia. As a result, they had 
regular cardiac check-ups. The cardiologist approached one of them to be genetically 
tested for HCM in order to gain more insight into the heart disease running in the 
family. The identification of an HCM mutation had prompted the genetic test trajec-
tories within this family. Compared to the Redford family, the presentation of the 
disease was milder and the variation in disease expression was striking: although 
some family members suffered from serious heart failure or had died after a sudden 
cardiac arrest, several carriers of the mutation had few to no complaints. From this 
family, members of three generations from many family branches participated. When 
I started the interviews, some members of the family had had a genetic test done, 
and others were still thinking over the issue. 
 In the Lewis family, too, the variation in disease expression was considerable: 
one member had had heart complaints from a young age and had died suddenly of 
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heart problems at the age of 53, while his brother and three sisters had experienced 
only mild complaints at older ages. Due to their chronic heart complaints, in 1999 
two of the sisters had been referred to the clinical geneticist by their cardiologist. 
Within months, a mutation for HCM had been found. I conducted interviews with the 
two sisters as well as their brother and other sister – all in their sixties at that time – 
and involved some of their adult children as well. This family was characterised by a 
high education level for almost all family members. 
 I came into contact with the Green family one year after a mutation had been 
identified in the blood of the 14-year-old daughter. The girl had experienced hyper-
trophy of the myocardium from young age, but when an echo had shown a further 
dramatic increase, DNA testing had been performed at the cardiologist’s suggestion, 
notwithstanding the fact that no other family members suffered from similar com-
plaints. I started interviewing her as well as her two brothers and both parents, and 
would have liked to talk with others in the family. This, however, appeared to be 
impossible. Additional testing had identified the mother as a mutation carrier, but 
none of her brothers wanted to deal with genetic testing or talk about the issue. 
 In the Anderson family, too, I interviewed just two young men and their parents. 
Both young adults, aged 20 and 21, had been diagnosed with thickened myocardia 
in the same week and, due to the assumed hereditary character of the complaints, 
blood had been taken for genetic testing. So far, no mutation had been identified. 
Cardiac investigation of the parents had revealed no abnormalities, which meant it 
was unclear how the sons had inherited the disease. As long as they were waiting for 
the result, the parents were hesitant to ask others in the family to participate in the 
study, as they did not want to cause concern among their relatives. I kept in touch 
with them for years, but during that period, testing yielded no result. 
 Finally, I met the Silverman family, a family of average size, with seven siblings 
born in the 1940s and ’50s, of whom two, a brother and a sister, had died around the 
age of 30. The other five had been diagnosed with thickened myocardia. One of 
them died in the course of the research, two years after I had interviewed her and 
some weeks after she had received a donor heart. Seven years before I met them, 
linkage analysis had been started, but had yielded no result. A family rift gave rise to 
problems in trying to make contacts with certain family members – I even needed 
additional help from the cardiologist to bring me into contact with one relative – but 
I ultimately held conversations with four of the five family members and their part-
ners and, later, some of their children.  
 I would have liked to follow a family that refrained from testing, but the profes-
sionals did not succeed in finding such a family. Fortunately, I was able to include at-
risk family members who, after being informed of the mutation in the family, explicit-
ly decided not to be tested. 
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Entering families’ lives 
The core of the present research consisted of these six families. I gained access to the 
families first by contacting one family member and, through them, making contact 
with relatives, such as parents, children, brothers and sisters, as well as nieces, neph-
ews, aunts or uncles, and even some spouses and other in-laws. Which of the family 
members would participate in the study was not a given beforehand, but it was 
during the process that I found out which other family members I would like to talk 
with. In all six families I tried to gain as broad a picture as possible. Thus, I met family 
members with and without the disease spanning two or three generations. I also met 
family members who had had a genetic test done and others who had explicitly 
refrained from testing or were still thinking over what to do. I particularly tried to 
meet those family members who had started the genetic test trajectory and were 
waiting for the result. It was interesting to meet partners as well. One of the first 
participants asked if we could arrange a meeting at a time when her husband could 
attend: ‘He has, of course, a lot to say about how we live with the disease’. From then on, 
I made sure to meet partners as well, at least for part of the interview. During such 
interviews, I regularly noticed that partners were unaware of each other’s ideas about 
genetics. Issues occasionally arose that they had never discussed before. In some 
cases, differences in opinion led to quarrels. 
 In total 57 members of the families participated, all of whom gave informed 
consent. In general, they were quite willing to accept the invitation for an interview, 
evidently welcoming the opportunity to talk about their experiences of living with 
the familial disease. In incidental cases – such as in the Silverman family – it took 
some time to penetrate the family due to tensions between relatives, but ultimately I 
was able to reach most of the family members I wanted to talk with. Inspired by 
Callon and Rabeharisoa’s (2004) study on ‘Gino’, a member of a muscular dystrophy 
family who refused to get involved in genetic testing, I would have liked to meet a 
comparable individual in an HCM family to gain more insight into people’s desire to 
live a life free from genetics. In the six participating families there were family mem-
bers who, according to others in the family, ‘ignored’ the familial disease as well as its 
assumed genetic character (‘they neither think about the issue, nor discuss it with others’ 
). Unfortunately, I did not manage to approach such a person, as they were either 
protected by their family members from what might prove to be too emotional an 
encounter, or did not consider it worthwhile to ask for an interview with me. As they 
were not part of any medical network, it was not possible to reach them via the 
professionals either. It is a limitation of the methodology used in the present study 
that such ‘hesitant voices’ could not be heard. 
 The contacts with the families took place between 2004 and 2008. In order to fit 
in with the participants’ everyday activities, I visited the family members in their 
C H A P T E R  1  
 26 
homes (except for two of them, whom I visited in their workplace). By doing this, I 
created the opportunity to let time pass as typically as possible and to enable other 
family members to join in. Before starting the interview, I spent some time talking 
about whatever was currently occupying them. The informal start varied from mak-
ing small talk with their young children to taking a short walk in the garden or watch-
ing some television with the participant. Starting from people’s actual, everyday 
activities enabled me to put their experiences in context. Moreover, it provided some 
points of departure to help remember the different family members, which were 
helpful in the data analysis phase. I kept a diary in which I made notes of contextual 
elements relating to the families. Although it has been quite some years since I met 
them, I still have a clear picture of the specific circumstances of the contacts, such as 
how I travelled there, the first moment we met, where we sat in the home or in the 
garden, and the atmosphere during the interviews. I also remember well the specific 
statements and experiences of most of the participants. Keeping the diary enabled 
me to keep these pictures fresh in my mind. 
Following families’ lives 
The methodology of ‘following’ families was operationalised in various ways. After 
the first in-depth interview, I always kept the option open to return for a follow-up 
talk. I kept in touch with all families, with more than half of the family members 
involved; sometimes even for years. Family members who took the lead in the genet-
ic testing or were actively involved in testing during the interview period, particularly 
those who had struggled with the decision to undertake testing or were waiting for 
the result, were interviewed once or twice more. Ten of these follow-up interviews 
were conducted in person, the rest by telephone. In addition, I had email conversa-
tions with three people, and, finally, I visited one participant in hospital.  
 The additional contacts enabled me to follow the processes the families were 
undergoing: how decisions to undergo testing or not were reached, how the family 
members reflected on these afterwards and how good as well as bad test results 
were perceived. It took time to follow these processes, as individual family members 
were typically tested one after the other. I also noted how events like pregnancy, 
birth, illness and death were experienced. Such events served as interesting oppor-
tunities for additional conversations. Particularly in families that had been involved in 
genetics for some time – such as the Silverman and the Lewis families, whom I met 
seven and four years after they had begun testing, respectively – I was alert to these 
events as they kept the issue of genetic testing in some sense topical. To follow the 
events in the families over time, I allowed some time to pass between interviews with 
individual family members.  
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In addition to interviewing family members, I read the letters they had received from 
the clinical genetic centres. These gave insight into how they had been informed of 
the risk of sudden death and advised them to be careful when playing sports. During 
the interview, I asked them to look back on that information. I also accompanied two 
Goldfield family members to a counselling session. This provided insight into how 
these family members dealt with and reacted to the exploration of their family 
history and the information given by the clinical geneticist.  
Exploring families’ lives 
During the first contacts with all participants I adopted as open-minded an attitude 
as possible, relegating to the back of my mind the things I had already heard from 
others in the family or from the professionals who had recruited the families. I made 
clear to the participants that I would not reveal any information other family mem-
bers had entrusted to me. Occasionally, participants showed interest in the views of a 
relative, at which point I explained that I was not the appropriate person to provide 
them with that information. To form an idea of how the participants lived with 
genetic risks and genetic testing possibilities, I started the interviews by inviting 
them to talk about their everyday experiences with the familial disease in a broad 
sense: how did they learn the disease ran in their family and how did they get in-
volved in genetic testing? Above all, I enabled them to talk in depth about the specif-
ic experiences and circumstances of their lives, and tried to get a grip on unexpected 
and less visible things happening in their lives. Emerging issues were then explored 
further in subsequent interviews. During each interview, I asked the participants to 
give concrete examples of events and to elaborate on them. For instance, they might 
describe how they had told their brothers or sisters the news about the gene, how 
they had acted at times when they had felt unwell and worried about their heart, or 
how they had prepared for the test result. In line with this, they often described 
events that had happened to others in the family. These stories not only gave insight 
into the events as such, but also revealed a lot about the circumstances the family 
members lived in and how they had experienced the situation. Sometimes emotional 
memories came to the fore. When I met spouses I asked them, among other things, 
what it was like being married into an HCM family.  
 The narrative character of the study implied that the main focus of the inter-
views varied depending on the situation. A number of topics, however, were dis-
cussed in all interviews in some way. To ensure that I presented these topics to all 
family members, I used semi-structured topic lists. I explored themes such as the 
family’s general and medical history and traditions, family care, the communication 
of test decisions and results as well as concerns and conflicts regarding the disease 
and genetic testing, and their contact with professionals. Furthermore, I addressed 
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issues surrounding living with children ‘at risk’, such as parental choices with respect 
to testing children, ideas about having children and upbringing. I particularly paid 
attention to how the decision whether to undergo genetic testing was dealt with, 
and asked them to recall their considerations about testing over time, and to elabo-
rate on the way family members dealt with it and how this affected them. I also asked 
with whom they discussed the family disease and the issue of testing. Finally, I asked 
them to elaborate on how they perceived their future lives.  
 All interviews lasted from one to two hours, and all (both in-person and tele-
phone interviews) were tape-recorded and fully transcribed verbatim. Quotes, edited 
for readability and anonymised, are given in the empirical chapters of this thesis. 
Performing the analysis 
During the research, empirical work and further study on the topics of genetics, 
kinship and family life went hand in hand. This ongoing research process meant that I 
did not analyse the empirical data by way of preconceived categories. In the course 
of time, I derived suitable theoretical concepts and new analytical points of depar-
ture from other studies and public debates on the subject. This led to the identifica-
tion of four major topics, which are analysed in the next four chapters. During the 
analysis process, after reading and re-reading the transcripts, I organised interview 
fragments according to the different topics. The two supervisors reviewed my initial 
coding, and assisted in refining the fragments and in developing new concepts in 
order to search for the patterns of meaning in the narratives. As the interview frag-
ments were new to them, their interpretations helped me to achieve more distance 
from the family members’ stories and to deepen the analysis. 
 Each of the four empirical chapters are based on specific concepts. For the first 
one – that is, chapter two in this book – I used concepts such as patterns of family life 
and care, the construction of risk and uncertainty, and the experience of health and 
disease in the family. The following chapter revolves around concepts related to 
raising children, such as parental responsibility and parental concerns, and the 
interests of children. For chapter four I started from the notion of discrimination. 
Although fear of genetic discrimination was not a specific theme during the inter-
views, it was striking to note that when participants talked about undergoing a 
genetic test, fear of discrimination with respect to insurance and employment often 
came to the fore. Finally, the point of departure for chapter five was the concept of 
autonomous decision making and the perception of future life and future risks. 
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1.6 Outline of the thesis: families narrating shared genes  
After this introductory chapter, chapter two continues with the topic of genetic 
testing as a family matter. It starts from the question how families actually live with 
genetics in their everyday lives. Another important issue raised is how families deal 
with the health and the at-risk status of their children. Subsequently, chapter three 
explores whether children profit from being genetically tested and whether parents 
are aided in parenting by learning about their children’s genetic make-up. By study-
ing the participants’ stories of testing sick and at-risk children, the notion of chil-
dren’s ‘best interest’, a basic concept in clinical genetic counselling, is questioned. 
Another important topic that came to the fore concerns the families’ fears of genetic 
discrimination. Chapter four therefore addresses the fear of non-insurability or high 
premiums and genetic discrimination by employers. Chapter five considers the 
notion of genetic testing forcing family members to take an active stance towards 
their future. Whereas in genetic counselling practices, the idea of anticipating the 
future is closely connected to the concept of autonomy, it can be questioned how 
this connection actually works in people’s everyday lives. In the concluding chapter, 
the main arguments are synthesised and we return to the central themes of family, 
kinship and genetics. I position my findings in the context of current debates on 
family relationships and the expectations of genetic technology. Finally, I interpret 
the way families make sense of genetic risks in their everyday lives in terms of the 
notion of ‘the good life’. 
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2.1 Introduction 
Genetic testing is a family matter. Not only do genetic tests for an individual often 
inevitably reveal the risks for family members, but conversely, family members 
sometimes have to contribute to an individual’s genetic diagnosis by giving blood 
and medical histories. This gives rise to important ethical dilemmas with respect to 
genetic information. In the medical context it is assumed that not just patients, but 
their relatives as well, have a right to know about a familial risk. This information 
might enable them to anticipate future health problems and to take preventive 
measures. For patients, however, it is not always a self-evident decision to share a 
positive genetic diagnosis with family members: some simply like to keep such 
information private. In order to find out how to deal with genetics in the context of 
the family, the American Society of Human Genetics, for example, explored ‘the 
potential for conflicts to arise within the health-care professional-patient relationship if 
the patient refuses to warn at-risk relatives about relevant genetic information’ (ASHG 
Statement, 1998, p. 474). According to this statement, professionals are only permit-
ted to directly contact family members and provide them with a patient’s infor-
mation in exceptional cases; particularly when therapeutic or preventive measures 
are available after a mutation has been identified. As a result of these restrictions, 
physicians focus on encouraging and helping their patients to inform relatives about 
a familial risk. In fact, good family communication is considered a solution to the 
ethical dilemmas of genetic information. 
 Following on from this, psychological and ethical research on communication 
about genetic risks within families has been a hot topic in the last decade (see e.g. 
Julien-Reynier et al, 2000; Hughus et al, 2002; Claes et al, 2003; Peterson et al, 2003, 
Forrest et al, 2003). From such studies we learn whether people are willing to share 
information, and what can be a barrier or a facilitator of communicating genetic risks. 
For example, these studies show that women play a central role in communicating 
with family members about genetics; that difficulties in disclosing information can be 
attributed to personal and emotional characteristics, such as family rifts, feelings of 
guilt and loss of contact after death or divorce; that the extent of a patient’s 
knowledge about the mechanisms of hereditariness plays an important role in the 
process of dissemination within the family; and that patients and relatives feel satis-
fied or dissatisfied for various reasons after the ins and outs of the familial disease 
have been disclosed. In doing so, these studies provide insights that are highly 
relevant for practitioners in improving counselling sessions. However, experiences 
with communicating genetic risks are mainly studied in retrospect and separately 
from the context of concrete family life. Moreover, the focus on disclosure of genetic 
information to and communication with family members implies that we gain little 
insight into the broader meaning of genetic risks for family relations and family life. 
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Recently, a growing number of social scientists and anthropologists have chosen a 
broader perspective for studying family life when families become involved in pro-
cesses of genetic testing. Instead of posing the question how to communicate about 
genetic risks in the family, these researchers investigate how families actually live with 
genetics in everyday life. They have shown, for example, how entering a genetic test 
trajectory generates new forms of responsibility (Hallowell, 1999), how the 
knowledge of being at risk influences the individual’s as well as family’s life (Huniche, 
2002), and how genetic knowledge transforms through social relations (Svendsen, 
2006). The anthropologist Finkler (2000) demonstrated how genetics might contrib-
ute to strengthening family ties and perhaps even alter the process of ongoing 
individualization in present-day society. Contrary to these binding effects, however, 
Sobel and Cowan (2000) reported on family life becoming burdened with tensions 
and conflicts.  
 In this article we merge these sociological and anthropological traditions to-
gether. Most studies on genetics and the family in this field have made clear that 
genetic testing has a considerable impact on family life. This might have to do with 
the fact that these studies have mainly been performed in the context of breast 
cancer or Huntington disease. Although genetic tests always bear a probabilistic 
character, the genetic tests for diagnosing or predicting these diseases are relatively 
accurate and based on a test result future scenarios can be sketched quite precisely. 
Yet for many other genetic diseases, such as several cancers, cardiovascular diseases 
and neuro-degenerative disorders like Alzheimer’s disease, the situation appears to 
be somewhat different. Tests to predict the genetic risks for these diseases are much 
more ‘in the making’. Because of the complex interplay between genes and the 
environment, as well as the involvement of many different genes, the clinical rele-
vance of mutations is hard to establish, and how to interpret a given test result 
remains uncertain. Recently, Lock (2008) put the impact of these genetic risks on 
family life into perspective. In families with Alzheimer’s patients, family members 
recognize that risk estimates based on genotyping have little practical meaning. Not 
surprisingly, in patient organizations for Alzheimer’s disease there is no drive for 
further development of genetic diagnosis. Contrary to the active mobilization of, for 
example, breast cancer patient organizations (Gibbon, 2008), Alzheimer’s patient 
societies are not overly interested in the possible genetic cause of the disease. In-
stead, they focus more on the daily care of the demented family member, with little 
hope that learning about genetic risks will improve clinical care in the near future.  
 In this article we have chosen another genetic disease to study how families deal 
with genetic risks in the making, namely familial hypertrophic cardiomyopathy (FHC). 
Contrary to Alzheimer’s disease, which often results in long-term institutional care, 
FHC is associated with sudden cardiac death in young people (Spirito and Autore, 
2006). More people have FHC than is often thought: the estimated prevalence is 1 in 
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500. Geneticists have shown that more than 200 mutations in 12 different genes play 
a role in the manifestation of the disease. Although there is increasing evidence that 
some gene mutations are associated with a severe and others with a more benign 
course of the disease, in general the relationship between genotype and phenotype 
is unclear. Even within one family, the expression of the disease can vary strongly: 
some carriers of a mutation have no complaints, while others suffer from serious 
heart failure or die after a cardiac arrest. In that sense, genetic tests for FHC are not 
definitive, but rather very much ‘in the making’. There are no means of curing or 
preventing a cardiac event, except some lifestyle changes such as refraining from 
competitive sports, regularly monitoring the heart muscle, or – still experimental 
strategies – taking certain drugs and implanting an internal cardio defibrillator.  
 After explaining the methodology in the next section, we then reconstruct how 
families pass through ‘genetic trajectories in the making’ by following the process of 
genetic testing. We will not subscribe to the argument of genetic testing as having 
either a little or a lot of influence on family life, but will rather focus on the work these 
families have to perform in dealing with genetic testing. It will become clear that, 
notwithstanding the differences in genetic trajectories and the differences in family 
styles, all families have to work to prevent genetic testing from intruding in their 
daily lives too much. 
2.2 Methodology 
We started this study from the idea that, to gain insight into the relationship be-
tween genetics and families, we should focus on processes more than on specific 
moments. Thus, in order to trace the influence of genetics on families’ everyday lives, 
we followed six families involved in genetic testing for FHC. During a period of about 
three and a half years (between 2004 and 2008), we spoke to members of at least 
two, and sometimes three, generations of these families. In total 57 people were 
interviewed in depth. The first author (EG) visited them at home and also had tele-
phone and email conversations with some; some were accompanied to the counsel-
ling session and one was visited in the hospital. In three families, genetic testing for 
FHC had started less than one year before. That enabled us to follow the entire 
process, from considering and discussing testing, to waiting on and receiving the test 
results. The other three families had been involved in genetics for a longer time 
(between two and seven years). This implied that for some family members, the issue 
of genetics had faded into the background; as a consequence, they had to look back 
on past experiences during the interviews. However, events such as pregnancy, birth, 
illness or death appeared to bring genetics to the foreground again, so that for all 
families the issue of genetic testing was in some sense topical. 
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The study was based in the southern and eastern parts of the Netherlands, but as 
some families had members spread all over the country, we visited people in other 
parts of the Netherlands as well. After approval from the local medical ethical com-
mittee, the clinical geneticist and the cardiologist who participated in the project 
group were helpful in bringing us into contact with the families. They informed some 
of their clients about our study – both in writing and orally – and asked them to 
participate. To allow for diversity in the families, the clinicians were asked to recruit 
families with the following characteristics: with and without a genetic testing result, 
few and many family members, and severe as well as mild manifestations of the 
disease. We started by interviewing one family member and, via these persons, made 
contact with relatives, such as parents, children, brothers and sisters, as well as 
nieces, nephews, aunts or uncles, and even some spouses and other in-laws. We 
allowed for some time to pass between interviews with various family members to 
enable us to follow the processes and events in the family. We did not follow families 
that refrained from genetic testing, but did include at-risk individuals who, after 
being informed about the mutation in their family, decided not to go through with 
the test. In general, the participants took part in our study without hesitation: they 
welcomed the opportunity to talk about their experiences of living with a family 
disease.  
 The interviews were semi-structured and presented comparable topics to all 
participants, but were open enough to go into depth on the specific experiences and 
circumstances of the individual families and family members. Themes such as tradi-
tions, caring, responsibility, communicating concerns and conflicts were discussed, 
but participants were also encouraged to talk about their everyday experiences with 
the familial disease in a broad sense. Emerging themes were then explored further in 
subsequent interviews. The interviews lasted from one to two hours and were tape-
recorded and transcribed verbatim. We analysed the narratives by identifying inter-
esting theoretical concepts in other studies on genetics and families, such as patterns 
of family life and care, construction of risk and uncertainty, experience of health and 
disease in the family, and perception of future life and future risks. The first author 
then identified the themes related to these concepts after reading and re-reading the 
transcripts. The two other authors independently reviewed the first coding, and 
assisted in refining the themes and developing new themes in order to search for the 
patterns in meaning in the narratives. We searched for similarities and differences at 
the individual level as well as at the level of the families. To demonstrate the results 
of this analysis, we will start by exploring how the families became involved in genet-
ic testing for FHC and how this process contributed to the awareness of a familial 
disease. We make use of pseudonyms in the description of our results. 
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2.3 Becoming aware of a familial disease  
From our study it emerged that there is no standardized trajectory for families to 
become involved in genetic testing. Finkler (2000) and Boenink (2008) showed that in 
‘breast cancer families’ it is common practice for healthy women to take the initiative 
for genetic testing because of their worries about a familial risk. In the FHC families, 
family members who already had complaints and were receiving regular care dealt 
with genetic testing first, mostly through being advised to do so by the cardiologist. 
However, this offer of genetic testing by a professional does not tell us how these 
patients and family members first became aware of the possibility of a familial dis-
ease. Comparable to Huniche’s (2002) distinction in her study on Huntington fami-
lies, we found three different patterns of ‘becoming aware’. In the first pattern, family 
members interpreted their own or their relatives’ heart complaints as familial long 
before genetic testing became an issue. 
We knew that it was in the family. (Christine Silverman) 
When her sister died they didn’t think about it, but when after a year her twin 
brother suddenly died of heart problems as well, it became a serious matter. At 
that time, in the eighties, all of them were invited to do a cardiac ultrasound [a 
technique for diagnosing thickness of the myocardium]. (Christine’s husband)  
In 1987 a cousin gave birth to a boy, but the little boy only lived for half a year. 
It turned out that he had thickness of the myocardium. Then my cousin was ex-
amined; she had this thickness as well and the same was the case with her 
mother, who is my aunt. That made us start thinking that this might be a famil-
ial thing. (Emily Goldfield) 
Eighteen years ago, when I was fifteen, I had a cardiac arrest; my father had the 
same when he was thirty-three. When I was in the hospital examinations were 
done and they told us that it was genetic. My brother turned out to have the 
same disease. (Nick Redford) 
In these families, disease and early death had been important ingredients of the 
family history for quite some time. This implies that the suggestion to do a genetic 
test – or in the Silverman family, linkage analysis – came as no great surprise. On the 
contrary, in two of these families, family members explained how the idea of a famili-
al disease had already been shaped in the processes of consultations with the cardi-
ologist. Emily Goldfield explained how Dr Newbury, the cardiologist of many of her 
relatives, always showed special interest in her family and kept close track of the 
developments of disease in the family. She had felt more or less prepared for the 
suggestion of genetic testing. 
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Several times Dr Newbury talked to me – and also with others in the family – 
about scientific research on genes. (…) So, when he asked me about genetic 
testing, I thought, why not? He’d like to have the information about all of us, to 
map our family. (Emily Goldfield) 
In contrast to this family, where it seemed that the cardiologist was eager to find out 
more about the genetic ‘origin’ of the disease, in the Redford family it was the family 
members themselves who had been looking forward to the possibility of DNA diag-
nostics for years. The family presented itself as having a highly positive stance to-
wards scientific research and technological progress, wanting ‘to know everything 
there is to know’. The issue of genetic testing had repeatedly been discussed openly.  
We [Nick, his brother and his father] always visited the doctors together and we 
regularly talked about the genetic character of the disease. We’d always ex-
pressed the desire that when the doctors had new scientific information, we al-
so wanted to be informed. So when the cardiologist asked us one day ‘Would 
you like to know whether your children may become ill as well?’, I reacted abso-
lutely positively. (…) I believe that insight into our genetic constitution is a step 
towards better health. (Nick Redford) 
 The second pattern of becoming aware of a familial disease came to the fore in 
the Lewis and the Anderson families. Here, the heart complaints of some family 
members were seen in the light of familial risk only after the option of a genetic test 
had been suggested. In the Lewis family, the sisters Marian and Tracey had always 
considered their struggles with their hearts and the early death of their brother as 
separate incidents: they had never thought of themselves as being part of a family 
with a genetic defect. As Marian said: 
Actually I never thought about my brother’s disease. My brother died of a car-
diac arrest when he was 53. I already had some heart complaints, but you al-
ways think it has to do with the age. (Marian Lewis) 
Her sister Tracey remembered how the family, years earlier, had even explicitly 
refused to consider the option of her brother’s heart complaints as having a familial 
character: 
My brother John suffered from heart problems from his twenties. He wanted to 
do missionary work in Africa, but after a medical check-up he was deterred 
from going. From then he had to undergo cardiac checkups regularly. Once his 
doctor asked about the health of his brothers and sisters and suggested that all 
of us come for such a check-up. At that time, we didn’t think it made much 
sense. (…) Even when my brother died, we didn’t consider it. It was only years 
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later, when we were visiting that doctor, that I reflected back on my brother 
and what had happened with his heart. (Tracey Lewis) 
Only after these two sisters had discussed the disease history with the physician did 
the pieces of the puzzle seem to fall together. Until then, there had only been vague 
suspicions, but the offer of the genetic test prompted them to redefine their heart 
complaints as symptoms of a shared family disease.  
 The Anderson family retrospectively said that there had been signals pointing in 
the direction of a familial disease for years. However, they only realized this after 
physicians presented the evidence of familial risks to them. Two young men – aged 
20 and 21 – went into the hospital with heart complaints in the same week: the 
youngest one, Dave, with a sudden cardiac arrest; and some days later the other, 
Christian, with heart complaints. Both were diagnosed with thickness of the myocar-
dium, and to the physicians it was beyond doubt that both brothers were suffering 
from FHC. This made their parents, Sarah and Peter, think back again on a remark 
that Dave had made some time before. 
Once Dave showed me how fast his heart was beating, but at the time I 
thought: ‘He’s been in a hurry, that’s normal’. (…) And one time when we dis-
cussed the heart complaints of Peter’s sister, he said ‘That’s what I have’. I an-
swered that he could also have my constitution. (Sarah Anderson) 
The offer of the genetic test had surprised the Anderson family. However, they 
emphasized that the idea of a familial risk was nothing compared to the shock of 
Dave’s cardiac arrest. When we interviewed the family again one year later, however, 
a genetic mutation had not been found. Sarah and Peter were not overly interested 
in that, because the boys’ actual disease kept them busy. 
We were screened as well, but nothing could be found. ‘It must be genetic’, they 
said, but that’s not the main issue for us. If it is genetic and comes from our side, 
well, okay. But, what concerns us most is that the doctors can’t tell us whether 
the myocardial thickness is still growing. (Sarah Anderson) 
 Finally, in one family the idea of a familial risk came completely out of the blue. 
The Greens had not experienced any signs of disease in the family before Karen – a 
14-year-old girl – was offered a genetic test.  
She’s had myocardial thickness since she was a little girl, but suddenly, a year 
ago, her heart problems got worse. The cardiologist was worried about that 
and referred us to a clinical geneticist. He asked whether there were heart prob-
lems in the family; but no. (Carl Green) 
We’d never thought about that. (Linda Green) 
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As there was no history of disease in the family, the information about the gene was 
indeed shocking news. The emotions that were stirred up during the interview, with 
Karen and her parents sitting at the kitchen table recalling the days when they 
received the test result, demonstrated that this shock was still felt in the family. 
 In sum, only one of the families in our study really became aware that FHC was 
running in the family through the suggestion to do a genetic test. The other five 
families already had some sense of ‘something’ running in the family. While three 
families had already considered themselves rather explicitly as a family with some 
sort of familial defect for many years, in the other two families, the offer of genetic 
testing – although not a complete surprise – prompted them to redefine their family 
history. Thus, in most of the families we studied, the issue of genetic testing had 
already been pre-shaped by the family members’ experiences of disease.  
2.4 Making it known in the family 
The different ways in which the families came to realize that a disease was running in 
their family were related to the ways these families had previously dealt with disease 
and other facts of life. Informing other family members about the genetic risk also 
brought the characteristic traits of the families to the fore; in other words, the fami-
lies dealt with the disclosure of genetic risk in a way that ‘suited’ their family. Over 
the years, families develop a specific style of sharing the ‘things in life’. While some 
families in our study talked about the genetic test in a more formal or businesslike 
way, other families shared the experiences and the results of testing in a more infor-
mal way. 
 In the Redford family, for example, we noticed a relatively formal manner of 
disclosure. Nick, his brother Duncan and his father Marc had always shared every-
thing to do with the disease intensively. Marc’s brothers, however, were more dis-
tant, and for him, informing them felt more or less like a formal duty. He simply gave 
them the news by phone, and that was the end of the matter. Marc and his wife Jane 
explained that, although it had never been verified by DNA testing, it was an ‘open 
secret’ that Marc’s father was not his biological father. It was therefore assumed that 
the information about Marc’s genetic risk did not have such important consequences 
for his brothers.  
Back then, I told them about the test, but they weren’t that interested. So, it was 
my thing. (Marc Redford) 
Marc has never been a family man. (…) But what we think is that they’re half-
brothers. (Jane Redford) 
We think that my father is not my real father. My biological father is somebody 
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else, my Uncle J; he married my mother’s sister. (Marc Redford) 
Marc doesn’t look like his brothers. (Jane Redford) 
No, I’m totally different. (…) But he [Uncle J] died because of his heart. (Marc 
Redford)  
A son of his also died because of his heart, and another one suffers from heart 
complaints. (Jane Redford) 
 Family members in the Green family were also informed in a more or less formal 
way. Further genetic research had shown that the gene came from the mother’s side, 
and thus concerned her parents and brothers. Carl and Linda sketched the family as 
close-knit, but the times at which they came together, particularly when playing 
sports, were not suited to discussing such issues. Moreover, Linda articulated that in 
her family people were not used to talking about such sensitive matters. However, 
Carl portrayed his family as direct and open, and said that he was more used to 
talking about ‘difficult’ subjects. Therefore, he found it easier to talk about the famili-
al risk, and he took the initiative to inform his in-laws about Karen’s situation.  
We informed her [Linda’s] brothers about everything; we were quite frank 
about it. We invited all of them together – her brothers as well as some of the 
sisters-in-law – and we made a copy of all the information and all the letters we 
got. (…) Imagine if one of them were to drop dead. It’s quite a dangerous gene 
and if we had kept quiet and something were to happen… Now it’s up to them. 
I performed the duty that I needed to do as a family member. (Carl Green) 
 Similar to this straightforward way of announcing the news, in the Goldfield 
family Emily composed a letter to circulate throughout the family. 
Dr Newbury asked me to arrange this and so I made copies and sent it to a 
number of family members. I explained the situation and asked them to spread 
it. (…) I told them that if they’d like to know more, I could help them. To some I 
just sent the letter, but with most of them I got in touch personally as well. (Emi-
ly Goldfield) 
Emily used the family letter to prevent anyone from missing out on the information, 
but with several family members she also discussed the issue personally and more 
informally. Although the reason for contacting her relatives was not a pleasant one, 
she described how it provided her with the opportunity to get in touch with relatives 
again. 
We get on very well together, but everybody has their own life. It was nice to 
meet each other once again and catch up with some things. (…) I got in touch 
with Ted, the son of Uncle George, and with his sister. I called her. (…) I later 
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heard they’ll both go for the test. He’s a trucker and from my mother I under-
stood that he has severe complaints. Some years ago Uncle George died, but it’s 
not sure whether he died because of his heart. We never had a lot of contact 
with him. My uncle and aunt were divorced and he [Uncle George] was the 
black sheep of the family. (Emily Goldfield) 
Doing this kind of ‘family work’ seemed to be quite Emily’s thing. In the first instance, 
she saw meeting Dr Newbury’s request as a responsibility, both towards him and 
towards her family. At the same time, she found that arranging family matters was 
something she genuinely enjoyed, just as her father had. She was visibly happy when 
explaining how her father was always organizing activities for the whole family 
before he died, such as annual parties, football games and bowling evenings to keep 
the family together. Emily described being brought up in a family with a culture of 
looking after one another and sticking together. Even though not all ties with family 
members were particularly strong and she had lost contact with some, this sense of 
family life enabled her to re-establish family contacts easily. 
 In contrast to Emily, few of her family members felt the need to pass on the 
news immediately to their children, brothers or sisters. Rather, copies of Emily’s letter 
were passed on during an incidental visit, for instance, and the issue was discussed 
between family members taking a walk together or during an unplanned phone call 
or a family dinner. The fact that these kinds of contacts were part of family life made 
it possible to bring up the issue of the genetic test when they thought it appropriate. 
One did not consider it necessary to hurry, in the knowledge that the ‘right moment’ 
would definitely come. 
 These more informal ways of informing family members about the genetic risk 
were characteristic of the Lewis and Anderson families as well. Often it was in the 
context of talking about someone’s concrete health complaints or a visit to the 
doctor that the issue of genetic testing was raised again.  
They call us regularly to ask after the boys’ health. (Sarah Anderson)  
We have good contacts with everyone in the family. And you run into each oth-
er while shopping and then they ask how things are, and we talk about the 
boys and about the test. They’re curious about the genetic test result as well. 
(Peter Anderson) 
 So far it is clear that discussing a familial risk resonated with the way these 
families handled other things in life. Strategies varying from explicitly disclosing 
genetic information to ‘waiting for the right moment’ can all be seen as expressions 
of the existing patterns of family life. At the same time, we were able to trace differ-
ences within families dealing with familial risk. The development of specific family 
styles of approach did not mean that individual family members could not think 
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differently about genetic tests. The Lewis family is a good illustration of this. Besides 
the sisters Marian and Tracey, we interviewed their other sister Barbara and their 
brother Joe, and we talked to both Marian’s and Tracey’s daughters. It appeared to 
have been Tracey who gave the news to Barbara and Joe. Tracey presented herself as 
a pivotal person in family matters. She explained how her home had become a family 
meeting place when, after the death of her mother, her father had come to live there 
for several years. After his death, she continued to organize family contacts with her 
brother and sisters, varying from a once-a-week dinner with her sister Marian to 
participating in a hiking group with her brother Joe and going on holiday with her 
sister Barbara. Taking this into consideration, it was not surprising that she took the 
lead in telling Barbara and Joe that her complaints had been identified as familial 
risks. Marian and Tracey both shared this news with their children immediately. That 
was only logical, they said, because their children had closely followed the process of 
doctor’s consultations and knew about the cardiologist’s advice to do the test. Yet, 
Tracey expressed a degree of unease. 
I didn’t want to burden them. It’s not the kind of information you want to hear 
and actually you can’t do anything to prevent the disease. They knew about me 
and at first they wanted to go for a genetic test as well, but I wondered what 
good it would do to them. Living with the knowledge that you could get that 
disease is not a nice prospect. (Tracey Lewis) 
Marian, in contrast, had no such doubts. 
My daughter doesn’t have complaints either, but I’m glad that she went for a 
cardiac examination. (Marian Lewis) 
 In the families we followed, family life was not completely disrupted or thrown 
out of balance when participants started informing other family members about 
their genetic test results. Every family included members who had greater or lesser 
difficulties discussing the issue of genetic testing, as well as members who did not 
articulate feeling uneasy about it. However, the way in which the families dealt with 
genetic testing was connected more to established forms of conduct in families than 
to the specific character of genetic tests. Families who struggled with talking about 
genetics also struggled to discuss other sensitive issues in the family. Whether they 
informed other family members formally or informally, in a businesslike or emotional 
way, depended on the family’s usual style and the nature of family life and family 
contacts. Thus, family life and its established patterns were not overly affected by the 
process of genetic testing. Next, we will examine whether this was still the case after 
the news about genetics had ‘filtered’ through the whole family. How did the families 
live with it over time? 
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2.5 Experiencing a familial disease in family life 
It appeared that, as time passed, genetics became less important than during the 
testing process, and that family relations were hardly affected by genetics as such. 
However, a lot of ‘family work’ had to be done to allow this happen.  
 Directly after the families in our study became involved in the process of genetic 
testing, family members reported more frequent family contacts. As discussed earlier, 
they informed others about the genetic test and about the risk of FHC, and discussed 
which distant relatives should be informed as well. They talked about what the best 
thing to do was, and showed interest when a family member was waiting for or had 
received a test result. However, after a while, the issue of genetic testing became 
more of a background theme. Peter and Sarah, for instance, told us about the initial 
stress related to the struggle of their oldest son Christian to find a way to deal with 
the consequences of the disease. At the beginning he seemed to be completely 
preoccupied by it: 
Christian used to be very pessimistic. He said: ‘I can’t find work, they won’t give 
me a job, and I have to leave this and leave that’. He couldn’t accept the ICD [In-
ternal Cardio Defibrillator]. (…) After he came out of the hospital he started 
drinking alcohol and using soft drugs. (…) He was in a very bad mood and once 
smashed everything here into pieces. (Peter Anderson) 
One year later, when we interviewed the Anderson family again, some peace had 
returned. It appeared that Christian had been able to pick up the thread of his life 
again. 
 In two other families, the Lewis and the Goldfield families, the family members 
had also put the seriousness of FHC, as well as its risks, into perspective. Firstly, 
regardless of the results of genetic testing, other things in family life – such as going 
on holiday, having an operation in the pipeline, suffering from other diseases or 
raising children – gradually became more important again. 
We’ve never allowed the issue of genetic testing to dominate our lives. When it 
was going on, we talked about it, but after that everybody picked up the 
thread. (…) Last month we had a family weekend and it wasn’t discussed at all. 
(Tracey Lewis’s daughter) 
Secondly, people in these families, whether ill or not, referred to the mild expression 
of FHC in most family members concerned, and the high ages of onset in several 
others.  
I’m not concerned about that. My mother has the disease, but everything goes 
on. So the gene doesn’t have much impact. (Mary Goldfield) 
C H A P T E R  2  
 48 
Thirdly, some emphasized that life was full of unforeseen events and having a heart 
complaint was nothing unusual.  
Nowadays so many people have a heart disease. (Emily Goldfield) 
Lastly, some healthy interviewees explained that they considered it quite possible 
that they were not genetically affected. 
Only by chance would all five of us have the gene. (Barbara Lewis) 
Despite the fact that many members of these families lessened the importance of the 
risks of FHC in everyday life, family events like pregnancy, childbirth, the worsening 
of complaints or even the death of a family member did raise the issue of the familial 
risk again.  
 In other families, however, genetics remained a more recurring theme to be 
discussed among family members. In the Redford family, for example, the topic 
continued to be important, not only because of the testing of young children, but 
also because this family made every effort to contribute to genetic research on FHC. 
Even after several years, Jane tried to involve a family member in the testing process 
for the sake of research. In the other two families, the Greens and the Silvermans, it 
was the seriousness of the actual disease more than the familial character of the risks 
that kept genetics on the agenda. Carl Green indicated that living with his daughter’s 
diagnosis of FHC was a hard task because it had revealed the risk of her sudden 
death.  
Since the test I’m more anxious. Each day I think about it and when I’m at work I 
always have my mobile with me. I check it several times a day to see whether 
they’ve called me. Yeah, all kinds of things could happen. I have three kids at 
home; but yes, it’s the apple of your eye, your daughter. (Carl Green) 
In the Silverman family, the seriousness of the disease had cast a shadow over the 
lives of the family members as well. Nora was particularly concerned about the risks 
for her children and grandchildren.  
I asked my cardiologist, ‘Can my children have another ultrasound?’ more than 
once. He didn’t consider it necessary. I’d like them to have an ultrasound, for in-
stance two times a year, to be sure about the current condition of their hearts. 
(Nora Silverman) 
Although anxious about the future, in everyday life Nora was much more engaged 
with the disease itself than with the familial risk. She indicated that the palpitations, 
the fact that her husband often trivialized her complaints and the serious worsening 
of her sister’s disease demanded a lot of energy. 
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The way the families integrated genetics into their lives demonstrates that while in 
some families genetics did not stay high on the agenda, in others it remained more 
important. However, in no family did the process of genetic testing and the detection 
of a familial risk affect family relations to a great extent. This was the case even in the 
Green family, where the news about the genetic diagnosis had come as a shock. 
When we talked to Carl and Linda, they told us that they felt disappointed by the 
indifference of family members after Karen’s diagnosis, but they also stressed that 
the family remained on good terms. 
We told her [Linda’s] brothers as well as her parents, but they weren’t very in-
terested. (…) In her family ties are very close. They often see each other. (Carl 
Green) 
Yes, at sport – we play korfball together – or the carnival society; it’s just a big 
group. I don’t think they understand the problem; it is rather difficult. Karen’s a 
heart patient, but she’s also very much alive; there’s nothing to see. (Linda 
Green) 
Linda would have liked to share her sorrows about Karen with her brothers and her 
parents, but, as she told us, it was not her nature to ventilate expectations towards 
her family. She would not run the risk of entering into battle. Playing sports together 
was still worth a lot. In a similar way, the Silverman family did not connect a family 
conflict to the issue of genetic testing. As long as Susan could remember, family life 
had been organized around disease, and because her complaints were the least 
serious, she did not feel that she was taken seriously by her brothers and sisters. As a 
consequence, she felt that she had become isolated from the rest of her family. In the 
interviews we had with her brother and two of her sisters, they emphasized that 
‘Susan has always been the outsider’; thus, also not acknowledging the familial 
character of the disease. When we talked to Susan a second time, she had recon-
structed the family history and now stated that the family relations had already 
worsened long before her brothers and sisters developed heart complaints. 
My father died when I was just eleven. Then my brother became the head of the 
family. I didn’t get along well with my sister-in-law. My mother always took 
sides with the strongest. We were no real family. (Susan Silverman) 
The story of the Silvermans illustrates that family members may ascribe family con-
flicts to different causes, but they clearly do not point to genetic testing as such as 
causing a major family rift. 
 The analysis of the stories of the FHC families has shown that genetics is less 
important for family life than is usually thought. Although the process of genetic 
testing can be disturbing, in everyday life families also have other – and sometimes 
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more important – things to deal with, and thus put genetic risks into perspective. 
Before these families started the process of genetic testing, disease had already 
played a role in kinship relations and the genetic test results did not change those 
relations. The patterns of family life – the emotional ties, the habits and rituals – did 
not alter through the involvement in genetic testing or the diagnosis as a family with 
a genetic disease. As demonstrated by Horstman and Smand (2008) in their analysis 
of families involved in genetic screening for familial hypercholesterolemia, the 
families in our study continued family life as they had before being diagnosed as ‘an 
FHC family’. 
2.6 Working to continue family life in the here and now 
The analysis shows that, although the results of genetic testing may have implica-
tions for the future, FHC families primarily live in the ‘here and now’. To some extent 
this might be related to the status of the test as a test ‘in the making’. However, it was 
only in some families that the tentative prediction of the risk of FHC was considered a 
reason for the lack of interest in possible future scenarios. In families that did show 
concerns for the future, these concerns were far less pressing than the worries about 
the present. After genetic testing, family life went on as usual: family members who 
used to go on holiday together, play sport, go to festivals or provide care in the case 
of operations continued to do so after becoming aware of the family risk. The Dutch 
philosopher Huijer (2005) has argued that people with a genetic risk might be con-
cerned about this risk, but in fact there is little ‘future in the present’.  
 In line with this, the analysis above shows that living with FHC primarily means 
living with the disease, instead of living with risk. In many respects the experiences of 
these families resemble the experiences of families living with chronic disease. 
Öhman and Söderberg (2004), for instance, described how people who live close to 
chronically ill people might be concerned about the future. But through living day by 
day and caring for the sick family members, life was made easier to live. This was not 
a state of denial or ‘head in the sand’ approach, but rather working hard to take life as 
it comes. In the same vein, Gregory (2005) studied how family members manage 
meal-related activities in order to deal with chronic, diet-related illness. She showed 
how family members did a lot of work to prevent family relations from becoming 
strained: special diets tended to be assimilated into family practices in such a way 
that family life was continued. Similar to families in which members suffer from 
chronic disease, the FHC families we studied continued living in the here and now, 
and were not preoccupied by the process of genetic testing.  
 The analysis also demonstrates that family life did not undergo major transfor-
mations after the testing for FHC. These families neither reported family ruptures or 
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conflicts, nor an increase in feelings of solidarity between relatives. This does not 
imply that processes of genetic testing do not affect families, but rather that genetic 
testing as such should not be ascribed too much power in shaping family life and 
family relations. Our analysis makes clear that families have to work to integrate news 
about a genetic risk into already established family relations, whether they are more 
or less close. They have to balance and deliberate the issue in order to get insight and 
come to terms with it. In the FHC families, ‘becoming aware’, ‘making known’ and 
‘experiencing’ genetics turned out to stay in line with established patterns of family 
life. In other words, the way in which they ‘do genetics’ can be understood in the 
context of the styles of family life that have already developed. These patterns, which 
had been formed long before genetic testing was introduced, created a framework 
for dealing with genetics in such a way that genetics was not as important as often 
assumed. 
 As we argued in the introduction, clinical geneticists and ethicists often pointed 
to the importance of ‘good communication’ in families to deal with the potential 
conflicts with respect to genetic information. Our analysis not only puts into perspec-
tive the raised potential for family conflict caused by genetic testing, but also makes 
clear that there are different family patterns that make genetics less important. This 
implies that we should be careful about assuming that there is a single norm for 
‘good communication’ and that families need help to live up to that norm. Instead, it 
is important to acknowledge and value the plurality of family life. Introducing new 
norms for ‘good family communication’ that do not fit with the established patterns 
in everyday family life might in fact provoke more rifts and conflicts than genetic 
information as such might bring about.  
 In reviewing our conclusions, the question might arise as to how specific our 
population is. The families we studied were quite varied in terms of size, socioeco-
nomic status and profession. As we did not study an extreme population, we assume 
that these families can be seen as representative for how FHC families experience 
genetic testing. It is more difficult, however, to determine whether our case is a 
specific Dutch case. Several authors have pointed to the national styles in dealing 
with health and health risks and the influence of cultural values on the practice of 
genetic testing (Aarden, Van Hoyweghen, Horstman & Vos, 2009; Jasanoff, 2005; 
Parthasarathy, 2005; Daemmrich & Krücken, 2000). The tendency to control health 
risks and trust in technology is often considered as typically American and as con-
trasting sharply with the ‘down-to-earthness’ in several West-European countries. 
These differences might have an effect on the way individuals as well as families 
experience technology. In the literature on prenatal testing, there are indications that 
while American women defer their pregnancy until they get good amniocentesis 
results (Rothman, 1986), Dutch women do not just rely on test results but rather 
express confidence in ‘nature’, or in feeling the movements of the foetus (Geelen, 
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Horstman & Drenthe-Schonk, 1999). With respect to family lives, in this issue several 
authors point to the fact that different values are constructed in different contexts. 
Boenink (2011), for instance, in her study on BRCA testing, shows that whereas in the 
Netherlands people are expected to have a type of relationship with their relatives 
that facilitates the request for their cooperation, Americans do not request help from 
their relatives quite as easily. The power attributed to genetic technology, as well as 
the implicit moralities in family life, may differ in different countries, and this implies 
that the work that families have to perform to live with genetic testing is different as 
well. 
 Finally, as regards the significance of this study for other diseases: particularly 
with respect to the case of Huntington disease, several authors have reported that 
genetics has a great impact on lives in the family, and at first glance this might 
contrast with the ‘normality’ of the processes of genetic testing in our FHC families. 
Unlike Sobel and Cowan (2000), we did not find changes in family relationships – like 
loss of family membership, role changes and problems in communication – after 
genetic testing had started. Nor did our families identify tensions relating to secrets 
or lies about genetic test results, as Konrad (2005) found in her study. It is generally 
assumed that the family dynamic in Huntington families is altogether different from 
that in non-Huntington families (Meer van der et al, 2006). This is because the charac-
teristics of the disease – particularly the personality changes and the progressive 
cognitive impairment – imply that living in a family with Huntington disease draws 
heavily on the energy and resilience of family members. Compared to the FHC 
families, in which some people saw the disease as just one of the many cardiovascu-
lar diseases one might suffer from, in Huntington families it does not appear to be as 
easy to put the disease and its risk into perspective (‘let’s not worry about it until the 
time comes’). However, while it is conceivable that being tested for Huntington – 
whether the results are negative or positive – influences the identity of the individual 
family members and thus also affects their relations with others in the family, it is 
questionable whether changes in family relationships can be ascribed to the testing 
as such. Horstman and Smand (2008) have argued that dealing with DNA diagnostics 
may be characterized as relating more or less to common family traits, and in a 
similar way Sobel and Cowan have concluded that families carry their patterns into 
the arena of the disease and the testing process. Also in Boenink’s (2008) study, the 
work that women in breast cancer families have to do to get a genetic diagnosis 
depends on already established relationships between family members. Although 
diseases and traditions or cultural values in dealing with genetics might differ, it is 
clear that families are no tabula rasa when genetics enters the picture.  
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3.1 Introduction 
Since the introduction of DNA diagnostic tests in the 1980s, the issue of genetic 
testing of children has raised many concerns (Bloch and Hayden, 1990). It was long 
argued that the testing of children should be postponed until they were able to give 
their own consent at the age of 18 (or 16 in some countries) (Clinical Genetics Socie-
ty, 1994). Only when concrete preventive or therapeutic measures were available was 
testing of younger children considered a serious option. Although in the clinical 
genetic setting this is often still considered ‘good practice’ (Parker, 2009), in new 
professional guidelines genetic testing of children tends to be framed in terms of ‘the 
best interests of the child’ (Borry et al, 2006; 2008). An autonomous choice might be 
considered as being in one’s best interest, but this is not necessarily the case. The 
notion of a child’s best interest allows more room for testing at a younger age and 
testing for psychological and social reasons. However, it also raises the question 
whether parents and professionals can weigh the child’s interest in practice. How can 
they make space for the child’s own perspective, and, considering the importance of 
the therapeutic perspective, will parental ideas and wishes not be overshadowed by 
the perspective of professionals? Moreover, while the early discussion about genetic 
testing of children mainly addressed predictive tests for a monogenic disorder such 
as Huntington disease, providing a clear yes/no test result, many newly developed 
tests only provide risk estimates, which further complicates the balancing of pros and 
cons. This raises the question how the uncertain and tentative character of these test 
results might affect the meaning of ‘the child’s best interest’. Here, we explore how 
families with hypertrophic cardiomyopathy (HCM) deal with this issue.  
 HCM is increasingly understood as a genetic disease (Hershberger et al, 2009) 
with an estimated prevalence 1 in 500, considered the most common genetic cardio-
vascular disease (Maron et al, 2006). Characterized by increased thickness of the 
myocardium, HCM is particularly associated with sudden cardiac death in young 
people (especially athletes), but it is also seen as an important cause of heart failure 
at a later age. Although almost 100 mutations in at least 12 genes play a pathogenic 
role, not all HCM genes have yet been identified, and tests for all identified genes are 
not yet available. This implies that testing still does not guarantee a conclusive result; 
in about 40 percent of the families with HCM who undergo testing procedures, no 
mutation will be found. In addition, the correlation between genotype and pheno-
type is generally unclear. Even within one family the expression of the disease can 
vary strongly; some carriers of a mutation have no complaints, while others suffer 
from serious heart failure or die after a cardiac arrest. This heterogeneity in the 
clinical presentation of the disease highlights the difficulty of determining the clinical 
and social relevance of a test result. As HCM usually follows an autosomal dominant 
inheritance pattern, the children of a parent who carries the mutation have a 50 
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percent chance of being a carrier, although the meaning of being ‘at risk’ or even 
‘affected’ is uncertain. Currently there is no cure for HCM, but following lifestyle 
advice (such as refraining from competitive sports), echocardiographic monitoring, 
implanting a cardioverter defibrillator (ICD), or taking certain medications may help 
to prevent a cardiac event. 
 Current medical guidelines recommend regular clinical screening of children at 
risk of the disease, but it is emphasized that after a negative result on a genetic test, 
these examinations can be stopped. Usually, genetic testing is postponed until the 
age of 10 or 12, given the low risk of cardiac events in early childhood. The testing of 
children often seems to be motivated by parental fear of the sudden death of a child. 
Testing might bring relief; yet uncertainty could well remain and it is questionable 
whether children can be equipped to live with the knowledge of the potential risk of 
sudden and unpreventable death. Theoretically, an ICD can be implanted from a very 
young age, but this tends to be deferred because growing children regularly need 
new operations to lengthen the leads of the device (Hassink et al, 2003). The litera-
ture that does exist on genetic testing of children for HCM (Charron et al, 2002; 
Hassink et al, 2003; Smets et al, 2008) emphasizes its controversial nature. 
 With this article we aim to contribute to the discussion on genetic testing of 
children, from the perspective of the concrete, everyday lives of ‘HCM families’. We 
show how the views on genetic testing in ‘the child’s best interest’ are constructed in 
the families involved. Based on the empirical analysis, we argue that these best 
interests should not be framed as the result of an instantaneous agreement between 
parents and professionals, but understood rather as a long-lasting process that takes 
place in the broader context of family and kin.  
3.2 HCM families and interviews 
In order to trace the issue of genetic testing and children in everyday life, we fol-
lowed six extended families involved in genetic testing for HCM for an extended 
period. After approval from the local medical ethical committee, the clinical geneti-
cist and cardiologist who participated in the research team helped to bring us into 
contact with these families. In the first phase of our study, the physicians worked as 
specialists in one of the two cardiogenetic centers in the Netherlands. During the 
course of the study, they both transferred to other hospitals in central and eastern 
Netherlands. Thus, they were able to recruit participants from a large pool of HCM 
families. As a consequence of the physicians’ places of work, this study was primarily 
based in southern and eastern Netherlands, but we also visited family members in 
other parts of the country. Clients were informed about the study in writing and 
orally. All who were asked by the professionals readily agreed to join the study, 
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evidently welcoming the opportunity to talk about their experiences of living with a 
familial disease and of genetically testing children. 
 Based on the literature about families and genetics, we assumed that in every-
day life families would deal differently with genetics and the testing of children. We 
therefore sought variety in the families we studied based on size, mutation, HCM 
severity, and testing of children.  
 Pseudonyms were given to each of the six families that participated. The Red-
ford family was relatively small and included two brothers and their wives, their four 
children and the grandparents of these children. The Goldfield family was very large 
with 14 brothers and sisters in the fourth generation and even more in the third and 
second generations. The other four families – the Lewis, Green, Anderson and Silver-
man families – were of a more average size. In all six families, recent births and 
growing children had prompted family members to confront the question how to 
deal with the familial risks for their children, and in three of them – the Green, Ander-
son and Redford families – the children had actually been tested. Family members 
from two generations, and in the Goldfield family three generations, participated. In 
the Green and Anderson families we interviewed teenagers and young adults, but we 
were not able to interview the children in the other families. Typically the children in 
question were too young to be interviewed themselves; sometimes they were not 
yet born; in other cases the parents had not yet discussed with them the issue of the 
familial disease.  
 There was inter- and intra-familial variation in the manifestation of the disease 
as expected. While many members of the Redford and Silverman families suffered 
from severe to very severe heart complaints even at young age, in the other four 
families the presentation was milder or the disease had affected only a few individu-
als. This variation in expression was most striking in the large Goldfield family, where 
some members suffered from serious heart failure or had died from a sudden cardiac 
arrest, while other carriers of the mutation had few to no complaints. The variation 
was also considerable in the Lewis family in which one member had had heart com-
plaints from a young age and had died suddenly of heart problems at the age of 53, 
while his brother and sisters had experienced only mild complaints at an older age. In 
the Green and the Anderson families, only young family members had been diag-
nosed with the disease. Finally, the results gained from genetic testing showed a 
mutation in four families. In the other two families, the Silvermans and the Ander-
sons, years of testing had yielded no result; linkage analysis had been started in the 
Silverman family about seven years before we first met the family, and the tests 
available for HCM had been performed in the Anderson family, but had not identified 
a mutation. 
 During a period of about three and a half years (between 2004 and 2008), the 
first author (EG) conducted in-depth interviews with 57 members of the six families. 
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Data collection began with an interview with an individual family member who 
served as the initial point of contact, from which the researcher then approached 
relatives including the immediate family, second-degree relatives, spouses and other 
in-laws. Family members were quite willing to accept the invitation for an interview, 
and it was rarely hard to find individuals willing to ask other family members to 
participate in the study. This only happened in two situations: in the Lewis family we 
spoke to one couple that wanted to protect their adult children from what might 
prove to be an emotional encounter, and in the Silverman family a family rift yielded 
problems with making contacts with some specific family members. 
 The researcher visited all respondents in their homes. After the first interviews, 
contact with all families was continued with more than half of the family members 
involved. Family members who took the lead in the genetic testing or were actively 
involved in testing during the interview period, and particularly those who struggled 
with the decision to undertake testing or were waiting for the result, were inter-
viewed once or twice more. These interviews were conducted by telephone in most 
cases, but in person with ten participants. In addition, e-mail contact was carried on 
with three people, and, finally, two of the respondents were accompanied to a 
counseling session and one was visited in hospital. These follow-up contacts enabled 
us to follow the processes the families were undergoing, how decisions to test or not 
to test a child were reached, and how the family members reflected on these after-
wards. We allowed some time to pass between interviews with individual family 
members to enable us to follow the events in the family over time. Although we did 
not follow families who did not undergo genetic testing at all, we did include at-risk 
family members who, after being informed of the mutation in their family, decided 
not to be tested. Besides interviewing the families, we spoke to four professionals 
involved in treatment and counseling of HCM families on their perspectives on 
children’s ‘best interests’. 
 The interviews with the families were semi-structured and presented compara-
ble topics to all participants, but were open enough to explore in depth the specific 
experiences and circumstances of the particular families and family members. 
Themes such as living with children ‘at risk’, parental choices with respect to testing 
children, ideas about having children and upbringing, concerns and conflicts be-
tween parents or with other family members, and contact with professionals about 
testing children were discussed. In addition, participants were encouraged to talk 
about their everyday experiences with the disease and the testing of children in a 
broad sense. Emerging themes were then explored further in subsequent interviews. 
With the professionals involved, we discussed their views on testing children as well 
as the specific test trajectories of the children in the families concerned. All inter-
views lasted from one to two hours, and all (both in-person and telephone inter-
views) were tape-recorded and fully transcribed verbatim.  
C H A P T E R  3  
 60 
We analyzed the narratives by identifying the theoretical concepts in other studies 
on genetics, kinship and family life. In earlier work (Geelen et al, 2011), we analyzed 
the patterns of family life and care, notions of health and disease in the family, and 
the perception of future life and future risks. In this article we focus on concepts 
related to raising children, such as parental responsibility and parental concerns, and 
best interests of children. The first author identified the themes related to these 
concepts after reading and re-reading the transcripts. Two other authors (KH, IVH) 
independently reviewed the initial coding, and assisted in refining the themes and 
developing new themes in order to search for the patterns in meaning in the narra-
tives. We reconstruct the genetic testing process first with respect to children who 
are actually ill, then ‘at-risk’ children, and finally children of ‘at-risk’ parents. 
3.3 Constructing ‘best interests’: testing sick children 
In the Green and Anderson families, testing of children who were actually ill was 
being considered. In both of them, the perspective on ‘best interests’ was contingent 
on many factors and was continually developing on the basis of concrete experienc-
es. In both families, professionals had taken the lead in the diagnostic process and 
the parents had agreed with their suggestion to undertake genetic testing for HCM. 
Karen Green had experienced thickness of the myocardium since a young age, but 
when her echo at the age of 14 showed a considerable increase in this thickness, the 
cardiologist suggested genetic testing as part of the diagnostic process. In the An-
derson family, the sudden heart complaints of brothers Dave and Christian, aged 21 
and 20 years, respectively, in the same week reminded the cardiologist of the possi-
bility of an inherited disease, and the diagnosis of myocardial thickness prompted 
the suggestion for the genetic test. Neither family was previously familiar with HCM, 
and both sets of parents thought genetic testing was in the best interests of their 
children, as they expected that a genetic explanation for the heart defect would 
result in therapeutic interventions. After testing, however, the families wondered 
whether it had indeed been in the children’s best interests. The diagnostic and 
therapeutic value of the HCM test appeared to be limited, and some unforeseen 
effects of testing induced further doubt.  
 After the mutation was detected in Karen, anti-arrhythmia medications were 
prescribed, but the main advice concerned lifestyle changes. At that time the identi-
fied mutation was related to a high risk of sudden cardiac arrest, and thus Karen’s 
doctors emphasized that only by following a strict regime of limited physical exertion 
could she avoid dying from a cardiac arrest. Neither Karen nor her parents, Linda and 
Carl, were prepared for this. In the interview, Karen expressed regret about the 
testing as she had had to give up playing korfball, her favorite sport. For their part, 
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Karen’s parents explained that the specific lifestyle advices had resulted in overanxie-
ty toward their daughter:  
The doctor banned her from playing sports and what he said meant that cy-
cling for ten minutes was already too much. In the weekends we ferried her to 
and from her work. (Linda Green)  
While the parents had expected medical treatment, testing had merely given rise to 
new concerns and a tense relationship with Karen. It had taken a year before they 
had been able to trust Karen to live her own life.  
 In addition, Karen’s parents became aware of possible problems with taking out 
insurance when they visited professionals to discuss testing their other children, two 
sons aged 20 and 18. The interview revealed that they were glad to have received the 
information about the possible consequences of testing for insurability, but also that 
they felt sad they had not known this before: 
When Karen was being tested, we didn’t really think about that. We would have 
been better off if we had known this before; we would have taken a different 
decision with respect to having Karen tested. (Carl Green)  
Now they felt getting insurance was as important an interest as getting a diagnosis.  
 Another issue that prompted some rethinking about Karen’s best interest was 
the reactions of others in the family. After Karen’s HCM mutation had been found, 
Linda and Carl had obtained genetic testing as well, without much forethought, and 
when it was revealed that Linda carried the mutation, they informed her family. 
However, neither her four brothers nor her parents decided to have the mutation 
analysis. Linda and Carl respected that, but they regretted the fact that the inherited 
nature of Karen’s heart disease was kept silent within the family. This silence had 
affected Linda badly. Although she had found ways of coping and continued to play 
sports with the family, she found it difficult to talk about this without crying. She 
considered the lack of communication in the family and her melancholic mood about 
this not in Karen’s best interest. 
 Also in the Anderson family, after the brothers Dave and Christian were tested, 
new meanings of ‘best interests’ emerged. No mutation had been found, but when 
interviewed, the parents did not seem overly interested in that outcome. As Sarah, 
the mother, explained: 
If it’s genetic, well, okay, but what concerns us most is that the doctors can’t tell 
us whether the myocardial thickness is still growing. (Sarah Anderson) 
Because the doctors had considered the boys’ hearts to be affected with a risk of 
severe arrhythmia high enough that ICDs had been implanted, the parents were 
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worried less about the possibility of inheritance and much more about the physical 
state of their sons. Moreover, the fact that their eldest, Christian, seriously struggled 
to get his life ‘back on track’ made them reconsider whether testing had really been 
in his best interest. For more than a year he had used alcohol and recreational drugs 
as a way of coping with the frustration of living with limited future prospects: 
I couldn’t handle it (the disease]. (…) It was hard to look other people in the 
face, explaining it over and over again. I was so embarrassed. (…) If I apply for 
a job, I will have to tell employers that I suffer from this disease and they’ll pre-
fer others for the job. (Christian Anderson) 
In a second interview, some years later, his parents stated that the identification of a 
mutation would ‘push him off balance again’, particularly as it would emphasize the 
reproductive risk. While they had initially viewed a positive test result with optimism, 
now they felt it would be best if a mutation were never found.  
 Although guidelines about genetic testing for children presuppose that any 
decision taken on testing should represent their best interests, the experiences of 
these two families with HCM testing show the challenges. These children were 
already being monitored or suffering from complaints, and focused on possible 
therapy, but through the testing processes the families learned that they had not 
considered all the aspects of living with a genetic diagnosis.  
3.4  Constructing ‘best interests’: testing at-risk children  
In some families genetic testing of children was an issue even though the children 
were asymptomatic. The Redford family decided to test their children beginning with 
the three-year-old twins, Philip and Julia, and some years later, their two cousins, 
Linsey (at the age of nine months) and Rosa (at birth). In contrast, the Goldfield 
parents declined predictive testing for their children. Different notions of ‘best 
interest’ were constructed in these two families. 
 We met the Redfords about one year after they had started the twins’ genetic 
testing process. The father, Nick, had had a cardiac arrest at 15 and, although DNA 
testing was not available at that time, cardiac examination of his father and brother 
had made clear that heredity played a role. For many years, he had felt that the risk of 
passing on the disease meant he would not have children. Yet, he and his wife finally 
decided otherwise and to accept the 50 percent recurrence risk. When the twins 
were three years old, DNA testing for HCM became available and Nick, together with 
his father and brother, immediately obtained genetic testing. When a mutation was 
found, it was clear that he would have the twins tested as well. In the interviews all 
three men expressed a highly positive stance towards scientific research and techno-
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logical progress. Nick hoped that the children might benefit from therapy in the 
future and felt that information about their genetic constitution enabled ‘better’ 
parenthood. 
I absolutely wanted to know it with regard to my parenting. We [Nick and his 
wife] assumed that we would be able to raise the children in a better way. (Nick 
Redford)  
Testing revealed that Philip was predisposed to HCM, while Julia was not. In spite of 
this ‘bad’ result for Philip, the affected family members, profoundly believed that the 
certainty brought about by the test was in the children’s best interests. They ex-
pressed confidence that it would help all who cared for with Philip to manage his 
physical exertion.  
Philip is allowed to do everything, but under supervision. We won’t encourage 
him to play soccer in a soccer club or do some other intensive sport, like biking. 
But he can play non-competitive sports, so that he won’t get too tired, for in-
stance swimming. (…) I recently told the schoolteacher. She’ll take it into ac-
count in the gym class. (Nick Redford) 
Not all members of the Redford family thought this way. Frances, Nick’s sister-in-law, 
was skeptical about precisely this restriction of freedom of movement. She felt that 
the positive test result had actually made Philip more ‘at risk’, as he was monitored 
much more than his twin sister: 
His grandfather and grandmother were very concerned about Philip and 
slowed him down all the time. Particularly when he started running, so at the 
age of three or four. (Frances Redford)  
Also Nick’s mother, Jane, saw the negative effects of testing.  
Actually there’s already a mark on this boy. When filling out insurance forms, 
you need to be honest. (Jane Redford)  
These quotes illustrate that while the Redfords appeared to be convinced of the 
value of testing children, the healthy in-law family members expressed concern.  
 We also discussed the testing of these very young children for HCM with the 
professionals involved and it is interesting to note that, while they had reacted 
positively to this family’s request, they had started to doubt their decision later. 
Around the time that the family was discussing the issue of testing the twins, some 
experimental studies on preventive treatment for HCM had appeared that seemed 
very promising, and the cardiologist, Dr Adams, explained that this had played an 
important role in considering the children’s best interests: 
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By then marvelous mice models with exactly the same disease had been made 
and experiments showed that when these mice were given a specific medica-
tion, they didn’t develop a hypertrophic myocardium. We wondered whether 
this knowledge could be translated into human beings. Although the reasons 
were rather weak, I’m an optimist and I think possibilities to do meaningful 
things will come within reach. (Dr Adams, cardiologist) 
It was after the test had been performed, that his initial optimism about medical 
treatment had been dampened, and that he realized having not sufficiently 
acknowledged in advance the consequences of negative results and the possibility of 
two different results. 
Being enthusiastic about the research, I didn’t foresee the implications for the 
family. Actually we didn’t have a detailed plan about what to do if the children, 
or one of them, might prove to be predisposed. If we had started a trial with 
medication, we’d have advised participation, but now we had nothing to offer. 
(Dr Adams, cardiologist) 
While Dr Adams had associated testing with hope of scientific progress and treat-
ment in the future, and had perceived it to be in their best interests from a therapeu-
tical point of view, for Dr Bartholet, the clinical geneticist, the specific history of this 
family had been the deciding factor to give his consent. He had argued that the 
serious manifestation of the heart disease in the family at an early age made it im-
possible to wait until the children could decide for themselves. Dr Bartholet also 
explained that this family’s ‘wanting to know everything there is to know’ about the 
disease had made it difficult to refuse the request. Both doctors told us that in dis-
cussing testing the children the father’s voice was articulated most. They wondered 
whether they had given too much weight to his perspective as he was their patient, 
considering to the ideas of the mother. 
 The Redford family remained convinced that it was in the best interests of the 
twins to obtain genetic information as early as possible. So, two years after the twins 
had been tested Nick’s brother, Duncan, and his wife Frances, requested their daugh-
ter Linsey to be tested when she was just four months old. Frances’ initial worries 
about over-concern for the child appeared to be vanished after the birth of her own 
child. During her second delivery umbilical cord blood was taken to test for the HCM 
mutation. The results of these tests, both positive and negative, enabled Frances to 
find closure on the issue of testing. The fact that she requested the testing despite 
her earlier reservations makes clear that the construction of the ‘child’s best interest’ 
is very much a result of interaction in the broader family. In the Redford family, not 
testing was not really an option.  
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Like the Green and Anderson families, the Redford family realized that their expecta-
tions for therapy were unjustified. They were also confronted with unexpected 
consequences, such as potential problems when taking out insurance, restricting 
physical activities and handling the two children differently. In spite of this, the 
Redfords did not regret testing the children. Their strong need for certainty might be 
related to the severe HCM complaints in this family. However, other families with 
severe heart complaints were not necessarily as eager for testing. 
 In the Goldfield family the cousins Harry and Ted, like the Redfords, had been 
diagnosed with pathological myocardial hypertrophy and suffered from quite severe 
heart complaints. Although they had not been genetically tested, they felt sure they 
had the HCM mutation that had been found in other family members, implying that 
their children had a 50 percent risk of being predisposed to the familial disease as 
well. They dealt with this differently. 
 Harry explained that in his daily life he pushed his heart disease and its genetic 
character into the background as much as possible, as he did not want to burden his 
two daughters (aged 16 and 12) with the knowledge of the risks of the disease. He 
considered them too young to think about testing. He stressed the importance of an 
open future for his children and perceived it as being in their best interests to leave 
the decision about testing to them. 
Why should I decide now for them? When they grow up to adulthood, they can 
do the test, if they want to know. (…) I think that I’d advise them to do it. If they 
don’t have the mutation, they can close the issue; and if they have, they know 
that the disease might develop. (Harry Goldfield) 
We were unable to follow this branch of the family further, since he did not give 
permission to interview his children and, he died from a sudden cardiac arrest during 
the course of our study. 
 In contrast, Ted and his wife Yollie felt it was hard to live with the uncertainty 
about their children’s (aged three and one year) possible predisposition. Due to the 
risk that the familial heart disease might affect the children as well, they had insisted 
on regular cardiac ultrasounds immediately after birth. After the identification of the 
mutation in the family, their cardiologist, Dr Newbury, had suggested testing the 
children genetically, as in the case of a negative result they could stop these ultra-
sound checks. The clinical geneticist, Dr Morgan, however, had recommended them 
to wait until the children were old enough to decide for themselves, as they were not 
yet at risk of a sudden cardiac arrest. In addition he had pointed to possible problems 
with taking out insurance in the event of a positive test result. Both parents regretted 
this delay, but while Ted argued that there was no ‘good age’ for genetic testing, 
Yollie emphasized the importance of certainty. 
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There are also some family members who suffer from severe complaints and I 
think the disease might affect them [the children] severely as well. I think life is 
more important than buying a house. (Yollie Goldfield)  
The interviews with Ted and Yollie showed that this family was not so convinced of 
the benefits of testing at young age that they tried to persuade the clinical geneticist. 
Contrary to the Redfords, who convinced the professionals of their strong desire to 
test the children, the Goldfields followed the professionals’ advice to wait until the 
children had grown up.  
3.5  Constructing ‘best interests’: struggling with children’s and parental 
interests 
In the HCM families involved in our study, the issue of testing children was some-
times linked to the issue of testing one of the parents themselves. Few children 
undergo predictive genetic testing before a mutation has been identified in their 
parents, providing that the parents are still living. That means that in situations 
where parents have no HCM complaints but are sure that they run the risk of the 
disease, the question whether testing a child is in his or her best interest is inter-
twined with how parents feel about testing themselves. In the families studied, the 
parents dealt with this intertwining of interests in different ways.  
 Some parents felt that knowing their own genetic status would be in the best 
interests of their children, as it would enable them to provide information to their 
children and potentially to safeguard them from testing. This means that they un-
derwent testing despite lack of interest in their own genetic status. Eileen Goldfield 
for instance, explained that: 
My cousin called me and asked me whether I’d go for a test. I said: ‘Of course, 
it’s important’. My father died from heart problems fairly young; I have no 
complaints, but it’s for Janey [her 20-year-old daughter] that I want to know. 
(Eileen Goldfield)  
When we first met Eileen, she was still waiting for her test result. She stated that, if it 
turned out that she was predisposed to the disease, her daughter Janey would be 
tested as well to see whether she ought to adjust her lifestyle by limiting her partici-
pation in sports. Eileen eventually received a good result, which meant that for Janey 
testing was no longer an issue.  
 Other parents expressed a completely different perspective. They reflected on 
the risk of HCM in their children, but knew that if they wanted to verify these risks 
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they would have to get tested themselves, and were reluctant to do so. Mike Gold-
field, the father of eight-year-old twins and a six-year-old daughter, explained:  
Why should I do a test? What good will it do me, if I know? Absolutely nothing. 
(…) I don’t worry about it. I’m healthy, the children are healthy, everybody is 
healthy; so what more do we want? (Mike Goldfield) 
Mike argued that as long as he felt healthy, he would refuse medical monitoring, 
which would prevent possible problems with taking out insurance. His father, 
though convinced that he was not predisposed, had been genetically tested for the 
heart disease to safeguard his children and grandchildren from concerns about being 
at risk. He had tested positive, and Mike did not want to go through the same ordeal. 
However, in our interview with Mike and his wife Ann it became clear that they did 
not agree about testing the children. Mike appeared to have most influence on the 
decision whether or not to test.  
 A similar attitude of not being overly keen on knowing about genetic risks we 
saw in the Lewis family. Laura, whose mother had been diagnosed with the HCM 
mutation and who herself had three children (aged six, four and two) explained that 
the issue of testing had crossed her mind, but that she had put it aside.  
I thought about it during my first pregnancy. But then I also thought that know-
ing about my predisposition wouldn’t gain me anything. If you could do some-
thing preventive, it would be different, but that’s not the case. (Laura Lewis) 
 Some parents who were reluctant to be tested themselves felt more or less 
compelled to do so in the interest of their children. For instance Louise Goldfield, 
mother of three children of 13, 9 and 5. Her mother had died recently, and although 
she had not been diagnosed with an HCM mutation, Louise was sure that she herself 
was at risk, as her mother had had heart complaints for a long time. Louise had 
decided to get tested for the sake of her children, but postponed it until she had 
recovered from a knee operation, and then postponed again as she realized she was 
unsure.  
For myself I don’t worry. I’d like to do the test for my children. But I feel dubious 
about it, because if I have it, should I decide to test them as well? (…) There can 
be certain problems for the children when taking out insurance later in their 
lives. But at the same time, I don’t want to bury my head in the sand. You can 
have a sudden cardiac arrest; our oldest son plays soccer. I don’t want to be 
confronted with comments from my children like ‘Mom, you knew about the 
disease and why didn’t we have that test?’ And, as I understand it, they can do 
something with specific medications; they’re working on it, it’s coming along. 
(Louise Goldfield) 
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Louise’s husband felt strongly that if she was found to have the predisposition, the 
children would be tested, but he had emphasized that the final decision would be 
hers.  
 The complexity of dealing with genetic testing was also illustrated by the Sil-
verman family, in whom no mutation had been identified, and the couple Chris and 
Kate struggled with the question what would be ‘good’ for their still unborn child. 
We interviewed them during Kate’s pregnancy. Feeling certain that Chris’s mother 
had an inherited heart disease, the midwife had sent them for a special ultrasound of 
the baby and suggested a genetic consultation to discuss the potential impact of the 
familial disease on the child’s health. Although Chris expressed willingness to do 
anything that might benefit his child’s health, he doubted whether he would have a 
genetic test if a gene was indeed identified in his family. 
I really don’t look forward to the result of that test. Imagine if they said: ‘we 
know what gene it is and we want to see whether you have the gene or not’, 
and they tell me ‘you have the gene; it’s yes or no’. If I had the gene, I’d really feel 
uncomfortable. (Chris Silverman) 
For this couple, the struggle to find their child’s best interest did not depend on 
mutation analysis, but on the perception that a disease is inherited, even in the fetus. 
3.6 Discussion  
The emphasis on the notion of ‘children’s best interests’ in professional guidelines on 
genetic testing of children implies that different parents decide differently about 
‘best interests’. In spite of the absence of clear therapeutical benefits, parents may 
decide to have their children tested in the hope this will change in the near future, or 
from the perspective that it is easier at a younger age to protect children from poten-
tially life-threatening effects and to support them in incorporating their genetic 
make-up into an emerging self-concept. At the same time, parents may decide to 
postpone testing their children to prevent expected problems with obtaining insur-
ance or to enable their children to make the decision themselves at older age. In the 
six families in this study, the parents thought about testing their children in different 
ways. This plurality does not appear to be specific for HCM families: recently Brad-
bury et al (2008) came to similar findings in families with breast cancer. 
 Our study demonstrates that living with heart disease and the risk of HCM, 
importance of possible problems with life insurance, and the emotional reactions to 
a positive test result and preventive measures (e.g. not playing sport) are contingent 
processes in the families. Families that are optimistic about scientific progress point 
to different experiences than families that are not overly optimistic or that do not 
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consider the test results of much benefit, given their diffuse or tentative character. 
Families that have experienced severe complaints in the past or have already been 
living with a familial disease for years consider a professional’s suggestion to get 
tested differently than families in which members scarcely suffer disease. Families 
that regularly and openly discuss the issue of testing take different positions in 
discussing the children’s best interests with professionals than those who are silent. 
In their study on family responsibility, Finch and Mason (1993) argued that responsi-
bilities towards children are not negotiated in a vacuum, but built upon a history of 
the relationship between parent and child, in which the biography of each is incor-
porated and shapes the form which responsibilities might take. As we have shown, 
family characteristics (such as size or strength of ties) or disease manifestations (e.g. 
the severity of the complaints) cannot predict how families will experience the 
testing procedure and how the best interests of the children are constructed.  
 We observed that parents were less concerned about the risk of their children’s 
sudden death than one might have expected, given the nature of HCM. At the same 
time, although we did not systematically discuss the issue of ‘genetic discrimination’ 
in insurance in the interviews, half of the families expressed fear of possible insurance 
discrimination as a reason to postpone genetic testing or regret the fact that a child 
had been tested. Despite Dutch legal restrictions on the use of genetic test results in 
insurance applications in the Medical Examination Act (1997), these families feared 
that positive genetic test results might lead to larger difficulties in getting insurance.  
 Consistent with our finding that ‘best interests’ are constructed in the context of 
family and kin, we have also demonstrated that they are constructed over time. 
Dealing with the issue of testing children is not, as often thought, related to the 
identification of a mutation in a family. Our study shows that families already deal 
with the issue when they experience a disease running in their family without having 
a genetic diagnosis. What is considered as being in a child’s best interest is not fixed: 
undergoing the process of testing or not testing as well as earlier experiences with 
testing or other related experiences might change this idea of best interests and 
generate new meanings. This dynamic and contingent process that takes place 
within the family, however, is not characteristic for genetic testing of children in HCM 
families, or even for genetic testing of children in general. In their study on how 
parents negotiate risks, Backett-Milburn and Harden (2004) showed how different 
parenting styles and particular familial events and experiences resulted in variations 
and changes in the assessment of risks, and therefore in different decision-making 
processes.  
 Neither the literature on genetic testing of children nor the professional guide-
lines address the intertwining of the interests of children and the parents. From our 
study, it appears that almost all parents decide in the interests of their children rather 
than their own interests. This supports findings from other studies; for instance, in 
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their study on the psychological impact of testing children for Long QTsyndrome, 
Hendriks et al concluded that ‘parents are more focused on the well-being of their 
children than on their own well-being’ (Hendriks et al, 2005, p. 111). The intertwining of 
children’s and parental interests, however, might prompt some parents to have 
themselves tested for the sake of their children, but lead others to decide the oppo-
site. 
 From our analysis of the experiences of these six families, it became clear that 
the sick or at-risk parents and family members were usually the ones to take the lead 
having the greatest influence on the decision whether or not to have the child 
tested. This was unquestioned by their partners and other family members. However, 
the healthy parent’s identification with the sick or ‘at-risk’ parent may result in the 
professionals having a patient-oriented perspective as well, such as in the Redford 
family where the professionals involved later acknowledged that, although their 
usual aim was to explore any possible differences of opinion between parents, they 
had been rather blind to the view of the mother who was not at risk.  
 Interestingly, the narratives of the families revealed that the meaning of ‘child’ is 
not related as much to a specific age, but to the way children live together with their 
parents. In the Green and Anderson families, the children aged above 16 still lived at 
home, which resulted in the parents playing an important role in their lives in gen-
eral, and in following the disease in particular. Guidelines may presuppose that 
children are involved in the decision from the age of 12, and speak for themselves 
from the age of 16 (or 18). Concrete experiences in daily life, however, show that the 
meaning of ‘child’ and concrete notions of autonomy and independence are con-
structed in de context of family life. In fact, our study shows that there is no strict 
boundary between child- and adulthood, or between taking an autonomous deci-
sion and being influenced by parents and family. In their study of families with 
familial hypercholesterolemia (FH), Horstman and Smand (2008) also found that, as 
long as children lived at home – irrespective of their age – their parents heavily 
influenced their lifestyle. After a child had been diagnosed with the FH mutation, 
low-fat diets, restrictions on smoking and support in physical activities became part 
of family life in the child’s best interest. Several other studies, too, have pointed to 
the arbitrariness of the usual age boundary between child- and adulthood. Ross 
(1997) asserted that children’s competency in health care decision-making cannot be 
related to a specific age. In the same vein, Fanos and Gatti (1999) showed how young 
people around the age of 20 who had left home, for instance to go to college, lacked 
parental support in processing the information about genetic risks.  
 As the families varied in terms of size, socioeconomic status, and profession, and 
thus, we did not study an extreme population. We assume that they can be seen as 
representative for how HCM families deal with the issue of genetic testing of children 
in the Netherlands. Several authors have pointed to the national styles in dealing 
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with health and health risks and the influence of cultural values on the practice of 
genetic testing (Aarden et al, 2009; Jasanoff, 2005; Parthasarathy, 2005; Daemmrich 
and Krücken, 2000). The tendency to control health risks and trust in technology is 
often considered typically American, contrasting sharply with the way West-
Europeans deal with health and risks. These differences might have an effect on the 
notion of children’s best interests. The literature on prenatal testing, for instance, 
indicates that for parents in the US is it common practice to test the fetus. Dutch 
parents, by contrast, appear to be less inclined to opt for prenatal diagnostics. More-
over, there are indications that while women in the US tend to defer their sense of 
being pregnant until they get good amniocentesis result (Rothman, 1986), Dutch 
women not only rely on test results but also express confidence in ‘nature’ or in 
feeling the movements of the fetus (Geelen et al, 1999).  
3.7 Conclusions 
Genetic testing of children and speaking in their best interests is less about following 
the guidelines or weighing up the pros and cons in the consulting room than about 
the context of the family in which best interests are considered. What is perceived as 
being in a child’s best interest is not stable, but may change throughout the process-
es, in which families become engaged with genetic testing. Parents as well as profes-
sionals reflect on and learn from these processes. To enable professionals to deal 
with the variety of family life, these learning processes should be documented 
closely.  
 Recently the Dutch ICIN working group on Hereditary Heart Diseases (2010) 
recommended involving a psychosocial worker in the testing procedure for children. 
As specialists in addressing family circumstances, they might be equipped to recon-
struct and highlight the best interests of children, address the potential psychosocial 
drawbacks and prevent feelings of doubt among parents about the decision to test 
their child. It should, however, be noted that all possible effects of testing and test 
results cannot be foreseen. Genetic testing of children will remain an ongoing learn-
ing process, not only for these psychosocial workers, but also for other physicians, 
such as clinical geneticists and cardiologists. Professionals should be aware that the 
decision to test a child genetically is a long-lasting process and of the parental strug-
gles that may ensue. 
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4.1 Introduction 
With the advent of the Human Genome Project in the 1990s, one of the most conten-
tious topics in public policy debates on genetic testing has been the use of genetic 
information by insurance companies and/or employers. Because insurance appli-
cants are obliged to make full disclosure of relevant information to private insurance 
companies, people feared that genetic testing may render individuals uninsurable, 
leading to a ‘genetic underclass’ (British House of Commons Science and Technology 
Committee, 2001). The term ‘genetic discrimination’ was coined to refer to the 
(negative) perceived differential treatment of individuals or their family members 
based on presumed or actual genetic differences rather than physical characteristics 
(Billings et al, 1992). The threat of genetic discrimination has hindered medical 
research; according to Francis Collins, ‘Unless Americans are convinced that the infor-
mation will not be used against them, the era of personalized medicine will never come to 
pass.’ (Collins, 2007). These fears also appear to disrupt health care delivery. To keep 
genetic information out of their medical records, and out of the hands of insurers 
and/or employers, patients sometimes refuse genetic testing that could benefit their 
health. Some of those who chose to undergo testing sometimes pay out of pocket or 
use assumed names to keep genetic information private (Apse et al, 2004). 
 To manage concerns about potential misuses of genetic information, policy-
makers and lawmakers worldwide have taken measures to ‘prevent’ genetic discrim-
ination (Joly et al, 2010). In Europe, the Council of Europe’s ‘Oviedo Convention of 
Human Rights and Biomedicine’ (Council of Europe, 2009) has clearly set the tone by 
prohibiting any form of discrimination against a person on grounds of his or her 
genetic heritage and restricting the use of genetic tests to health purposes or scien-
tific research. Since 1997, a substantial number of the European countries have 
enacted genetic non-discrimination regulations. In the United States, the Genetic 
Information Nondiscrimination Act was signed into law in 2008 to provide protection 
against genetic discrimination for employment and health insurance (Wadman, 2008; 
Hampton, 2008). These regulations should help alleviate public fear of genetic dis-
crimination, enabling the progress of genetic research and use of genetics in clinical 
and preventive care. 
 Despite these significant legislative efforts to protect individuals from the 
potential of genetic discrimination, its nature and extent have largely been undocu-
mented. Research that validates the claim that genetic discrimination is occurring 
has been limited, both in scope and design. Reports of genetic discrimination have 
been criticized for being anecdotal (Otlowski et al, 2003), and allegations of discrimi-
nation have usually been based on the presence of disease in contrast to genetic 
predisposition (Billings et al, 1992; Christiaans et al, 2009; Lapham et al, 1996; Low et 
al, 1998; Marang-van de Mheen et al, 2002; Morrison, 2005). The most comprehensive 
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study of genetic discrimination in asymptomatic individuals has been completed in 
Australia (Barlow-Stewart, 2009; Otlowski et al, 2007; Taylor et al, 2007; 2008). It 
documents numerous cases of genetic discrimination, the majority of which relate to 
the insurance industry and employment relations. In a recent Canadian study, Bom-
bard et al (2008; 2009), explored concerns and experiences of genetic discrimination 
among asymptomatic individuals in Huntington disease families based on family 
history and genetic test results, and reported that nearly 40 percent of the partici-
pants experienced genetic discrimination in the social sphere or in the domains of 
insurance or employment. Although limited evidence for genetic discrimination is 
gradually being collected, still little is known about the origins and backgrounds of 
fears of genetic discrimination and about how individuals react to (the risk of) genet-
ic discrimination. Building further on Bombard’s pioneering research, this article will 
extend the research from a monogenic condition, which exemplifies the almost-
certain character of genetic predictions (e.g. Huntington disease), to hypertrophic 
cardiomyopathy (HCM), a disease for which the relationship between genotype and 
phenotype is much more complex. 
 HCM is considered the most common genetic cardiovascular disease (affecting 1 
in 500 persons worldwide). The disease is associated with sudden cardiac death at 
young age (especially athletes), but also seen as an important cause of heart failure at 
a later age Herschberger et al, 2009; ICIN, 2010). Geneticists have shown that several 
hundreds of mutations in at least 27 genes, mainly coding for sarcomere proteins, 
have a role in the manifestation of the disease (Bos et al, 2009). Genetic testing, 
however, still does not guarantee a conclusive result; in about 40 percent of the 
families with HCM who undergo testing procedures, no mutation will be found. HCM 
follows an autosomal dominant inheritance pattern, which means that children of a 
parent who carries the mutation run a 50 percent risk of being a carrier as well. The 
meaning of being ‘at-risk’ or even ‘affected’, however, is uncertain, because of the 
variable expressivity as well as the variable penetrance of the disease. Even within 
one family the expression of the disease can vary strongly; some carriers of a muta-
tion demonstrate no clinical symptoms, whereas others have an increased thickness 
of the myocardium or severe arrhythmia, and suffer from serious heart failure or die 
after a cardiac arrest. Currently there is no cure for HCM, but following lifestyle advice 
(such as refraining from competitive sports), echo- and electrocardiographic moni-
toring, or an implantable cardioverter defibrillator, may help to prevent a cardiac 
event. Taking certain medications or septal reduction therapy are both associated 
with functional improvement and long-term survival (Fasa and Sigwart, 2010). Ge-
neticists as well as cardiologists often see the possibilities of predictive genetic 
testing as a way to assess the risks of the disease long before clinically manifest 
dysfunctions appear and, with that, as a way to ‘control’ the disease in asymptomatic 
relatives by close cardiological follow-up. The lack of interventions to prevent the 
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development of HCM and the uncertain meaning of being ‘at-risk’ and even of being 
‘affected’, however, seem to be barriers for the uptake of a genetic test (Bos et al, 
2009; Marian, 2010). This article demonstrates that the fear of genetic discrimination 
may also importantly affect decisions about genetic testing in families with HCM. 
 In contrast to the Huntington disease research, which was based in Canada, a 
country where there are no specific laws addressing the use of genetic information 
by insurers or employers (Bombard et al, 2008; 2009), our study situates the concerns 
of genetic discrimination in the context of the Netherlands, with existing protective 
legislation. The Dutch Medical Examination Act (MEA) (1997) restricts private insurers 
and employers in requesting a genetic test and using genetic test results from indi-
viduals who want to obtain a civil employment contract, a pension or a life or disabil-
ity insurance. The act states that – for life insurance below a predefined ceiling of 
160,000 Euro – no questions may be asked about untreatable hereditary disease or 
about the results of genetic tests for such diseases in the applicant and his/her 
relatives, except in case of an already manifest disease. As HCM is an untreatable 
hereditary disease according to the MEA definitions, HCM mutation carriers are 
protected by the Act in the case of non-manifest disease and when requesting 
insurance below the predefined ceiling. However, if HCM applicants apply for insur-
ance beyond the predefined ceiling, they will have to make full disclosure of their 
HCM risk, potentially resulting in an increased insurance premium. This means that 
the MEA does not 100 percent protect HCM mutation carriers in insurance and there 
is currently public debate on how to interpret the Act’s definitions (Christiaans et al, 
2009; Dutch Health Council, 2001). The aim of this article is not to investigate wheth-
er or not the Dutch insurers and/or employers actually violate the Act and perform 
‘genetic discrimination’, but to have a better understanding of the origins and back-
grounds of fears of genetic discrimination and its possible impact on the uptake of 
HCM genetic testing. 
4.2 Methods  
This article discusses data derived from a broader empirical longitudinal qualitative 
study concerned with the way families involved in genetic testing for HCM deal with 
a disease running in the family and with genetic testing in their everyday lives. In 
previous articles Geelen et al, 2011a; 2011b), we have described the processes of data 
collection and data analysis in detail; here we will give a summary related to the data 
to be reported in this article.  
 After approval from the local medical ethical committee, the clinical geneticist 
and cardiologist who participated in the research team helped to bring us into 
contact with six extended families living with HCM. To allow for diversity in the 
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families, the clinicians were asked to recruit families with and without a genetic test 
result, with few and many family members, with severe as well as mild manifestations 
of the disease, and families where children had been genetically tested. As the 
physicians worked as specialists in one of the two cardiogenetic centres in the Neth-
erlands, it was easy for them to recruit families for our study. All who were asked by 
the professionals readily agreed to join the study. 
 In semi-structured interviews, participants were asked to explain how they 
learned the disease was running in their family, to describe the impact of living with 
the disease and with genetic testing, and to go into their decision on the non/uptake 
of genetic testing. Particularly, they were encouraged to talk about their everyday 
experiences with the familial disease. In the interviews, when talking about the 
non/uptake of a genetic test, fear of discrimination in insurance and employment 
was often articulated. This was striking considering that regulation has been enacted 
in the Netherlands since 1998 to protect against the use of genetic information in 
insurance and employment, in case of non-manifest disease and below a predefined 
ceiling.  
 The article’s analysis largely draws on interviews with four of the families in-
volved in our study. The four families presented here were all white Dutch families, 
who differed in terms of size, place of living, social-economic status, profession, and 
disease and genetic status. To demonstrate the processes that shaped fears of genet-
ic discrimination, this article presents four case studies, in which we describe in depth 
how these fears were articulated, experienced and interpreted by these families. 
Pseudonyms have been used to protect the identity of the participants.  
4.3 Results 
The Goldfield family: postponing genetic testing 
In the Goldfield family, taking up genetic testing for HCM became an issue after a 
mutation had been identified in 53-year old Emily. Initially, many family members 
showed enthusiasm about the possibility of genetic testing. in the family, they 
recalled that many had suffered from heart complaints and some had died of a 
sudden cardiac arrest. During the first interviews, hopes were articulated of genetic 
testing as a way of breaking the Goldfield’s family tradition of illness. However, after 
the clinical geneticist’s suggestion about possible problems of insurance in case of a 
positive test result, the initial enthusiasm seemed to have been remarkably dimin-
ished.  
 When discussing their decision to have a genetic test done, many family mem-
bers referred to the story of Ted, one of Emily’s cousins. Ted, diagnosed with clinically 
manifest HCM, had to pay an extremely high premium for life insurance and it was 
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uncertain how long he could have his job as a truck driver. His story had given rise to 
the family idea that as Goldfields, in having a disease running in the family, they 
should always take caution with insurers and employers. It became clear that the 
clinical geneticist had triggered pre-existing fears of discrimination; it was in the light 
of Ted’s previous experiences with ‘that devil of insurance’ that the clinical geneticist’s 
information was perceived as a warning. As Emily explained, it had resulted in the 
idea of being better off without a genetic diagnosis: 
You might be restricted in all your actions and refused by insurance; so what 
the eye doesn’t see, the heart doesn’t grieve over. If you really don’t know about 
being predisposed to increased thickness of the myocardium, you don’t commit 
insurance fraud when saying you are healthy. 
The effect was that hardly any in the Goldfield family decided to take a HCM genetic 
test. Instead, most family members took action to ‘safeguard’ their future, for in-
stance by buying a house before doing a genetic test. Genetic testing was postponed 
as a strategy to avoid ‘genetic discrimination’.  
The Green family: regretting genetic testing 
In this family, Karen, a teenager who had experienced thickness of the myocardium 
since a young age, recently had a genetic test done. The cardiologist had recom-
mended this as part of the diagnostic process, when her echo had showed a consid-
erable increase in the thickness of the myocardium. After a mutation for HCM had 
been identified, Karen’s two elder brothers, aged 18 and 20, were also offered genet-
ic testing. At this stage, the clinical geneticist’s suggestion of possible difficulties with 
insurance stimulated the parents to postpone testing their sons: 
It is not allowed to be silent about DNA; if the insurance company does a check 
and asks the biobank for information, they might get into problems. So it is bet-
ter to wait until they have bought a house. 
In the Green parents’ stories, genetic testing emerged as something other than ‘just’ 
another diagnostic tool; it was associated with themes like privacy and the prospect 
of an ‘open future’. Both parents articulated a fear of ‘big brother is watching you’ 
and worried about the family’s genetic information falling into the hands of third 
parties. These fears not only resulted in the postponement of testing their two sons, 
but also in strong feelings of regret about the decision to have Karen tested. 
You hope you are making progress, but we don’t get any further. Actually it 
gave us a fright; we had a lot of troubles taking out funeral insurance for her. 
U N R A V E L L I N G  F E A R S  O F  G E N E T I C  D I S C R I M I N A T I O N  
 
 81
For the parents, genetic testing had ‘deepened the hallmark’ of cardiovascular 
disease in Karen, reinforcing the feeling that she would be a subject to discrimination 
throughout her life. 
The Anderson family: fearing a genetic test result 
When we first met the Anderson parents and their two sons Dave and Christian, aged 
20 and 21, the boys had already been waiting for their genetic test results for a year. 
At that time both the boys had gone to the hospital with heart problems in the same 
week, and both had been diagnosed with increased thickness of the myocardium. As 
this had reminded the cardiologist of the possibility of a genetic disease, they had 
blood drawn for a genetic test. 
 In the first interviews, Christian explained that, since the HCM diagnosis, he had 
been worrying about his future, especially considering the idea that because of his 
‘heart abnormality’, employers would discriminate against him. 
If I apply for a job, I will have to tell employers that I suffer from this disease and 
I think they’ll prefer others for the job. 
For more than a year, he had been using alcohol and recreational drugs as a way of 
coping with the frustration of living with limited future prospects. In a second inter-
view with the parents – one year after the initial interview – they expressed their 
relief that Christian had gradually succeeded in keeping away from alcohol and drugs 
and, against his expectations, had found a job. However, they now started to fear the 
possible impact of Christian’s forthcoming genetic test result, as the identification of 
a genetic mutation might ‘push him off balance again’. Although Christian had 
regained his stability, genetic testing was considered as a way of ‘shaking up his 
identity’ again; a positive genetic test result of HCM might open up old wounds of 
dealing with the consequences of being ill. 
 The Anderson parents also started to worry about the test results in the context 
of having children: 
It’s not just better for Christian himself to have no result, but also for the chil-
dren he might have in the future. As long as you don’t know anything about a 
gene, you don’t have to tell anybody. 
Ignorance of the genetic test results of their sons’ disease was considered an attempt 
to deny its ‘genetic character’. Although their heart complaints could be viewed as 
genetic, as long as this had not been confirmed by the test, they felt there was still a 
possibility of ‘keeping it silent’ and away from third parties. 
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The Redford family: coping with genetic test results 
Nick Redford, in his thirties, had had a sudden cardiac arrest at the age of 15. Alt-
hough at that time, a DNA-test was not available, family history and heart examina-
tions of his father and brother had made clear that his complaints had a genetic 
character. Nick remembered that the HCM diagnosis, as well as the emphasis on a 
strict regime of limited physical exertion, had given him difficulties in the years he 
was finishing school and finding a job. Also later, when buying a house, he had 
experienced problems related to his disease, such as extremely high insurance 
premiums, and, after the implantation of an ICD, he had no longer been permitted to 
drive a car for work purposes.  
 These negative experiences, however, had never held Nick back from seeking 
the latest biomedical knowledge for the future of his young twins, a boy and a girl. 
On the contrary, they resulted in high hopes for possible treatment that would 
enable his children to escape the family’s biological fate. When the twins were three 
years old, DNA-testing for HCM became available. The children were tested and it 
turned out that one of them, the boy, had the mutation, whereas the girl did not. 
Although some in the family – particularly Nick’s mother – expressed concern, be-
cause of a fear that ‘there was already a mark on this boy’ and that it was just the way 
that ‘when filling out insurance forms, you needed to be honest’, Nick did not experi-
ence any feelings of fear or regret at all. He referred to his experiences with living 
with the disease, by emphasizing that he had always found ways in dealing with the 
problems with which he had been confronted. For example, to avoid issues with 
employment discrimination, he had started his own company. When Nick had to take 
out life insurance as part of a mortgage he had kept the amount insured below the 
predefined sum to prevent having to do a medical examination. Furthermore, in 
terms of preventing possible discrimination problems with his car insurance, Nick 
had his own specific strategy:  
I always have golf equipment in my car. If I have an accident when driving the 
car for work purposes, I can say that I am going to play golf and travel for pri-
vate purpose.  
Nick’s own preceding experiences, and the strategies he had developed to avoid 
discrimination, prompted the belief that he would also be able to help his son in 
successfully coping with the HCM mutation and its possible problems of discrimina-
tion.  
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4.4 Discussion and conclusions 
Our findings indicate that although Dutch policymakers try to prevent public fear of 
genetic discrimination by installing genetic non-discrimination regulations in the 
Netherlands, in practice, the HCM families that participated in our study were still 
concerned about insurance and employment discrimination. This study analyzes the 
processes that shape fear of genetic discrimination and provides an insight into the 
influence of at-risk families’ perceptions of fears of genetic discrimination for the 
uptake of genetic testing. The results support previous research on the concerns and 
experiences of genetic discrimination in the context of Huntington disease in Canada 
(Bombard et al, 2008), but this study is the first to provide a detailed description of 
the social mechanisms of fears of genetic discrimination. Moreover, it addresses both 
a disease like HCM for which the relationship between genotype and phenotype is 
quite complex compared with monogenetic disorders and a national context where 
genetic non-discrimination regulation exists (Dutch MEA). Although it has been 
argued that fears of genetic discrimination will be eased because of the more uncer-
tain character of many monogenic as well as multifactorial diseases (Prainsack, 2008), 
this study highlights that families living with such an ‘uncertain’ disease also ex-
pressed fears of genetic discrimination in the contexts of insurance and employment. 
Additionally, the study indicates that the installation of genetic non-discrimination 
regulations does not appear to alleviate these concerns of genetic discrimination. 
 Most importantly, our findings suggest that fears of genetic discrimination in at-
risk family research participants of HCM did not result from (the possibility of) genetic 
testing as such, but were primarily nested in pre-existing experiences of discrimina-
tion within these families. These ‘family histories’, encompassing shared experiences 
of discrimination, living with disease in the family, ‘being a member of an affected 
family’ and so on, seemed to affect the way family members decided to undergo or 
refrain from genetic testing. As such, when a clinician offers genetic testing for HCM, 
it may trigger memories of living with a cardiac disease that wreaks havoc in their 
family and the consequences of which they are all already too familiar with from 
early childhood. These pre-existing concerns of discrimination seemed to have an 
important role in justifying the non-uptake of genetic testing for the HCM family 
members and did not only result in postponement (e.g. the Goldfield family), but also 
in feelings of regret over having the genetic test done (e.g. the Green family) or the 
wish of never knowing the genetic test results (e.g. the Anderson family).  
 So, to understand the non/uptake of genetic testing, families’ previous experi-
ences of the families in coming to terms with their disease, and its societal conse-
quences, must be taken into account (See also Clarke et al, 2011). In particular, our 
findings highlight the broader context of the family and ‘family history’ of living with 
HCM and the work that families have to do in coping with genetic testing and genet-
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ic discrimination in light of previous family experiences of discrimination. This atten-
tion to the way families have managed to live their lives with disease and the strate-
gies developed to cope with discrimination or exclusion may also explain why some 
families (e.g. the Redford family) develop a positive account of genetic testing for 
HCM. This study provides further insight into the impact of genetic testing on the 
family and highlights a need to pay special attention to the familial contexts during 
pretest and post-test counselling (Geelen et al, 2011a; 2011b). These results also 
suggest the need for further research on genetic discrimination in this area. 
 The findings of this study also indicate the limits of a narrow concept of ‘genetic 
discrimination’. Genetic non-discrimination regulations that have been enacted to 
protect people from ‘genetic discrimination’ in order to enable the uptake of genetic 
testing tend to focus on the novelty and specifics of ‘genetic discrimination’. Howev-
er, when genetic testing entered the HCM families’ lives, these families already had 
previous experiences with ‘disease in the family’ and with related problems of dis-
crimination. Although previous experiences such as these are not taken into account 
in these genetic-specific regulations, they do seem to affect decision making about 
HCM genetic testing. In addition, the narratives of the families in this study seem to 
resonate a fear that is not directly related to exclusion from insurance or employ-
ment, but to larger concerns of privacy protection and disclosure of issues that are 
preferred to be kept as ‘family secrets’. Within such a view, the offer of genetic testing 
for HCM can be considered as a ‘hallmark’ of preceding concerns of discrimination of 
these ‘family secrets’.  
 Further, the families in our study seemed to be concerned about the risk that 
their children may be discriminated against in future; this was the case even when 
these children were still unborn. In this regard, our study is instructive in that both 
‘asymptomatic individuals’ and symptomatic individuals expressed concerns of 
genetic discrimination. Although the Dutch MEA protects HCM mutation carriers in 
case of non-manifest disease (the healthy ‘at-risk’) from ‘genetic discrimination’, 
these people expressed fears of discrimination as a reason for non-uptake of genetic 
testing or regret for having the test done. It is remarkable that also those family 
members with already manifest symptoms of HCM, for whom genetic testing is much 
more a diagnostic tool than a predictive one, expressed fear. Since, these people 
already faced high insurance premiums or exclusion in employment because of 
disease. Notwithstanding the MEA, family members of patients were not confident 
that information about their genetic make-up would be kept private. In contrast, 
they genuinely worried about the genetic information falling into the hands of third 
parties such as insurers or employers, and resultantly, running into further difficulties. 
While legal definitions of genetic non-discrimination regulations focus on the 
boundary between symptomatic and asymptomatic individuals in offering protec-
tion against genetic discrimination, in the experiences and interpretations of individ-
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uals and families at-risk, these boundaries were not so clearcut. Recent studies on the 
prevalence and extent of genetic discrimination have only described that people 
experience genetic discrimination based on family history (Bombard et al, 2009). Our 
findings may help to understand how the (initial) reactions to and concerns of genet-
ic discrimination indicate concerns, not only from asymptomatic individuals, but also 
from symptomatic individuals. 
 Furthermore, these fears of genetic discrimination in the context of symptomat-
ic individuals seem to resonate with broader experiences of stigmatization in living 
as a family with cardiac disease. This refers to more diffuse verdicts of social un-
worthiness, prejudice and stereotypes towards their family, and with these families’ 
coping with this kind of ‘family picture’ (Lemke, 2009). This study provides further 
insight into the role of these more ‘indirect’ forms of discrimination and broader 
experiences of stigmatization. It also highlights the need to pay special attention to 
the types of experiences that limit the choices and options available to persons or 
families ‘at-risk’ (Bombard et al, 2009; Lemke, 2009; Lock and Nguyen, 2010). These 
results suggest the need for further research into how experiences of indirect forms 
of discrimination may affect concerns relating to genetic discrimination.  
 Finally, whereas the interpretation of the Dutch MEA has been a topic of debate 
in the Netherlands, for example in the context of two recent Dutch reports of discrim-
ination experiences (Christiaans et al, 2009; Marang-van de Mheen et al, 2002), our 
study suggests that the causes of (persistent) fears of genetic discrimination should 
not be only confined to the definitions of the law and its difficult wording. Our study 
highlights that fears of genetic discrimination are often expressions of preceding 
experiences with living with the societal consequences of disease in families, where 
familial experience ranged from asymptomatic to symptomatic individuals and was 
based on their mutual interactions within the family. In other words, people’s (persis-
tent) fears of genetic discrimination may have less to do with ‘misunderstandings’ of 
the law or ‘insufficient information communication’ about the workings of the laws, 
but may be rather nested into previous experiences of being a member of a ‘family 
at-risk’. 
Limitations of the study  
In the interpretation of our findings, several considerations should be taken into 
account. First, the family members who agreed to participate in our study may be a 
self-selected group and may demonstrate specific perceptions and experiences of 
genetic testing and genetic discrimination. However, we did not study an extreme 
population. In the light of the variety of participants’ characteristics, we assume that 
these families and family members can be seen as representative for how HCM 
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families experience genetic testing, and perceive and cope with the fear of genetic 
discrimination. 
 The data was based on experiences from a Dutch sample whose concerns and 
experiences may not apply to other populations, particularly in the light of the 
specific Dutch genetic non-discrimination regulations. In genetic counselling, how-
ever, it is the perceptions and fears of the clients that are important, and thus these 
research findings also provide clinicians in other countries a framework to under-
stand and contextualize the experiences and fears that clients share with them. 
Nevertheless, different national styles in dealing with risks, and different cultural 
values with respect to genetic testing (Jasanoff, 2005; Parthasarathy, 2005; 
Daemmrich and Krücken, 2009), might have an effect on the way individuals as well 
as families experience genetic technology and the risks of genetic discrimination.  
 Finally, because the sample consisted of families in the trajectory of genetic 
testing for HCM, the study findings may not necessarily apply to other genetic and 
non-genetic populations.  
Implications of our results 
Our findings have implications for clinical geneticists as well as cardiologists who 
work with HCM families. In counselling about genetic testing for HCM, it is instructive 
for these professionals to acknowledge that providing information on genetic non-
discrimination legislation may not be sufficient in justifying the decisions of the HCM 
patients to non/uptake genetic testing. This may not be sufficient as justifications for 
genetic testing and fears of genetic discrimination may be nested in broader ‘family 
histories’ and narratives of discrimination. This implies that counselling sessions 
should be focusing less on the information provision of genetic non-discrimination 
legislation and more on the role of family dynamics and individual strategies to cope 
with the social consequences of living with HCM as possible barriers for uptake of 
genetic testing. By acknowledging the way genetic discrimination ‘connects’ with 
the broader ‘family histories’ of HCM families may be an important factor in realizing 
the potentials of genetic testing in clinical practice. 
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5.1 Introduction 
In contemporary society, protecting one’s future health is increasingly considered a 
characteristic of modern Western citizenship. People demonstrate that they are 
responsible citizens by taking an active approach to their future health, performing 
risk management and engaging in preventive health strategies. Particularly within 
genetic counselling, attention for future health is increasing. Healthy at-risk people 
are explicitly prompted to reflect upon their inherited constitution, consider different 
meanings of being affected and project these into potential futures. This notion of 
‘making’ and controlling the future is particularly reflected in the principle of auton-
omy, which is an important moral value in health care. In genetic counselling, auton-
omy is connected to a policy of non-directiveness: people should decide for 
themselves whether or not to take a genetic test; they should determine their own 
future without interference by a professional. While in genetic counselling ideas of 
anticipating the future and notions of autonomy are closely connected, we have little 
insight into how this connection works in people’s everyday lives. In this article we 
address this issue with respect to families living with hypertrophic cardiomyopathy 
(HCM). We analyse how members of these families deal with time – with the past, the 
present and the future – and show how these ideas relate to the notion of autonomy. 
Firstly, we sketch the background to the study and some current debates on auton-
omy and on the notion of time in sociology. Secondly, we introduce our cases – 
families living with a genetic risk of HCM – and explain our methodology. We then 
present the results of the analysis, and finally conclude with a discussion of different 
patterns of dealing with the future and reflecting on the notion of autonomy.  
5.2 Reflecting on autonomy and time 
Within medical practice, the importance of autonomy is undisputed; it cannot be 
imagined without this normative notion. As Stirrat and Gill state, ‘We live in the “time 
of the triumph of autonomy in bioethics”, in which “the law and ethics of medicine are 
dominated by one paradigm – the autonomy of the patient”’ (2005, p. 127). This, how-
ever, does not entail a complete lack of criticism. Several authors have argued that 
values such as justice have been undervalued in health care practice (Callahan, 1990; 
Tronto, 1993), while others have proposed more relational (Agich, 1993; Widder-
shoven, 2000) or emotional aspects of autonomy (Nussbaum, 1990). Care ethics, 
hermeneutic ethics, narrative ethics and phenomenological ethics have attempted to 
give shape to new ideals of personal autonomy and professional authority in health 
care. The individualistic value of autonomy has been complemented by notions of 
interdependence, frailty and relationships.  
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In addition to such criticisms of the concept of autonomy itself, the practical limits of 
the ideal of autonomy have also been a focal point of discussion. Sociological studies 
on autonomy have pointed to the differences between the principle of autonomy 
and the way it plays out in daily practice. Even when professionals do not apply 
pressure, the idea that people can actually make a free choice and control the course 
of their own lives has to be put into perspective. Firstly, it has been argued that 
patients, by definition, are in need of help, and therefore often lack the competence 
and independence that the principle of autonomy presupposes (Ackerman, 1982; 
Pelligrino, 2006; Tobias and Souhami, 1993). Secondly, the neutrality of information 
has been questioned, and it has been stressed that professionals’ own values and 
assumptions will inevitably influence patients’ decisions, as professionals will always 
make choices about the disclosure of medical and medical risk information based on 
the ideas about their patients’ capability or otherwise to cope with or understand 
certain information (Buetow et al, 1998). Finally, ‘anticipated decision regret’ has 
been considered a mechanism that strongly motivates people’s decisions to use 
every offer of care, as they fear not having made use of all available possibilities 
(Tijmstra 1987). 
 With the development of genetic testing practices, criticism of the idea of 
autonomy has focused on the notion of self-controlling individuals. In debates on the 
value of autonomy, it has been emphasised that people live in a world with others 
and that genes ‘do not just provide an individual with an identity, they also relate per-
sons to one another and give them an identity as “relatives”’ (Strathern, 1995, p. 104). In 
contrast to clinical medicine, which is particularly oriented towards individuals’ 
complaints, in clinical genetic practice contact comes about through the risk of a 
specific hereditary disease; thus, by definition, family members are involved in that 
contact. The information derived from genetic testing and/or pedigree analysis does 
not primarily pertain to individuals, but inevitably involves biologically related kin as 
well. This renders the individual patient the ‘family patient’ (Bourret, 2005), a ‘bioso-
cial body’ that can be constructed only in relation to his or her family (Felt and Müller, 
2011). The emphasis on autonomy, however, might detract from what specific 
decisions mean for people, for family members, and for people’s relationships with 
their family members. Recently, sociological and anthropological studies have ex-
plored the gap between guidelines with respect to autonomy and daily genetic 
practices. As genetic tests for an individual not only reveal risks for family members, 
but family members’ blood and medical histories may be needed to contribute to an 
individual’s genetic diagnosis as well, potentially at-risk individuals need to do a lot 
of work to gather all the available information (Gibbon, 2007; Boenink, 2008).  
 In a similar vein to this criticism of the idea that people can control their own 
lives, the implicit idea that autonomy guarantees people’s control over their own 
future has also been criticised. In recent decades, time sociologists and philosophers, 
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such as Barbara Adam, have pointed to how, in the course of history, perceptions and 
meanings of the future and sense of time have come into being in different ways 
(Adam, 1998). In ancient and traditional cultures, the temporal domain was consid-
ered as belonging to the gods, and the unknowable future pre-existed as fate. In this 
deterministic worldview the future was fixed and people had to take life as it came, 
dealing with unexpected events as best they could. Past, present and future made up 
a single entity. Only with the advent of modernity was the future no longer seen as 
determined. The understanding of time was replaced with the idea of the future as a 
‘fortune’, which entailed an ‘empty’ future ours to make, shape and exploit (Adam, 
2010). Past, present and future became differentiated, and people had to forge a 
relation between the past and the present. In a context in which the future was seen 
as the result of choices, people were stimulated to predict the future in order to 
regulate uncertainties. The idea of making and controlling the future implies a linear 
relation between past, present and future, which means that the past is considered a 
source of knowledge of the present and the foundation for a predictable future. 
Within genetic practice this perspective on time dimensions, which is closely tied to 
the standard notion of autonomy, can be recognised: prior findings concerning the 
relations between disease processes and specific mutations, as well as the activation 
of past memories in the family, are used to make causal connections between earlier 
and later events and to move people in new, particular directions.  
 In present-day, post-modern risk-societies, however, the idea of ‘owner’ and 
‘maker’ of an empty future turns out to be fiction, as ‘past empty futures begin to 
impose themselves on the present, restricting choices and options’ (Adam, 2010, p. 368). 
In her work, Adam refers to the many creations produced in the present and extend-
ing over a distant future that have brought about progress, but also unexpected 
catastrophes, such as environmental disasters. The complexity of post-modern life 
appears to have decreased our grip on the future, and it can be questioned whether 
it is still realistic to assume that probable futures can be calculated based on data 
gathered from a known past. In the context of genetics, research has shown that 
future life is often not as predictable as previously thought. People can be confront-
ed with unclear, ambiguous test results (van Zwieten, 2008) or with new uncertain-
ties and new dilemmas, such as how to live with a positive genetic test result when 
nothing can be said about when and how the disease will affect them (Boenink, 
2008). Due to the complex interplay between genes and environment, as well as the 
involvement of many different genes, it is hard to foresee whether and how geno-
type findings will be phenotypically expressed (Geelen et al, 2011a; Lock, 2008). These 
findings imply that genetic test results do not ‘represent’ the future, and raise the 
question whether it is really possible to understand and foresee future life in terms of 
risks of a genetic disease, and to take decisions to protect future health on that basis.  
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Against the background of these discussions on the notions of ‘making-the-future’ 
and ‘future time’, this article analyses the narratives of members of families living 
with hypertrophic cardiomyopathy (HCM). It identifies people’s articulations and 
representations of the future in relation to pre-symptomatic genetic testing: the way 
they experience, imagine and give sense to future time. What relationships do they 
construct between the past, the present and the future in a context where the pro-
tection of future health is strongly emphasised? What does this imply for the actions 
they take in the present?  
5.3 Following families living with HCM 
This study is based on the assumption that genetic testing stretches over time and 
autonomy is shaped over the course of that time instead of at a specific moment; 
people usually take time to decide to undergo testing, obtaining a test result can 
take months or even years, and the entire genetic testing process can drag out as 
family members undergo successive tests. With this in mind, we followed six extend-
ed families involved in genetic testing for HCM: what processes did these families go 
through after the option of genetic testing entered their lives? 
 HCM is considered the most common genetic cardiovascular disease, affecting 1 
in 500 people worldwide. It is associated with sudden cardiac death at a young age, 
especially in athletes, but is also seen as an important cause of heart failure in later 
life (Hershberger et al, 2009; ICIN, 2010). Geneticists have shown that more than 1400 
mutations in at least 11 genes, mainly coding for sarcomere proteins, play a role in 
the manifestation of the disease (Maron and Maron, 2013). Genetic testing, however, 
still does not guarantee a conclusive result; in about 40 percent of the families with 
HCM who undergo testing procedures, no mutation will be found. HCM follows an 
autosomal dominant inheritance pattern, which means that children of a parent who 
carries the mutation run a 50 percent risk of being a carrier as well. However, the 
meaning of being ‘at risk’ or even ‘affected’ is uncertain, due to the variable expres-
sion and penetration of the disease. Even within one family, the expression of the 
disease can vary strongly; some carriers of a mutation demonstrate no clinical symp-
toms, while others have an increased hypertrophy of the myocardium or severe 
arrhythmia, and suffer from serious heart failure or die after a cardiac arrest. Currently 
there is no cure for HCM, but following lifestyle advice (such as refraining from 
competitive sports), echo- and electrocardiographic monitoring, or implanting a 
cardioverter defibrillator (ICD) may help to prevent a cardiac event. Certain medica-
tions and septal reduction therapy are both associated with functional improvement 
and long-term survival (Fasa and Sigwart, 2010). Although there are no real means to 
safeguard the future, geneticists as well as cardiologists often see pre-symptomatic 
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genetic testing as a way of assessing the disease risks of relatives long before clinical-
ly manifest dysfunctions appear and thus of controlling the disease in asymptomatic 
mutation carriers through close cardiological follow-up and lifestyle advice. 
 Our study draws on ethnographic fieldwork and qualitative sociology (Gupta 
and Ferguson, 1997; Hammersley and Atkinson, 1995). This approach is appropriate 
to gain insight into the social processes that develop specific interpretations of 
dealing with genetic test decisions in the context of family and kin. People’s stories 
show how they experience themselves and how they live their lives. In previous work 
(Geelen et al 2011a; Geelen et al 2011b), we described the processes of data collection 
and data analysis in detail; therefore, here we give only a summary related to the 
data reported in this article.  
 In total 57 people were interviewed in depth. The first author (EG) visited them 
in their homes and also had telephone and email conversations with some; some 
were accompanied to the counselling session and one was visited in the hospital. As 
we were interested in the events happening in the family over time, and in the 
processes families as well as individual family members were undergoing, many were 
subsequently interviewed once or twice more.  
 In semi-structured interviews, participants were asked to reflect on how they 
learned that the disease ran in their family and how they got involved with genetic 
testing, to describe the impact of living with the disease and with genetic testing, to 
explain their decision with respect to undergoing (pre-symptomatic) genetic testing 
or not, to discuss their considerations with regard to testing over time, and to elabo-
rate on how family members dealt with it and how it affected them. Particularly, they 
were encouraged to talk about their everyday experiences with the familial disease 
and the possibility of genetic testing. 
 In the narratives of the family members, pseudonyms have been used to protect 
their identities. 
5.4 Dealing with the future in everyday life: four cases 
A strong belief in making-the-future 
The first pattern we distinguish in the way our participants represented the future 
was identified in the Redford family. In this family the possibility of pre-symptomatic 
genetic testing had been welcomed with open arms as a way to gain control over the 
future lives of their young twins, a boy and a girl. Nick Redford, the father of the 
twins, aged 33 at the time of the first interview, had had a cardiac arrest at 15. At that 
time DNA testing for HCM was not available, but family history as well as cardiac 
examination of his father and brother had made clear that heredity played a role. 
Nick had always suffered from serious heart complaints and had been confronted 
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with many setbacks in playing sport, finishing school and finding a job. Due to these 
experiences, for many years he had felt that the risk of passing on the disease meant 
a future without children. Yet, he and his wife finally decided to accept the 50 per-
cent recurrence risk. When explaining this change of heart, Nick expressed a highly 
positive stance towards scientific research and technological progress: ‘My motiva-
tion [to have children, EG] was that I’ve seen that knowledge and technology develop. 
Nowadays many possibilities to make life liveable are already available. I’m absolutely 
convinced that within ten years this disease will be treatable’. This quote illustrates a 
strong belief in a future in progress, a future to be made. 
 It therefore comes as no surprise that as soon as genetic testing for HCM had 
become available, Nick had seized the opportunity immediately. He had been tested 
together with his father and brother, and when a mutation was found, the twins – 
three years old at the time – had been pre-symptomatically tested. Nick stated that 
‘insight into their genetic constitution is a step towards better health’. His eagerness to 
face his children’s genetic make-up stemmed from the assumption that he could 
deal with the outcome, whatever it may be. He was convinced that new possibilities 
in the future would make his children’s lives brighter than his own life had ever been, 
and he would thus be able to deal with a bad result. Nick linked the knowledge of his 
children’s genetic make-up to being a ‘better’ parent. ‘For me the question was, how to 
raise them; should I protect them or let them go?’, Nick said, adding that he was sure 
that ‘growing up with the knowledge is better than being confronted with it later in life’. 
Through being well informed in the present, he expected that his children could live 
more healthily as well as happily in the future. 
 Testing had revealed that one of the twins, Philip, had the mutation, while his 
sister, Julia, did not. During the first interview with Nick, which took place one year 
after the children had undergone the genetic test, he explained that in spite of 
Philip’s ‘bad’ result, he had felt relieved: ‘To increase his life expectancy, Philip can grow 
up without any pressure to play competitive sports (….) We did that test to keep things 
under control; that’s the benefit of genetics’. Testing his children had created a new 
present, a present with the opportunity to bend their future into a positive direction. 
Yet, not all members of the Redford family thought this way. Particularly Nick’s sister-
in-law had expressed concerns about the fact that Philip was now restricted in his 
freedom of movement. In response to her comments that life needed to be lived in 
the present as well, Nick defended himself by emphasising: ‘We allow Philip to do 
everything he wants; he can play sports, even football; he just has to take it a bit easy’. 
 Two years later we met Nick again. Philip was now old enough to be aware that 
he was under the supervision of a cardiologist. ‘We don’t relate his heart check to the 
heart complaints I suffer from’, Nick said. Notwithstanding his own serious heart 
problems at the time – he had had several heart surgeries in the past year and was 
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still in poor physical condition – he showed a strong belief that Philip could escape 
the family’s biological fate. 
 Nick’s story demonstrates an experience of time as linear. Testing was seen as a 
way to escape the family’s past and to realise another, better future. The analysis 
makes clear that Nick believed in making the future and that for him genetic testing 
was a vehicle to break through the linearity between past, present and future.  
Unable to believe in making-the-future 
In contrast to the strong belief that the future is to be made we saw in the Redford 
family, in the other families some family members were not able to believe that with 
genetic testing they could make the future their own. This second pattern of repre-
senting the future was characteristic of, among others, the 45-year-old Patricia 
Goldfield.  
 Throughout the first interview we had with Patricia, it became apparent that the 
identification of the mutation in the family had confused her, as ‘it was told that the 
good echo I had no longer gives me any guarantee of a future without the heart disease’. 
Patricia explained that several of her family members had died sudden deaths, that 
heart disease was present in her side of the family – her mother had been diagnosed 
with a mildly thickened myocardium and most of her six brothers and sisters suffered 
from hypertension – and that she herself had fluctuating blood pressure and occa-
sional arrhythmia. As a result, she had had a heart examination, which, fortunately, 
had shown no signs of abnormality. Since then she had felt relieved and looked upon 
her future as being quite free of the family disease. With the evidence that the dis-
ease was genetic, however, she again felt her present life burdened with the risk of 
the disease. She genuinely struggled with the question whether she would be able to 
find peace through being tested. 
 Patricia started the interview by explaining that from the moment the mutation 
had been identified, she had intended to have the test done. When asked about her 
motives, she particularly emphasised her children’s future: ‘If I definitely don’t have it, 
my children don’t either (…), so then we can close the book’. Patricia pointed to the 
biological relationship between her and her children and to her interest in ruling out 
the risk of the disease for them. During the interview, however, various comments 
about how she lived her life with the risk of HCM and the possibility of genetic test-
ing raised doubts as to whether she really wanted to be tested. 
 Patricia had to delay her own decision while waiting for her mother to undergo 
the test, as, in line with the guidelines in genetic practice, children do not typically 
undergo predictive genetic testing before a mutation has been identified in their 
parents (provided they are still alive). Her mother, however, had a lot on her mind, 
and took no initiative when it came to getting tested. If this were to take too long, 
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Patricia indicated that she would consider going herself, although this, too, was 
unlikely to happen in the short term: ‘I’m so busy with anything and everything, I’ve got 
my work, we still have a wedding, several birthday parties, exam celebrations and we’re 
going on holiday’, she said, emphasising the importance of having her mind at rest 
when she was due to receive the test result: ‘You can’t know in advance how that [a 
potential bad result, EG] will affect you’. This association between testing and the 
possibility of getting bad news gave her cause for concern and hesitation about 
being tested. Another reason for us to doubt whether she genuinely wanted to go 
through with the test was her lack of belief that knowing whether she had the muta-
tion or not would do her any good: ‘Initially I thought there might be some medicine, 
but the cardiologist told me that at the moment you can’t do anything.’ 
 This lack of belief in a controllable future also emerged from the second inter-
view we had with Patricia one year later. By then her mother had had the genetic test 
done and had been informed that she did not have the mutation. As a consequence, 
testing should no longer have been an issue for Patricia. Yet, it still appeared to haunt 
her: ‘My mother has that thickened myocardium, it’s so strange (…) I have to accept it 
[that I don’t have the mutation, EG], but I regularly question whether that test was done 
well; maybe they made a mistake. It’s hard to put that out of my mind.’ This meant that 
Patricia continued to think about whether she herself should get tested or not. In 
light of the experience with her mother’s test, however, it seemed that no test result 
– be it positive or negative – would give her any sense of control over her future life. 
 As with Nick’s story, Patricia’s story demonstrates a linear experience of time; 
past, present and future were related to one another in a linear fashion. Her mother’s 
diagnosis and her own heart problems generated fear for her children’s future. 
However, in contrast to Nick, Patricia did not believe in the idea of making-the-future. 
Her mother’s good genetic test result did not help her gain a sense of control and 
free her of her concerns; as a result, having her own genetic test would not be help-
ful. The analysis shows that to her, the future was something that happened rather 
than something to be controlled. 
Refusing to believe in making-the-future 
In the Goldfield family we saw yet another pattern of representing the future. For 
example, 55-year-old Katherine – a cousin of Patricia – explicitly refused to believe 
that the future could be controlled and that undergoing a pre-symptomatic test 
would provide her with a better future life.  
 Katherine explained that from the moment the mutation had been identified in 
the family, she had never considered undergoing a genetic test. This, she empha-
sised, was in line with how she always had dealt with the risk she ran with regard to 
the family disease: ‘I’ve never had much interest in that hereditariness. (…) I never had 
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the cardiac echo that others in the family had fifteen years ago’. She associated this 
attitude with her philosophy of life: ‘There’s no time like the present’. In the same vein, 
she did not concern herself with certain physical complaints that she related to her 
stressful life: ‘Sometimes I have heart palpitations and feel oppressed in my chest, but 
then I think it’s nothing serious, so I’ll see’. Katherine could imagine having the muta-
tion – she had even a premonition about having it – but she did not want to worry 
about that: ‘Knowing in advance that I’ll suffer at some point from heart complaints and 
have limited physical possibilities, I’m sure this would make me a very difficult women’, 
she explained, adding that she felt no need at all to worry: ‘I’m not waiting for that 
genetic knowledge. Why should I? There’s no therapy available’. Moreover, notwith-
standing the fact that many of her relatives suffered from severe heart problems, 
some experiences in the family had prompted her to feel free to deal with the future 
the way she did: ‘Many in the family who have the disease grow old with it. When I look 
at my mother, she has this thickened myocardium, and she’s already 83 and hardly has 
any complaints, so why should I worry? I also think that it’s more serious in the male line; 
the disease seems to hit men in particular.’ 
 Katherine’s preference to let life run its own course and leave the future to 
chance did not mean that she did not engage with hereditariness. She closely fol-
lowed the events within the family concerning the genetic disease, and could explain 
precisely how others in the family perceived genetic testing as well as their test 
results. Further, despite fostering a present without the ‘burden’ of genetic 
knowledge, she was not indifferent towards her as well as her children’s health. 
Several times during the interview, she said that in the case of actual complaints she 
would absolutely take the family history and family knowledge of the gene into 
account. ‘I’ll never bury my head in the sand; if I were to have heart problems, I would go 
to the doctor immediately. I particularly think of the risks my two daughters [aged 17 and 
15, EG] run. Some years ago I requested for a cardiac echo for them. (…) It’s important to 
know about the heart disease running in the family and that it’s in my as well as my 
children’s medical records; it will back me up if I have to demand proper examination or 
treatment from a doctor.’ For Katherine, therefore, knowledge of the family risk did 
afford her a certain degree of control; not so much to predict or control the future, 
but for diagnostics in the present.  
 About a year later, we interviewed Katherine a second time. Although she had 
still not been tested, she could imagine that things might change at some point: ‘I’ve 
kept the letter and maybe in ten years, when life is quieter, I’ll think, “okay, I’ll go for a 
test”. But I’ll only do this if therapy has become available to prevent further thickening of 
the myocardium.’ More interest in knowing about her genetic make-up was therefore 
explicitly linked to more certainty about measures to be taken to prevent disease in 
the future. 
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Although she preferred to live her life in the present, leaving room for coincidence 
and chance, Katherine’s story shows elements of linearity. Her attentiveness to 
potential heart complaints by her daughters in light of the family disease is evidence 
of a present life related to the past in a rather direct way. When describing her moth-
er’s experiences of living with a thickened myocardium, Katherine was making a clear 
reference to her own future. She believed in predictability, but she refused to believe 
in a future to be made by her. 
Protesting against making-the-future 
We saw a fourth pattern of representing the future in the 37-year-old Natalie Lewis. 
After an HCM mutation had been identified in her mother as well as in her aunt (her 
mother’s sister) about 4 years before we first met her, she had felt a certain degree of 
pressure to think about pre-symptomatic testing and to imagine her future. From the 
outset, however, she had protested against the idea that her future life could be 
constructed on the basis of a genetic test result. 
 Reflecting on her decision not to undergo a genetic test, in the interview it 
became clear that Natalie did not believe in the abstract information generated by a 
genetic test. In the first place, she was clearly doubtful about the hereditary character 
of the heart disease from which her mother had already suffered for years. She 
remembered the sudden death of an uncle, 13 years before, but did not believe this 
event in the past was related to her mother’s current complaints and her own future: 
‘For me there’s no indisputable evidence of a family disease. I don’t see a clear disease 
pattern; the complaints are so different. I find it difficult to believe that I’m at a high risk of 
disease.’ Secondly, Natalie relativised the advantages of having a genetic diagnosis. 
With respect to the impact identification of the mutation had on her mother’s life, 
Natalie described a sort of ‘tunnel vision’: ‘I’m convinced of the fact that stress is the 
greatest cause of her tiredness, but knowing about this gene absolutely prevents her from 
picking up any other bodily sign. Her complaints may be attributed to many other things, 
but due to that diagnosis these are ignored. Imagine if she were to develop symptoms of 
diabetes or get dizzy – the first thing she’ll think about is her heart disease. I wonder 
whether it’s that good to know, and so I try to persuade her to see her complaints and the 
mutation separately, at least partly.’ Thirdly, she questioned the predictive power of a 
genetic test result. ‘Say I get the genetic test done; after that I’ll know whether I’m a 
carrier of the gene or not, but actually I won’t know anything; I can have the gene without 
having the disease.’ 
 Just as for Katherine, for Natalie, not being engaged in genetics did not mean 
she did not worry about the future or was not engaged with her health. Quite the 
contrary – as a consequence of the confrontation with the risk of a heart disease, she 
had been motivated to increase her fitness programme. In addition, she had decided 
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to place herself under the supervision of a cardiologist and have cardiac echos. When 
talking about her motives for doing so, with visible anger she took the family letter 
received via her mother. ‘HCM can cause sudden death; it might be important to know 
whether you have the disease as well. Regular examination by a cardiologist is advisable’, 
she read loudly, adding, ‘I really question whether they think about the unrest that’s 
caused by this letter.’ Her mother’s genetic test result had forced her to reinterpret the 
family history although she had been reluctant to do so, and in view of the infor-
mation in the letter, it had been impossible to ignore her at-risk status. In this light 
she could not understand why her cousins undertook no action at all. While she did 
not believe she could get her future under control with a genetic test result, for her, 
the least she could do was to have an echo to find out about the actual condition of 
her heart. 
 One good echo, however, did not mean the end of the story. During her preg-
nancy, the midwife framed her as well as her unborn child’s actual and future health 
in terms of the risks of the family disease. Again, genetics became part of Natalie’s 
life. Feeling responsible for her child – ‘It wasn't just my own health, but also my child’s; 
that felt completely different’ – she had another cardiac echo. That diagnostic tool 
provided her with what she wanted to hear: information about the present. 
 The analysis of Natalie’s story shows that she believed neither in the predictabil-
ity of the future nor in the making of the future. Although it was under protest, she 
acknowledged that she was at risk of a heart disease and took measures, such as 
having a cardiac echo and increasing the amount of exercise she did. By doing this 
she was not trying to control her future; she was aiming to feel well and to ensure 
she was healthy in the present. 
5.5 Conclusion 
The development of genetic testing and genetic counselling very much imply a 
notion of autonomy in which people take an active stance towards their fu-
ture, trying to foresee and control their future and their future health. In the above 
analyses we have shown how family members in families with HCM deal with the 
future in the everyday processes of making decisions about genetic testing. The four 
cases show that people imagine and deal with the future in different ways. In a 
certain sense, all four family members presented above related to the past as well as 
to the future: genetic testing brought their family history as well as the future risk of 
disease into their present lives. However, whereas Nick considered genetic 
knowledge as a way to manage his own as well as his children’s future lives, the three 
women – Patricia, Katherine and Natalie – focused primarily on their own as well as 
their children’s wellbeing in the present. They were, respectively, unable to believe in, 
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refused to believe in, or protested against the very notion that genetic testing would 
help them to control their future lives. What do these different ways of dealing with 
the future tell us about the kinds of autonomy that are articulated in these stories? If 
autonomy is to be understood as a future-oriented habitus that aims for control 
while valuing the present only as a means to control the future, we should interpret 
the cases of Patricia, Katherine and Natalie as showing a lack of autonomy. Our 
analysis, however, demonstrates that things are not so straightforward.  
 Callon and Rabeharisao (2004) and Huniche (2011) have documented members 
of families living with a genetic disease – ‘Gino’ and ‘Colin’ – who did not want to be 
informed about the disease, totally rejected participation in genetic networks, purely 
focused on the present and made no plans for the future. Although in genetic prac-
tice it is generally assumed that making use of genetic services demonstrates a 
greater sense of responsibility than not drawing on these resources, both authors 
concluded that individuals who do not allow medical genetics into their lives cannot 
be judged as living morally flawed lives. Compared to Gino and Colin, who made 
clear that they wanted neither to engage with genetics nor to take responsibility for 
their future, the three women in our analyses did in fact relate to genetics. Their 
future perspectives changed after genetic testing had entered their lives, and alt-
hough they were sceptical about the power of genetics, they did follow the norm of 
being engaged with genetics. They were informed about the genetic disease and 
actively followed the genetic testing and processes of dealing with disease that 
others in their families were undergoing. They simply had different ideas about what 
would be the best thing to do. As they did not want to change their lives radically, 
they followed various other strategies for living with the risk of a genetic disease, 
such as having echos and being alert to actual symptoms. 
 The work of contemporary philosophers like Nussbaum (1986) and de Mul 
(2006) also offers some clues to the question what kind of autonomy is expressed by 
those who are not eager to be informed of their genetic make-up in order to make 
and shape their future lives. Both authors have argued that the myth of making and 
controlling life loses its force given that many things that happen in people’s lives are 
beyond their control: ‘Life is as it is, but it could have turned out differently. Who we 
are and who we will be is not so much the result of our own choices, but much more 
a matter of bad luck; also our best luck often enters our lives by chance’ (de Mul, 
2006). This means that responding to unexpected circumstances and balancing 
between order and coincidence have to be seen as important elements of people’s 
lives. An attitude of ‘good things take time’ or ‘time will tell’ cannot be seen as ne-
glecting to take responsibility for the future or as a lack of self-control. In other 
words, the expression of autonomy should not just be seen as being eager to know 
and getting one’s future life under control, but also as allowing for coincidence and 
openness. 
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In line with this, time sociologists and philosophers argue in favour of a notion of 
autonomy which gives more space to the different ways of articulating the future. 
Current debates on the relation between various time dimensions in post-modern 
life put the idea of making the future into perspective. It is argued that with the 
growing complexity of postmodern society, the future is increasingly conceptualised 
as part of the present, as people are only able to control the near future and so 
cannot take responsibility for the distant future. Past, present and future become less 
differentiated or, as Huijer (2005) has stated, future and past are enfolded into the 
present. How the near future will come to pass depends on the choices people make 
in the present based on their past experiences and on their knowledge of the future. 
This idea of time compression, called the ‘extended present’ (Nowotny, 1985) or 
‘time-as-present’ (Huijer, 2010), means that being oriented towards the present does 
not imply a blinkered life: people do in fact think about the future and pay attention 
to their past. Following Adam (1998), Huijer (2008) offers a notion of time as a plurali-
ty of heterogeneous time concepts and experiences. Due to the endless possibilities 
people have in contemporary society, the time constellations they live in are contin-
uously changing. This means the idea that we only live in the present (a narrow 
variation) can coexist with ideas of time as linear (wider variations of living in the 
present).  
 This is reflected exactly in all four of our cases: although in everyday life the 
participants balanced the present and the future in different ways, they all aimed to 
live good lives in the present as well as to anticipate the future. Nick was highly 
oriented towards the future, but also towards the present: he did not just want his 
son to live as risk-free as possible in the present in order to create a healthy future; 
rather, he also wanted him to have a liveable life in the present. The three women 
were very much oriented towards the present, but were engaged with the risks of 
the family disease as well. Following Nussbaum and de Mul, it may be concluded that 
these different balances with respect to the present also demonstrate the multiple 
faces of autonomy. This contrasts with the notion of autonomy as strongly tied to the 
idea of making-the-future. 
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Chapter 6 
Reflecting on families and genetics 
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6.1 Introduction 
In this thesis I have analysed how Dutch extended families live with genetics. As the 
four empirical chapters have shown, different families ‘do’ genetics differently. 
Notwithstanding this variation, in the lives of these six families genetics was not as 
much of an issue as is often thought. Whereas genetic testing has become a major 
public issue since the 1990s, families do a great deal of ‘work’ that makes the issue 
not so important. In this final chapter, I summarise the insights provided in the four 
empirical chapters. How do families live with the promises of genetic testing and 
how do genetic testing trajectories affect their lives? In addition, I discuss these 
insights in the context of current debates on the sociology of the family and on 
medicalisation and geneticisation. In the last section I reflect on the insights yielded 
by my study by interpreting them in terms of the work of the philosopher Martha 
Nussbaum (1986, 1990). Her notion of striving for ‘a good life’ appears to cover well 
the work these families do and may serve as a starting point to reflect on the aims 
and techniques of professional clinical counselling. 
6.2 Families living with genetic testing 
In the first empirical chapter, I readdressed the idea of genetic knowledge as an 
inevitable challenge to family and kin relationships. In all families in this study, the 
family members who first dealt with genetic testing already had complaints. In most 
of the families heart disease or sudden cardiac death had already been incorporated 
into the family identity. In that sense it was not so surprising that for these families 
the offer of genetic testing or the news of a mutation was rather a confirmation of 
what was already more or less known; for them genetics became just one more part 
of a longer history. In contrast, in the family with no known history of heart disease – 
the Green family – the suggestion to the 14-year-old Karen to undergo genetic 
testing and her positive test result came as a shock. During the testing trajectories 
followed for this study, it became clear that families shared genetic information with 
their relatives and lived with this genetic knowledge in different ways. In line with 
established family patterns, some immediately announced the news to the family, 
while others held back and waited for ‘a good moment’. Although in some families 
the topic of genetic testing gradually became less important as time passed, in other 
families it remained a recurring theme; particularly events such as disease, birth or 
death and the testing of children could keep genetics on the family agenda. One of 
the main conclusions of this first empirical chapter was that, notwithstanding family 
members’ struggles and doubts in dealing with newly raised questions and concerns, 
getting involved in genetic testing did not have a major influence on their everyday 
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lives. This, however, was the result of a great deal of ‘balancing work’. Karen Green’s 
mother, for instance, though she felt sad and disappointed that she could not share 
her sorrows about Karen’s genetic diagnosis with her brothers, went on playing 
korfball with them, and so actively prevented genetic testing from significantly 
affecting their shared family life. In the Lewis family, although Marian considered her 
sister rather careless in informing her children, she tried not to be too meddlesome 
and to ensure that the weekly joint dinner remained a nice family event. In addition, 
other things in life, such as organising a removal, settling a divorce, celebrating a 
wedding party or finishing a degree – but also dealing with the heart disease from 
which many family members suffered – were often given higher priority than the 
issue of genetics. Thus, differences in living with genetics related not so much to the 
effects of genetics as such, but much more to the expression of existing differences 
in attitudes to life. Genetic testing in the families was not as important as family 
‘work’. 
 An important issue with which the parents in all six families struggled was their 
children’s genetic predisposition. While parents often accepted quite readily their 
own membership of a family with a familial disease and risk of developing that 
disease, they found it much more difficult to accept that their children were at risk. 
This was not only the case in families where a mutation had been identified and pre-
symptomatic testing was a serious option, but also in families where the heart dis-
ease running in the family had not (yet) been identified as genetic. In chapter three, I 
described the different ways families thought about and dealt with the testing of 
children. In the two families where children already had health complaints, the 
decision to do a genetic test appeared to be taken easily: the Green as well as the 
Anderson parents strongly believed that their children might benefit from a genetic 
diagnosis. However, as was shown, during the process these initial high hopes grad-
ually changed into doubt, disappointment or regret. With respect to pre-
symptomatic genetic testing, parents often had difficulties deciding what to do: it 
was not clear whether knowing about their child’s genetic make-up would be bene-
ficial or not. Some parents, such as the cousins Ted and Harry Goldfield, stressed the 
children’s right to make their own decisions later in life. Both felt that they should not 
take such decisions for their children, and wondered whether ‘knowing’ would really 
provide them as parents with information that would be of indispensable value in 
raising them. In contrast, the Redford parents expected that genetic testing would 
enable their children to escape their biological fate. Memories of their experiences of 
the disease from their own youth stimulated these parents’ concerns about their 
children’s risks, and they believed that the younger the children were tested, the 
better. In any event, a child’s positive test result implied a great deal of balancing 
work. Philip Redford’s social network, such as friends and school teachers, was in-
formed to discourage him from engaging in strenuous physical activity. At the same 
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time, his parents tried to make his heart disease more or less normal and to prevent 
him from already feeling like a ‘patient’. In the families’ stories it also became clear 
that parents struggled with the fact that their children’s and their own interests were 
intertwined when it came to genetic testing. Whereas some, such as Eileen Goldfield, 
decided to have themselves tested to find out whether their children were at risk, 
other parents doubted about this for years or did not end up taking this step at all.  
 Fear of potential genetic discrimination sometimes led parents to postpone 
testing of their children, or – as was particularly the case in the Green family – to 
regret the fact that a child had already been tested. In chapter four these fears were 
examined against the background of Dutch anti-discrimination legislation. While this 
legislation aims to provide protection against genetic discrimination with respect to 
insurance and employment and to alleviate public fear, in some families a positive 
genetic diagnosis was still related to potential discrimination. These fears were not 
the result of genetic testing; rather, they followed from the families’ experiences with 
discrimination due to the disease. For instance, the fact that Ted Goldfield, who had 
been diagnosed with a thickened myocardium, had to pay high insurance premiums 
and experienced uncertainty about his job led to caution with respect to genetic 
testing among many of his relatives. For them, buying houses, securing life insurance 
or changing jobs had higher priority than being informed about genetic risks. This 
chapter pointed out that the notion of genetic discrimination, which forms the basis 
of anti-discrimination regulations, is too narrow to understand families’ fears, as 
these fears refer not only to threats to privacy posed by insurance companies or 
employers; in the Green and the Anderson families, genetic testing was associated 
with a feeling of ‘big brother is watching you’. These families’ concerns that infor-
mation about the familial disease would leak to third parties meant that they pre-
ferred to keep it a family secret. However, the prospect of living with a positive 
genetic diagnosis did not result in fear in all six families involved in the study. Nick 
Redford found several strategies to cope with potential problems of discrimination, 
such as starting his own company and keeping golf equipment in his car to mask car 
trips for work ends. 
 Chapter five focused on how family members related the promises of genetic 
testing as articulated in public discussions to their own lives. While in public debates 
genetic testing is framed as an opportunity to control one’s future life and future 
health, the present analysis of how the future was represented in families’ everyday 
lives showed a more nuanced picture. Whereas for one family member – as revealed 
in Nick Redford’s story – genetic testing could serve as a possibility to escape the past 
and realise a better future, others did not have such high expectations. Patricia 
Goldfield’s mother received a negative genetic test result, but because the mother 
had previously been diagnosed with a thickened myocardium it was impossible for 
Patricia to believe that genetic testing would help her to ‘make’ her future life. For 
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one of her nieces, Katherine Goldfield, the limited prevention options also resulted in 
a kind of refusal to believe she could ‘make’ her future. At the same time, the mild 
manifestation of the heart disease among many family members reinforced her 
notion of not being too concerned about her own future. Finally, Natalie Lewis, who 
protested against the notion of ‘making’ the future, could see no good in her moth-
er’s genetic diagnosis. The fact that these women did not have high hopes of genetic 
testing did not mean that they did not relate to genetics. The genetic underpinning 
of the familial heart disease had forced them to reflect on their inherited constitution 
and face their at-risk status. This resulted in precautionary measures: by living as 
healthily as possible in the present and by being alert to disease symptoms, they 
tried to decrease the risks of developing complaints or facing sudden death. In other 
words, not believing in the possibility of controlling the future by means of genetic 
testing did not result in indifference to the familial disease. The stories of the family 
members illustrated that engaging with genetics changed their perspectives of the 
future on the one hand, but at the same time did not restrain them from striving for 
wellbeing in the present. I concluded that for families living with this familial heart 
disease, genetic testing cannot be considered an indispensable tool to shape a 
‘good’ life: acknowledging contingencies and focusing on the present are also im-
portant for leading a good life. 
 In the four empirical chapters I showed that the introduction of genetic testing 
in families with HCM has quite an impact in these families in the sense that they have 
to deal with new questions, issues and concerns, but that genetic technology does 
not ‘determine’ family life. My methodology of following extended families over time 
enabled me to conclude that genetics is just one of the many ingredients and chal-
lenges in families’ lives, and it may mean different things in different families. The 
stories of HCM family members have revealed the various kinds of family ‘work’ in 
dealing with the opportunity for genetic testing, in putting the promises of genetics 
into perspective and in giving meaning to genetics in such a way that suited their 
everyday lives. From my study it appears that the question that came to the fore 
during the rise of genetic testing – that is, whether genetics might either ‘make’ or 
‘break’ the family – appears to be framed inadequately, ascribing too much power to 
genetic testing. It has been shown that what ‘makes’ family life is families. In the next 
section, I discuss further how these insights can contribute to the debate on the 
geneticisation of the family. 
6.3 Geneticisation of the family? 
As was mentioned in the first chapter, the start of the Human Genome Project and 
the so-called ‘genetic revolution’ was accompanied by fierce debates about the 
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societal impact of genetic technology. There were both high hopes and strong fears 
that these new technologies and the new knowledge of DNA would affect social life 
and people’s identities enormously. Concern about the assumed major influence of 
genetic technology was expressed in the sociologist Lippman’s (1992; 1993) coinage 
of the term ‘geneticisation’, a concept that echoed the notion of medicalisation 
introduced in the 1970s by Illich (1976) to criticise the power of the medical profes-
sion with respect to the experience of health and disease. Geneticisation means that 
the discourse of health and disease is increasingly dominated by genetics, thereby 
reducing health and disease to an issue of DNA and neglecting the social dimension 
of health. Although the notion of geneticisation was initially fruitful in mobilising a 
critical perspective of genetic technology, a decade on, geneticisation was put into 
perspective. For instance, several scholars pointed to the contested, complex and 
uncertain understanding of diseases as genetic. Cox and McKellin (1999) mentioned 
the role of social and biographical processes in disease, and Hall (2005) sketched the 
importance of heterogeneous networks in the making of diagnoses and diseases. 
Hedgecoe (2001; 2002) argued that the notion of geneticisation ascribed too much 
power to genetic technology as such in transforming society and health care and 
neglected the work people do during the processes in which genetics and society 
become mutually attuned.  
 The geneticisation thesis was further challenged by the introduction of the 
concept ‘biosociality’, which expresses the interrelatedness between ‘the biological’ 
and ‘the social’ (Rabinow, 1996; Gibbon and Novas, 2008). It is argued that in the 
interaction between the biological and the social, new genetic knowledge is shaped, 
but also new social binds are established. A well-known example of ‘biosociality’ is 
the phenomenon that the development of new DNA tests for specific diseases and 
new genetic knowledge about these diseases goes hand in hand with the emer-
gence of new patients who organise themselves into new patient organisations, thus 
shaping new communities and new kinds of solidarity (Gibbon 2002; 2008; Rabe-
harisoa, 2003; Rabeharisoa and Callon, 2002). Members of such groups meet to share 
their experiences and lobby to put their disease on the public agenda. Some perceive 
this kind of activism as ‘biological citizenship’ and as an expression of genetic re-
sponsibility (Rose and Novas, 2004). Yet, the idea of biosociality has not escaped 
criticism either. Lock (2008) demonstrated in her study on families with Alzheimer’s 
disease that hereditary risks were scarcely discussed beyond the social circle of the 
immediate family. This was related to feelings of shame among family members as 
well as to the complexity of estimating the contribution of ‘susceptibility genes’ to 
the course of Alzheimer’s disease. According to Venkatesan (2007), the development 
from genetic to genomic technology, based on research on the whole genome 
instead of on single genes, made the idea of biosociality outdated: genomics would 
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imply that diseases become more individualised and the ‘target’ of these new tech-
nologies is in fact the individual. 
 Considering the debates on genetics and society, the question arises how 
concepts like geneticisation and biosociality relate to the subject of the family. 
Finkler (2000) interpreted the reunification of family members in breast cancer 
families during processes of genetic testing in terms of geneticisation. In her work, 
the geneticisation of the family implied that a highly fragmented family developed a 
rather intensive family life again. Konrad (2003), too, pointed to the geneticisation of 
social life in Huntington’s families: the promises of future genetic therapies raise new 
relational ‘webs’ of kinship, as family members had to negotiate what they wanted to 
know about their relatives. Getting involved in genetic testing was strongly associat-
ed with the idea of genetic responsibility towards family members, not only with 
respect to communicating genetic information (Hallowell, 1999), but also concerning 
one’s choice of partner and the decision to have children (Novas and Rose, 2000). 
 While the impact of genetic testing on families is not underestimated, several 
studies over the last decade have concluded that genetics does not have the over-
whelming influence on families’ lives as previously thought. These conclusions are at 
least partly related to the nature of the disease families live with. From studies exam-
ining families who get involved in genetic testing for ‘susceptibility genes’, as in the 
case of Alzheimer’s disease (Lock et al, 2006; Chilibeck et al, 2011), it becomes clear 
that the complexities and unpredictability of risk mean that practices of genetic 
testing do not transform family and kin relationships in a fundamental way. Aban-
doning the initial simple causal genetic explanation of disease and embracing com-
plexity implies that it has become more unclear what genes may reveal. Yet, recent 
studies on families with diseases with a higher predictive power, such as breast 
cancer (Boenink, 2011; Gibbon 2011) or Huntington’s disease (Huniche, 2011), also 
show that DNA is not the leading principle in families’ lives. Huniche points out that 
genetic responsibility is not necessarily seen as the social norm these days; those 
who do not engage with genetics – such as Colin in her analysis (see chapter 5 of this 
thesis) – can also live ‘good’ lives. Clarke et al (2011) demonstrate that parents who 
are carriers of a genetic disease do not necessarily buy into the benefits of an early 
genetic diagnosis when they consider having their children tested. While geneticists 
stressed the future health benefits for the children concerned, families hesitated: in 
considering what would be best for their children, their points of reference were 
rather practical matters of daily life, such as life insurance and mortgages, future 
careers and relationships, as well as current child and family happiness. 
 The relationship between family, kin and genes from a global perspective was 
the subject of a special issue of Social Science and Medicine (Horstman and Finkler, 
2011). Some of the studies included in this issue show, intriguingly, that the identifi-
cation of risks and diseases as genetic varies around the world. Even in cases where 
C H A P T E R  6  
 112 
health care organisations present a disease as genetically inherited or as a genetic 
risk factor, people may attribute it to other factors. Examples include Cuba, where the 
major risk factor for breast cancer in women apparently has origins external to the 
body (Gibbon, 2011), and indigenous populations in Mexico, where type 2 diabetes is 
associated with strong emotions, traumatic events or dietary factors (Everett, 2011). 
Such beliefs about the causes of disease imply that people diagnosed with the 
disease in question do not regard it as a family issue and therefore see no need to 
discuss it with family members. Boenink (2011), too, further illustrated the notion 
that genetics affects families in different cultures and health care settings differently. 
Concentrating on predictive genetic testing for familial breast cancer, she compares 
the role family members play in the testing processes in the Netherlands, offered in 
clinical genetic centres, and the United States, where testing is offered directly to 
consumers. In the Netherlands the blood of family members is needed to make 
genetic test results less ambiguous, meaning that they are involved in genetic test 
trajectories from the outset, while in the United States the client is treated as an 
individual, independent of her family. Thus, it may be that contact with family mem-
bers is made only after a mutation has been identified.  
 Overall, these studies show that in everyday family life, genetics is not as much 
of an issue as is often thought. In our contribution to the special issue (which forms 
the second chapter of this thesis), we conclude that it is families’ ‘balancing work’ 
that plays down the importance of genetics (Geelen et al, 2011). This rendering of 
genetics as ‘ordinary’ is in line with a study by Karen-Sue Taussig. Her book, Ordinary 
genomes, provides an ethnography of genomics as practiced in the Netherlands, and 
casts an interesting light on the ways in which Dutch people typically encounter 
genetics in their everyday lives. Taussig contends that in the Netherlands ideas about 
genetics are shaped by the desire for ordinariness and the commitment to tolerance. 
According to her, the common Dutch saying ‘Just act normally, that’s already crazy 
enough’ expresses the emphasis on ordinariness in Dutch social life that encourages 
people to normalise genetics. In that sense, approaching developments in genetic 
technology in terms of geneticisation ‘yes’ or ‘no’ can no longer be seen as fruitful. 
Rather, the focus should be on the meaning of genetic technology for families and 
the work that is done in ‘normalising’ genetics. 
 In view of the discussions mentioned above on the relationship between family, 
kin and genetics, it is noteworthy that few large sociological studies on family and kin 
relationships pay attention to the topic of genetics. While interest in family and 
kinship has become an established topic in genetic research and counselling, the 
impact of genetic technology is not addressed in family sociology. Notwithstanding 
the growing awareness that genetics neither ‘makes’ nor ‘breaks’ the family, this 
thesis has shown that it does affect family life, as do financial problems, leisure 
activities, (un)employment, divorce, etc. This lack of attention for genetic practices in 
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family sociology is all the more strange considering that families are essential for 
research into genetics: the further unravelling of familial diseases will be hampered if 
families do not offer their blood and experiences. In that sense, the family is of crucial 
societal importance not just for informal care and childrearing, but also for the 
further development of genetic technology. In other words, the contributions of 
families to genetic research to a certain extent shape the possible future impact of 
genetics on families.  
 It is somewhat surprising as well that research on the ethical aspects of new 
trends in genomics, namely whole genome sequencing and direct-to-consumer 
testing, pays scant attention to the family. This might seem logical as these tests are 
directed at the individual, but it may be questioned how personal these technologies 
actually are. The announcement in Science of James Watson’s own genome sequence 
in 2007 pointed to the potential impact on his sons, highlighting the fact that an 
essential feature of a genome is that one shares most of it with someone else, and 
the consequences of embodying such a sequence are thus shared equally (Marshall, 
2007). 
6.4 Living ‘a good life’ with genetics 
The family stories have demonstrated that living with genetics gives rise to many 
new questions, such as how to deal with the option of visiting a clinical geneticist, 
how to communicate the notion of a familial disease as well as genetic information 
to relatives, what to do about the possibility of genetic testing, and how to deal with 
a genetic test result. For many of the family members, these were moral dilemmas 
rather than just difficult questions. They had to ‘work’ to justify their decision and to 
be both a ‘good’ person as well as a ‘good’ family member. In that sense, genetic 
testing is very much a moral issue. Dealing with a question like ‘When will I tell my 
brother that I visited the clinical genetic centre?’ requires not only a factual answer, 
such as ‘next week’, but also consideration of questions such as ‘Shall I inform both 
him and my sister together?’, ‘How important is it to let him know soon?’, ‘Will it 
frighten him?’, ‘Will he also talk to his children about it?’, ‘Will it be emotional for me 
to discuss it with him?’ and ‘Shall I ask my husband to join me?’ The way in which 
family members deal with these questions reflects their values in terms of what it 
means to live a ‘good’ life.  
 In the course of my research I discovered the work of the philosopher Martha 
Nussbaum (1986, 1990), and although I am neither a philosopher nor an ethicist, it 
seems to me that her work may help to interpret and understand the moral dilem-
mas that members of the HCM families had to deal with after becoming involved in 
genetic testing. In the Aristotelian tradition that Nussbaum draws upon, the question 
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‘what is the right thing to do in this situation?’ does not primarily refer to a set of 
universally applicable rights, duties or principles, as in most modern philosophical 
theories of ethics, but to a shared normative understanding of ‘a good life’ and of 
how ‘a good person’ may operate within this shared context. Virtues are not thought 
of as individual character traits, but as shared precepts and guidelines that have to be 
further developed in each individual life and each situation with its particular peculi-
arities. While in the original Aristotelian tradition it is expected that this shared virtue 
framework will offer a rational moral ‘solution’ to each moral dilemma, Nussbaum 
puts moral perfectionism into perspective. She notes that there is no such thing as 
the moral act in each situation, because moral frameworks may contain fundamental-
ly conflicting elements. Therefore, Nussbaum prefers to take the question ‘how to 
live?’ rather than ‘what to do?’ as the leading principle (Boenink, 2000). She observes, 
moreover, that human life is characterised by coincidence and bad luck. Thus, in her 
philosophy, people – though they may try their best – are not in control; instead, 
they are vulnerable.  
 In her book The fragility of goodness, Nussbaum examines this fundamental 
ethical phenomenon; that many of the valued constituents of a well-lived life are 
vulnerable to factors outside the individual’s control. Inspired by Greek tragedies, in 
which human beings are presented as playthings of the gods and therefore cannot 
pursue all the ideals to which they have committed themselves, Nussbaum states 
that human luck depends on tuché, uncontrollable coincidence. In managing a 
virtuous life, good luck can turn bad unexpectedly and easily: loved ones may sud-
denly leave us, disease or distress may overpower us, we may work hard and never-
theless fail. The fact that we are not in control is an inevitable characteristic of human 
life, which is also fundamentally social. The interdependence of human beings 
implies a lack of control, but it also stimulates people to lead moral lives and to 
reflect on themselves.  
 In their everyday lives, people continuously have to deal with moral issues that 
bring forth conflicting demands, leading to what Nussbaum calls ‘tragic’ decisions. 
According to this notion, it is impossible to seek moral perfectionism since vices and 
virtues always go hand in hand and one cannot foresee all the consequences of a 
particular act. Those who value harmony might avoid conflicts and bend the truth, 
while those guided by love of work run the risk of neglecting kin and friends. Thus, 
each manner of living and each choice has a price; what is more, even when we think 
we understand the consequences of our decisions, we remain in the dark. As life is 
uncertain, irregular and liable to change, what should be seen as a ‘good’ life always 
depends on the specific context. Not telling the truth or neglecting kin or friends may 
be judged differently in different situations. And what we consider acceptable now 
may be seen as unacceptable later. Although people try their best, things may simply 
turn out differently from what they had hoped or expected. Even a well-considered 
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decision to tell one’s brother about a visit to the genetic centre may prompt anger on 
his part.  
 Nussbaum argues that in order to find the best manner of living that is worthy of 
one’s dignity, people must develop the ability to deal with tuché, with coincidence 
and bad luck, and with uncertainties and the unforeseen. From an ethical perspective 
it is important to acknowledge that we lack control, and that the quest for a good life 
is complex and may do harm: moral dilemmas cannot be solved without feelings of 
regret and we always run the risk of becoming aggrieved. The art of leading a good 
life, then, is not to lose sight of the alternatives we were forced to give up, to 
acknowledge our vulnerability and to face the tragic character of many choices. To 
promote the art of leading a good life, Nussbaum appeals to people’s self-reflexivity. 
Further, in contrast with many other ethical theories that stress the importance of 
rational argumentation in moral decision making, Nussbaum considers emotions an 
important element of moral deliberation. Rather than as obstacles to intelligent 
evaluative judgements, Nussbaum perceives them as a source for these judgements. 
Naturally, emotions should not be taken for granted, but in reflecting on emotions 
people will learn about who they are and what a good life means to them.  
 What can be said about how the six extended HCM families dealt with the 
dilemmas of genetic testing they were confronted with? The stories demonstrate 
that in making decisions family members were guided by a shared understanding of 
values within the family and within specific relationships with relatives. In Nuss-
baum’s terms, such values were not universal principles, but socially constructed 
points of reference that family members could also expect their relatives to use. 
‘Doing good’ required manoeuvring on the ‘waves of lives’ guided by these ‘beacons’ 
to justify their decisions. In the HCM families, such manoeuvring could lead an indi-
vidual to communicate the news about the gene immediately with the one family 
member, while remaining silent about the issue for varying periods with others. It 
could also be deemed wise to discuss genetics with a specific relative, but to delay 
such discussion until a time considered better for that relative, for instance after they 
had finalised a divorce or recovered from an operation. As virtues and values about 
how to live varied within the different extended and nuclear families, family mem-
bers gave different meaning to the risks of disease, to the promises of the test or to 
ideas about their future lives, and they made decisions in various ways. Decisions 
about having a test done or not, or having children tested, provided opportunities 
for moral work for many family members. The ‘moral perception’ of situations and 
the manoeuvring work that family members did meant that time was used to let 
ideas and decisions ripen. The families’ stories point to notions of ‘waiting until the 
time is right’ or ‘letting time pass’. Over the long course of testing trajectories, events 
in the family could happen that gave rise to new perspectives or feelings. For exam-
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ple, relief about one’s own test result could change into feelings of sadness if a 
sibling were diagnosed with the gene.  
 The family members’ stories highlighted numerous moments of conflicting 
virtues and the ‘tragic’ character of decision making. The decision to undergo a 
genetic test, for instance, could result in identification of an individual as a carrier, 
and so transform uncertainty into despair as well as betray the risks of others. Painful 
and conflicting elements came to the fore with respect to testing a child: a positive 
test result could be seen as way to turn the tide, but could also bring back memories 
of parents’ own experiences with disease and give rise to feelings of fear. In that 
sense, the stories made clear that there was no morally ideal decision and that what-
ever choice the parents made about the testing of their child would come with a 
price. The stories also demonstrated that family members experienced feelings of a 
lack of control. For instance, Tom Goldfield, in his eighties, decided to be tested to 
safeguard the future of his six children (‘I’ve never had heart complaints and if I do the 
test, my children won’t have to go; they’d have to take a day off to go to the clinical 
centre’ ). Unfortunately, the positive test result instead caused unrest among his 
children. Tom and his wife had undergone the test with the best of intentions, and 
realised that they had not been able to foresee this situation: ‘We can’t help it that 
now the children have to think about the test’. 
 Finally, I raise the question what the interpretation of my investigation in terms 
of Nussbaum’s ‘good life’ might yield for clinical professionals. Genetic testing is 
often presented as a technology that can increase control with respect to health risks 
and disease, and the modern ethical notions of ‘autonomous decision making’ and 
‘genetic responsibility’ fit this style of thinking. From Nussbaum’s perspective of ‘a 
good life’, it is important to acknowledge the limits of control as well. The idea that 
genetic testing implies ‘tragic’ choices and requires moral work for families may 
throw fresh light on genetic counselling as well.  
 Although professionals cannot solve the dilemmas families are confronted with 
in genetic testing trajectories, counselling can be used not just to provide infor-
mation about genetic risks, but to help them identify which values they find im-
portant and to support them in their manoeuvring work. ‘Good’ professional work 
then means trying to find out how to gear this work towards families’ attempts to 
lead good lives. For professionals there are no precepts or guidelines for this kind of 
support; it is manoeuvring work for them as well. They have to support people in 
learning new things about themselves and others. Professionals cannot prevent 
people from making decisions that lead to grief or other unforeseen consequences. 
Although they have to work in accordance with professional standards, they too lack 
control. Recall the testing of the young twins in the Redford family, which was after-
wards interpreted by the professionals as: ‘We did our best, but we couldn't prevent the 
different test results from potentially generating problems in raising the children’.  
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Nussbaum’s work implies that, rather than presenting genetics to families as an 
instrument to control specific health risks, the notion of control should be put into 
perspective and the work that families themselves have to do to live a good life with 
respect to genetics should be emphasised. Nussbaum notes that telling stories about 
the lives of others enables us to learn to imagine what another person might feel in 
response to various events, as well as to identify with others and learn something 
about ourselves. By the same token, I conclude that documenting stories about 
families’ experiences with genetics may provide professionals with a larger repertoire 
when discussing with families the relevant topics surrounding genetics, and can also 
contribute to new ideas with respect to good care in the era of genetics. 
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Epilogue 
‘Thank you very much for giving me the opportunity to tell my story’, Susan Sil-
verman said at the end of the interview. 
‘Actually I should thank you; it was great for me to listen to what you had to 
say’, I responded. 
‘I’ve never told someone so much about my family before, and I notice that by 
explaining things out loud they’ve become much clearer to me. It’s all been in 
my head for years, but I was never able to be free of it’, Susan went on. 
Susan was one of the first participants in my study and the first member of the 
Silverman family I talked with. When I phoned her to ask if she would participate in 
the study, she was initially hesitant. ‘Are you sure you want to talk with me about the 
disease? It might be better to talk with my brother or sisters. They all suffer from the heart 
disease. They all have severe complaints and I have just a mild thickened myocardium’, 
she said, as if she was afraid her story would not be interesting enough. When I 
explained that I intended to meet her as well as others in the family, we agreed on a 
time.  
 Her isolated position within the family was the common thread running through 
the interview: ‘I don’t talk about my own complaints to my brother and sisters, as I have 
nothing in comparison to them. They can share their disease experiences with each other. 
From a physical point of view, I don't feel what they feel; I’m very distant from them. We’re 
next of kin, and I would never have thought that such ties could be broken by something 
like a disease.’ From Susan’s perspective, the familial disease had pulled the family 
apart, and several times during the interview she expressed her surprise as well as 
her grief about that: ‘I have the feeling that because they suffer so much from the disease 
I can’t understand them, but on the other hand, they could try to understand me.’ After 
the interview, I kept in touch with Susan. However, due to her poor relations with 
others in the family, she was unable to help me to recruit family members for my 
research, so I needed additional help from the cardiologist. He put me in contact with 
Susan’s brother, and through him, I met other family members. 
 Susan’s brother and sisters all mentioned the scarce contact with her, but ex-
plained that this had been the case as long as they could remember. ‘Even before our 
youngest brother and sister died of heart problems and it became clear that there was a 
heart disease running in our family, she was the outsider’, one said. This did not imme-
diately prompt me to actively approach Susan to explore in more depth how she 
perceived the relationships she had previously had with her brother and sisters. 
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However, some years after I had contacted her for the first time, Susan phoned me. 
Initially she seemed interested in the progress of the study, but bit by bit she started 
telling me about herself. Again she brought up her loneliness within the family, and 
at a certain moment she began to explain how her ideas about this had changed. 
Whereas she had long seen the familial disease as having caused the tensions be-
tween her and her relatives, after the interview she had realised that it had all started 
more than 40 years before, after her father’s death: ‘My brother became the head of the 
family and I always took a back seat. This is actually how we live these days.’ Although 
the awareness that the familial disease was not as important as she had previously 
thought implied that she was now even more ashamed of her family than before, she 
appeared to feel fine.  
 Some years after that phone call, Susan’s husband called me. Their daughter 
wanted to get pregnant and was wondering whether the child’s predisposition to 
the heart disease could be determined during the pregnancy. He recalled my visit, 
and decided to enquire as to whether we had already published the study results. We 
agreed that I would send him the articles that had been published so far. Soon after, 
we had another telephone conversation. He told me that, when reading the articles, 
he especially recognised our description of the emotional work that had to be done 
by families with this heart disease. His daughter had been through a difficult time 
searching for information about the disease, visiting doctors and having heart exam-
inations. ‘Fortunately they didn’t find any clinical symptoms. So, now she has to take the 
risk …. I’m sure that further examinations would be too emotional, particularly for my 
wife’, he said, and it was clear he was glad she had let the matter rest and had not 
pressed to reopen the laboratory research on the family’s blood. 
 Reflecting on the process of my research, it is clear that while my understanding 
of the families involved came about through my interaction with them, that same 
process affected their lives as well. It was not only Susan Silverman’s ideas about the 
familial disease that were affected through participation; in the other families, too, by 
studying their lives I also intervened in them. The mere invitation for an interview 
prompted people to rethink their ideas about the familial disease and about genetic 
testing, and sometimes new perspectives were generated. Lucy Goldfield, for in-
stance, told me how she had discussed genetic testing with her partner once more 
prior to the interview: ‘So far I’ve not informed my children about the heart gene in the 
family, but I suddenly realised that they’ve reached the age where they can join me in 
making my decision about genetic testing.’ During the interview, Lucy’s ideas devel-
oped further: ‘Now that I tell you this, I’m thinking of the totally different characters of 
my daughters, which means there will be a real chance that they’ll think about it differ-
ently; that could make it complicated for me to involve them.’  
 I also encountered in my contacts with Sacha Goldfield, that the experience of 
telling one’s story could prompt the participant to rethink the opportunity for genet-
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ic testing. During the interview she showed to be in no hurry either to tell her adult 
children about the familial risk of HCM or to discuss the issue with her general practi-
tioner or a clinical geneticist. However, when I contacted her six months later, she 
told me that she had had the genetic test done: ‘You gave me pause for thought. After 
you visited me, I thought, what can I lose by doing the test? I realised that I could easily 
go. So I made an appointment and told my children about it.’ From then on, she lived 
with full knowledge about her genetic make-up; fortunately, she had received a 
good result from the genetic test. 
 At the end of this thesis, rethinking these changes in perspective and the emer-
gence of new solutions and new dilemmas, I can only hope that I did not turn things 
upside down too much for my participants, and that they are doing well after having 
told their stories. I would like to thank them gratefully, as they enabled me to write 
this book. 
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Abstracts of publications  
Chapter 2  
Geelen E, Van Hoyweghen I and Horstman K (2011). Social Science and Medicine, 
72:1752-1759. 
 The literature shows that genetic testing could stimulate solidarity among 
family members, but also lead to major conflicts. To prevent negative effects, clinical 
geneticists and ethicists have stressed the importance of ‘good communication’ 
within families. In this qualitative study, we followed six extended families in the 
southern and eastern Netherlands involved in genetic testing for familial hyper-
trophic cardiomyopathy for three and a half years. In total 57 members of these 
families were interviewed in depth, most more than once. Our analysis shows that 
genetic testing does affect families, but that families perform a lot of ‘balancing work’ 
in order to prevent genetic testing from becoming too all-encompassing. There is 
much more continuity in family life than is often thought. Moreover, as these families 
demonstrate different styles of family work, establishing a single norm of ‘good 
communication’ in clinical genetics might in fact be more harmful for family life than 
genetic testing itself. 
Chapter 3  
Geelen E, Van Hoyweghen I, Doevendans PAFM, Marcelis CLM and Horstman K 
(2011). American Journal of Medical Genetics Part A, 155A:1930-1938. 
 Professional guidelines on genetic testing of children have recently shifted their 
focus from protecting the child’s autonomous choice to professionals, together with 
parents, striving to work in the child’s ‘best interest’. This notion of ‘best interest’ 
allows room for therapeutical as well as psychological and social considerations, and 
gives rise to the question how parents and professionals weigh up the child’s best 
interest in practice. In this qualitative study, we followed six extended families in-
volved in genetic testing for hypertrophic cardiomyopathy in the Netherlands for 
three and a half years. In total 57 members of these families were interviewed in 
depth; many of them more than once. Our empirical analysis shows that the best 
interest of a child is constructed via long-term processes in the broader context of 
family and kin. In this context, ‘best interests’ are considered and reconsidered. We 
conclude that a child’s best interest should not be framed as the result of an instan-
taneous agreement between parents and professionals. In dealing with genetic 
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testing of children, parents as well as professionals reflect on and learn from the 
processes of generating new meanings of ‘best interest’. To enable professionals to 
deal with the variety in family life, these learning processes should be documented 
closely.  
Chapter 4 
Geelen E, Horstman K, Marcelis CLM, Doevendans PAFM and Van Hoyweghen I 
(2012). European Journal of Human Genetics, 20:1018–1023. 
 Since the 1990s, many countries in Europe and the United States have enacted 
genetic non-discrimination legislation to prevent people from deferring genetic tests 
for fear that insurers or employers would discriminate against them based on that 
information. Although evidence for genetic discrimination exists, little is known 
about the origins and backgrounds of fears of discrimination and how it affects 
decisions for uptake of genetic testing. The aim of this article is to gain a better 
understanding of these fears and its possible impact on the uptake of testing, by 
studying the case of hypertrophic cardiomyopathy (HCM). In a qualitative study we 
followed six Dutch extended families involved in genetic testing for HCM for three 
and a half years. Semi-structured interviews were conducted with 57 members of 
these families. Based on the narratives of the families, we suggest that fears of dis-
crimination have to be situated in the broader social and life course context of family 
and kin. We describe the processes in which families developed meaningful interpre-
tations of genetic discrimination and how these interpretations affected family 
members’ decisions to undergo genetic testing. Our findings show that fears of 
genetic discrimination do not so much stem from the opportunity of genetic testing 
but much more from earlier experiences of discrimination of diseased family mem-
bers. These results help identify the possible limitations of genetic non-
discrimination regulations and provide direction to clinicians supporting their clients 
as they confront issues of genetic testing and genetic discrimination. 
Chapter 5 
Geelen E, Van Hoyweghen I and Horstman K. BioSocieties (under review) 
 In genetic counselling the meaning of autonomy is related to the notion that 
people who become engaged with genetic testing have to take an active stance 
towards their future. By considering their genetic risks and by taking preventive 
measures, people are expected to foresee and control their future lives and future 
health. However, it is not clear how people engaged in genetic testing actually deal 
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with the future. This article aims to provide insight into the way connections be-
tween the idea of making-the-future and notions of autonomy are actually made in 
people’s everyday lives. In this qualitative study, we followed six extended families 
involved in genetic testing for hypertrophic cardiomyopathy in the Netherlands for 
3½ years. By analysing four cases, we show that people imagine and deal with the 
future in various ways and have different ideas about the opportunities for control. 
Autonomy appears to have multiple faces. It also becomes clear that making-the-
future and living-the-present are not opposing or excluding repertoires but that 
traces of both are apparent in all cases analysed.  
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Samenvatting  
Familie werd traditioneel gezien als een belangrijke bron van sociale cohesie. In de 
hedendaagse Westerse samenleving lijken familieverbanden echter minder belang-
rijk. Onder invloed van onder meer de toename van echtscheidingen, grotere mobili-
teit van mensen en vrouwenemancipatie heeft een proces van individualisering 
plaatsgevonden. Daarmee is de vanzelfsprekendheid van mensen om zichzelf pri-
mair als lid van een familie te zien verdwenen en is vrije keuze in familiecontacten de 
norm geworden. Toch wordt het idee dat de familie aan betekenis heeft ingeboet 
ook gerelativeerd. Het kerngezin is voor een kind nog steeds de belangrijkste bron 
van normen en waarden, en ook al trekken familieleden minder met elkaar op uit 
gewoonte of plichtsbesef, in tijden van ziekte of overlijden vormen ze nog steeds een 
grote bron van steun voor elkaar. In het licht van de veranderende betekenis van 
familie, rijst de vraag hoe het bestempelen van een ziekte als ‘genetisch’ het leven 
van families beïnvloedt. Immers, genetische diagnostiek impliceert betrokkenheid 
van de familie. Er is bloed en informatie van andere familieleden nodig om diagnos-
tiek voor een individueel familielid mogelijk te maken. Bovendien onthult de uitslag 
van een genetische test mogelijke risico’s voor familieleden. Dit proefschrift richt zich 
op wat processen van genetische diagnostiek teweeg brengen in families.  
 De verwevenheid tussen families en genetica moet gezien worden tegen de 
achtergrond van de veranderende perspectieven op genetische technologie. Hoofd-
stuk 1 gaat onder meer in op de speculaties over de invloed van het Human Genome 
Project. Aanvankelijk werden de debatten over de rol van genetica gekarakteriseerd 
in termen van hoop en vrees. Enerzijds werd de verwachting geuit dat een beter 
begrip van de moleculaire mechanismen van ziekte en gezondheid zou leiden tot 
betere diagnostiek en nieuwe, op de persoon toegesneden behandelmethoden. 
Anderzijds was er angst dat ziekte en gezondheid meer en meer gedefinieerd zou-
den worden in termen van DNA, waarmee de sociale en culturele benadering ervan 
naar de achtergrond zou verdwijnen. Het idee dat mensen vastgeklonken werden 
aan hun biologische lot, boezemde bezorgdheid in voor discriminatie en voor be-
dreiging van de vrijheid om zelf vorm te geven aan het leven. Hoewel optimisten en 
pessimisten geheel andere ideeën hadden over de mogelijke rol van genetica, 
deelden zij hetzelfde deterministische perspectief, namelijk dat genetica hoe dan 
ook een stempel zou drukken op het leven van mensen. Rond de eeuwwisseling 
groeide het inzicht dat bij de manifestatie van een ziekte niet enkel één specifieke 
mutatie een rol speelde, maar dat er altijd sprake was van een samenspel van ver-
schillende genen en dat ook omgevingsfactoren een rol speelden. In plaats van 
heldere antwoorden genereerde de identificatie van een gen veel onzekerheden. 
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Duidelijk werd dat eerdere beloften van genetica een te fraai beeld gaven van ge-
zondheidswinst en dat ook angst gebaseerd was op te hoge verwachtingen over het 
voorspellende karakter van genetica. 
 Vanuit het idee dat technologische innovaties de opvattingen over een goed 
familieleven beïnvloeden, is het de vraag wat de verandering in het perspectief op 
genetica betekent voor wat er in families gebeurt wanneer ze een genetisch testtra-
ject starten. Waar aan het begin van deze eeuw betoogd werd dat genetische di-
agnostiek familiebanden zou kunnen verstevigen of juist onder druk zou kunnen 
zetten, wordt de invloed van genetica op families meer en meer gerelativeerd. 
Echter, hoewel genetica families ‘maakt’ noch ‘breekt’, kan niet gezegd worden dat 
pocessen van genetisch testen families onbewogen laat. 
 In deze studie volgde ik families die leven met hypertrofische cardiomyopathie 
(HCM), een erfelijke hartziekte. In de medische literatuur wordt deze ziekte vooral 
geassocieerd met plotse hartdood bij jonge mensen, voornamelijk atleten. Toene-
mend inzicht in de genetische aspecten van de ziekte heeft niet geleid tot meer 
duidelijkheid voor families. Integendeel, iemand die een test laat doen voor HCM, 
krijgt vaak te maken met een langdurig traject dat onvoorspelbaar verloopt en 
waarin veel onzeker blijft. Een testuitslag kan lang op zich laten wachten en soms 
komt er helemaal geen uitslag. Als er een specifieke mutatie wordt gevonden, blijft 
de betekenis voor een individueel familielid onduidelijk. Het ene familielid kan al op 
jonge leeftijd klachten hebben, terwijl een ander met dezelfde mutatie oud wordt 
zonder problemen. Tot nog toe is geen medicatie beschikbaar om in een vroeg 
stadium ziekteverschijnselen te voorkomen.  
 Om inzicht te krijgen in wat genetica in het alledaagse leven van families te-
weeg brengt, zijn zes families gevolgd in het traject van genetische diagnostiek. Er 
zijn interviews gehouden met 57 leden uit deze families op een aantal achtereenvol-
gende momenten, gesprekken gevoerd met counselors betrokken bij de zorg en 
observaties gedaan van de testprocedures in het laboratorium. De zes families waren 
uiteenlopend qua grootte en de ernst van de ziekte in de families verschilde. In een 
deel van de families was een mutatie geïdentificeerd; in andere families wachtte men 
nog op een uitslag. Variatie was er ook in de tijdsduur waarin de families bezig waren 
met genetisch testen: sommige waren net gestart, andere al jaren geleden. In enkele 
families waren of werden ook kinderen getest. Centrale thema’s in de interviews 
waren het leven als familie, besluitvorming rond genetisch testen, testen van kin-
deren, omgaan met de uitslag en verwachtingen ten aanzien van de toekomst. 
Theoretische concepten en analytische vertrekpunten ontwikkelden zich in de loop 
van de studie. De vier empirische hoofdstukken in dit proefschrift zijn elk gebaseerd 
op specifieke concepten, die gerelateerd zijn aan patronen van familieleven, con-
structie van risico’s, ervaringen met ziekte en gezondheid, verantwoordelijkheid van 
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ouders, belangen van kinderen, genetische discriminatie, autonoom beslissen en 
perspectief op toekomstig leven en toekomstige risico’s. 
 
Hoofdstuk 2 start vanuit de veronderstelling dat goede familiecommunicatie van 
belang is om familieleden de kans te geven een goed besluit te nemen over gene-
tisch testen én neemt het idee onder de loep dat genetische kennis een onvermijde-
lijke invloed heeft op familie en familierelaties. Beschreven wordt dat in families vaak 
geen sprake is van een onverwachte confrontatie met de informatie over de erfelijke 
ziekte. De analyse in dit hoofdstuk laat zien dat de manier waarop families leven met 
genetische kennis sterk uiteenloopt. Verschillen zijn echter niet zozeer het effect van 
de testen, maar veel meer een uitdrukking van al langer bestaande verschillen in 
levenshouding. Daarnaast blijkt dat gebruik van genetische diagnostiek niet een 
overweldigende invloed heeft op families. Familieleden hebben niet alleen andere 
prioriteiten, ze staan ook niet toe dat het testen teveel invloed heeft op hun alle-
daagse leven. Er wordt veel werk verzet om genetisch testen niet te belangrijk te 
maken en relaties niet te laten lijden onder verschillen in opvatting erover. Boven-
dien zijn familieleden vaak meer bezig met de ziekte in het heden dan met de moge-
lijkheid ziek te worden in de toekomst. De bevinding dat wat genetische testen in en 
met een familie doen, slechts begrepen kan worden in de context van de bestaande 
levensstijl van die familie, betekent dat er in de genetische counselingspraktijk nooit 
één professionele norm kan zijn voor ‘goede familiecommunicatie’.  
 
Hoewel het erfelijke karakter van de ziekte geen prominente rol speelt in het alle-
daagse familieleven, maken veel familieleden zich wel zorgen over de mogelijkheid 
dat ook kinderen de aanleg hebben. Ouders kunnen zich er doorgaans nog wel bij 
neerleggen dat ze zelf deel uitmaken van een familie met een erfelijke ziekte, maar 
accepteren dat ook hun kinderen risico lopen, is minder eenvoudig. Hoe binnen 
families wordt aangekeken tegen genetisch testen van kinderen wordt behandeld in 
hoofdstuk 3. Nadat professionele richtlijnen aanvankelijk uitgingen van de bescher-
ming van de eigen keuze van het kind, staat sinds een aantal jaren de notie ‘belang’ 
van het kind centraal. Dit hoofdstuk laat allereerst zien dat deze notie impliceert dat 
ouders verschillend beslissen over genetisch testen van hun kind. Waar voor sommi-
gen testen van jonge kinderen vanzelfsprekend wordt, laten anderen de rechten van 
hun kind om op oudere leeftijd zelf te bepalen wel of geen genetische test te laten 
doen zwaar wegen. Daarnaast blijkt uit de verhalen dat wat als ‘belang’ van het kind 
gezien wordt, in de loop van de tijd verandert. Zo kan na een positieve testuitslag de 
therapeutische betekenis ervan tegenvallen of de familie zich gaan bemoeien met de 
opvoeding van het kind, en komt wat goed is voor het kind in een ander daglicht te 
staan. De analyse maakt duidelijk dat testen van kinderen niet gebeurt in een vacu-
um, maar samenhangt met de familiegeschiedenis en de relatie die ouders met hun 
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kind hebben. Het is in de context van het alledaagse familieleven dat belangen van 
kinderen tot stand komen. 
 
Angst voor mogelijke genetische discriminatie leidt bij ouders soms tot uitstel van 
testen van hun kind of tot spijt over het feit dat het getest is. In hoofdstuk 4 wordt 
deze angst onderzocht tegen de achtergrond van bestaande Nederlandse anti-
discriminatie wetgeving. Hoewel de wetgeving beoogt mensen te beschermen, 
wordt in families een positieve testuitslag wel geassocieerd met discriminatie. De 
analyse van vier case studies maakt allereerst duidelijk dat de angst voor discrimina-
tie niet zozeer het resultaat is van de genetische testen, maar te maken heeft met 
eerdere ervaringen met discriminatie in de familie. Opvallend is dat, terwijl de wet-
geving een onderscheid maakt tussen symptomatische en asymptomatische familie-
leden, in het familieleven die grens zo scherp niet is: ook familieleden met manifeste 
klachten, waarvoor de genetische test dus eerder een diagnostisch dan een predic-
tief instrument vormt, ervaren soms angst om gediscrimineerd te worden. Daarnaast 
is opvallend dat in de families angst voor genetische discriminatie niet enkel geasso-
cieerd wordt met de dreiging vanuit verzekeringsinstanties of werkgevers. Soms leidt 
een gevoel van ‘big brother is watching you’ tot de wens de informatie over de ziekte 
in de familie als een familiegeheim te bewaren. Betoogd wordt dat de notie van 
genetische discriminatie, dat de basis vormt voor de anti-discriminatie wetgeving, te 
smal is om te begrijpen wat er in families leeft. Er is aandacht nodig voor de manier 
waarop families leven met de (risico’s op) ziekte en omgaan met de angst voor 
discriminatie.  
 
Hoofdstuk 5 start vanuit het idee dat genetische diagnostiek families aanzet een 
actieve houding aan te nemen ten opzichte van hun toekomstige gezondheid. In de 
analyse worden aan de hand van casusbeschrijvingen vier verschillende patronen in 
toekomstbeleving onderscheiden. Het eerste patroon betreft een sterk geloof in een 
maakbare toekomst: genetisch testen wordt verwelkomd als een mogelijkheid met 
het familieverleden te breken. In het tweede patroon wordt de toekomst gezien als 
iets dat mensen overkomt. Kern van het derde patroon is het idee van ‘pluk de dag’, 
waarbij men het leven neemt zoals het komt. In het vierde patroon leidt ongeloof in 
de abstracte betekenis van genetische informatie tot protest tegen het idee dat de 
toekomst maakbaar is. Waar in het eerste patroon de focus ligt op de toekomst, 
wordt in de andere drie patronen vooral gestreefd naar welbevinden in het nu. Dit 
betekent echter niet dat deze familieleden zich niet verhouden tot de toekomst. De 
casusbeschrijvingen laten zien dat zij door alert te zijn op symptomen en gezond te 
leven in het heden, trachten te voorkomen dat ziekte of plotse dood in de toekomst 
toeslaan. De bevindingen in dit hoofdstuk kunnen nieuw licht werpen op de manier 
waarop in de counselingspraktijk autonomie als leidend moreel principe gearticu-
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leerd wordt. De nadruk die daarmee wordt gelegd op de wil de toekomst onder 
controle te brengen, doet immers geen recht aan families waarin men de tijd de kans 
wil geven en toeval wil toestaan. 
 
In hoofdstuk 6, het slothoofdstuk, worden de belangrijkste bevindingen uit de 
empirische hoofdstukken allereerst geplaatst in de context van discussies over 
geneticalisering van de familie. Door de confrontatie met het genetisch lot zouden 
familieleden elkaar gaan zien door een genetische bril en zouden familierelaties 
gegeneticaliseerd raken. Met de omarming van complexiteit en onzekerheid in de 
genetica is meer en meer duidelijk geworden dat processen van genetische diagnos-
tiek familierelaties niet fundamenteel veranderen. In het licht van die bevinding is 
het niet langer zinvol om de verwevenheid van families en genetische technologie te 
duiden in termen van wel of geen geneticalisering. Dit proefschrift toont dat het niet 
zonder meer de relativering van het voorspellende karakter van de testen is die 
genetica minder belangrijk maakt, maar dat het de families zelf zijn die werk verzet-
ten om genetische risico’s en genetische diagnostiek ‘gewoon’ te maken. In de 
beoordeling van de impact van de ontwikkeling van genetische technologie zal dan 
ook dit familiewerk centraal moeten staan. 
 Vanuit het idee dat veel van het werk dat families verzetten in het traject van 
genetisch testen moreel werk is, worden in de laatste paragraaf van dit hoofdstuk de 
familieverhalen geïnterpreteerd in termen van Nussbaum’s notie van ‘het goede 
leven’. In haar opvattingen over ‘het goede leven’ relativeert Nussbaum het idee van 
morele perfectie. Immers, in hun alledaagse leven krijgen mensen te maken met 
kwesties die tegenstrijdige antwoorden vragen en daarmee leiden tot ‘tragische’ 
beslissingen. Het leven wordt bovendien gekarakteriseerd door toeval en onzeker-
heden. De verhalen van de familieleden laten zien dat er bij het nemen van een 
beslissing over genetisch testen geen absolute normen zijn die mensen als leidraad 
nemen, maar dat het gaat om schipperen en balanceren. Daarbij laten ze zich leiden 
door wat in de familie of in specifieke familierelaties als goed doen wordt gezien. 
Professionals kunnen niet voorkomen dat mensen keuzes maken die uiteindelijk 
verdriet of spijt opleveren, maar ze kunnen familieleden wel helpen zoeken naar wat 
ze belangrijk vinden in het leven en helpen onderkennen dat ze in het leven controle 
ontberen.  
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‘lessen’ in nemen wat er op je pad komt en vertrouwen houden in een goede afloop 
zijn me goed van pas gekomen. Mam, van jou leerde ik niet alles meteen voor waar 
aan te nemen. Het heeft zijn vruchten afgeworpen. Jammer dat je er niet meer bij 
kunt zijn; je had ervan genoten. 
 Tenslotte zijn er ‘mijn’ vier Uiterwijkjes om te bedanken. Al die jaren hielden 
jullie mijn alledaagse leven op gang en lieten jullie me zien en voelen wat echt 
belangrijk is. Met jullie beoefende ik ‘de kunst van het goede leven’. Lieve Jonas, 
Naomi en Roel, geweldig dat jullie erbij zijn gaan horen; veel dank voor alle leven in 
de brouwerij. Ik hoop met jullie allemaal nog een lange toekomst te delen. Lieve Jos, 
al zo veel jaren mijn man en zoveel meer. Wat fijn dat we 25 jaar geleden terugkwa-
men in Maastricht en ik aan deze tocht beginnen kon. Dank je voor je onuitputtelijke 
geloof dat ik er zou komen, voor je geduldig verdragen als ik teveel aan het werk of 
niet te genieten was, en voor alles wat we samen delen. Lieve kinders, lieve Anouk, 
Jorik en Renske, mede door jullie nam ik de tijd voor dit proefschrift. En omdat ik de 
tijd nam, kunnen jullie me nu als paranimfen en ceremoniemeester terzijde staan. 
Het werk is af en ik ben blij dat het zover is. We gaan er samen van genieten. 
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